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Despite the several advances in cardiovascular therapies, cardiac diseases 
still remain the leading cause of morbidity and mortality in developed 
countries. Current therapies essentially aim at either counteracting 
symptoms or slowing pathological progression, whereas no treatment able 
to stop or revert these diseases is available. The development of novel 
therapeutic strategies thus appears of pivotal importance. In this context, a 
number of studies conducted over the last several years have indicated 
various growth factors and microRNAs that are able to protect the 
myocardium against ischemia or sustain the failing heart. None of these 
molecules, however, have progressed towards clinical experimentation and 
which factor might turn out into a clinically effective biotherapeutics still 
remains largely unclear. 
In this scenario, this Thesis explores the possibility to exploit viral vectors 
based on the Adeno-Associated Virus (AAV) as tools to directly select for 
factors exerting beneficial effects in ischemic tissues in vivo, without a 
priori knowledge of the actual function of the investigated molecules.  
Following the birth of genetic engineering, the screening of genetic libraries 
has provided a powerful means for the rapid identification of genes and 
peptides possessing desired characteristics. Library screening has 
generated important biological information, but all the approaches 
attempted so far, based on biochemical assays or cell culture systems, 
have suffered a major limitation, in that they cannot predict the in vivo 
relevance of the selected molecules.  
In contrast, the currently availability of AAV vectors, which can be 
produced at very high titres, infect post-mitotic cells very efficiently, and 





significant transgene silencing, now allows development of a radically new 
strategy to directly select for potentially therapeutic genes directly in vivo.  
An outline of the novel, in vivo Functional Selection (FunSel) strategy, is 












































Figure 1 In vivo AAV-based Functional Selection (FunSel) strategy 
The construction of the AAV plasmid library entails individual cloning of genes 
coding for secreted proteins into an AAV-backbone plasmid and production of the 
corresponding pools of recombinant AAV vectors with different serotype specificity 
according to the applications. The pools are directly delivered in vivo and different 
types of ischemic damage are induced to trigger the selection of protective 
candidates. Several weeks after the onset of degeneration vector genomes still 
present in surviving tissues, in principle enriched for protective genes, are 
recovered by PCR and recloned into the AAV-backbone plasmid to create a new 
pool of AAVs, which is re-submitted to further cycles of in vivo selection, up to the 







A pool of AAVs, corresponding to a collection of vectors each one coding 
for a different growth factor, hormone or cytokine, are used to transduce a 
given tissue in vivo (e.g. the skeletal muscle or the heart); each vector 
infects an individual cell. After delivery, an insult is inferred to the 
transduced tissue, e.g. by inducing acute ischemia; this will trigger 
selection for factors exerting e protective effect against the damage. At a 
few weeks after the onset of tissue damage and degeneration, the animals 
are sacrificed in order to recover, by PCR, the viral transgenes still present 
in the surviving tissues, in principle enriched for genes promoting either 
tissue viability or regeneration. Then, the obtained PCR inserts are re-
cloned into an AAV-backbone plasmid to create a new pool of AAVs, which 
are re-submitted to further cycles of selection, up to the definition of one 
or more candidate therapeutic genes.  
 
This Thesis provides a proof-of-principle verification of the 
feasibility of the FunSel approach and describes two novel factors 
(ghrelin and INSL6), identified by in vivo selection, that are 
effective in protecting the myocardium after infarction in vivo.  
 
The Thesis initially reports a series of mathematical considerations that 
supports the theoretical feasibility of FunSel using AAV vectors. By taking 
into account all the variables possibly involved in AAV transduction and in 
the function of a possible therapeutic factor, the multiplicity of vectors and 
the complexity of the vector pools are ideally defined. 
Then, the Thesis experimentally validates the feasibility of generating 
pooled AAV vectors for in vivo skeletal muscle and heart transduction. 
Using a set of 100 different AAV2 vectors, coding for various secreted 
proteins, including several hormones and growth factors, the Thesis 





maintain the representation of each individual vector, transduce a target 
tissue at equal efficiency and are comparably expressed over time. 
After this extensive, preliminary validation analysis, FunSel was applied to 
different in vivo models of tissue degeneration. In particular, we set up 
models of hind limb ischemia and myocardial isoproterenol-induced 
damage, in order to trigger the functional selection of pools of AAV vectors, 
previously delivered to the target tissues. At different time points after the 
onset of degeneration, viral genomes present in surviving tissues were 
recovered, re-cloned to obtain new vector preparations and re-submitted to 
additional cycles of selection, up to the definition of a few candidate 
therapeutic genes.  
By three round of selection in the model of muscle ischemic damage, 
FunSel generated a marked enrichment for surviving myocytes transduced 
with AAV9-Ghrelin, a neuro-hormone involved in endocrine metabolism. 
Whereas, a single cycle of selection in the model of cardiac toxic damage 
was sufficient to appreciate a clear enrichment for AAV vectors coding for 
the Insulin-like peptide 6 (INSL6), a poorly described member of the insulin 
gene family.  
Finally, the cardioprotective potential of ghrelin and INSL6 was further 
characterized by a series of morphological and functional assays in a model 
of myocardial infarction. The persistent AAV9-mediated expression of these 
genes in the heart preserved cardiac function and reduced infarct size, as 
assessed by echocardiography and morphometric analysis. Interestingly we 
observed that, in animals treated with AAV9-Ghrelin or AAV9-INSL6, the 
marked improvement in cardiac contractility was paralleled by a decreased 
number of apoptotic cells at early time points after infarction. Moreover, 
ghrelin counteracted the induction of markers of cardiac damage, like 
miR21 and MMP-2, and prevented the deregulated expression of markers 




Taken together, the results presented in this Thesis support the feasibility 
of the AAV-based, in vivo FunSel approach for the identification of factors 
exerting a beneficial function against myocardial ischemia.  
This study encourages further extension of FunSel for the analysis of the 



































1.1 CARDIOVASCULAR PATHOLOGY 
 
Cardiovascular diseases (CVDs) include a broad range of pathologies that 
affect the heart and the circulatory system. The two most prevalent forms 
of CVD are coronary heart disease (CHD) and stroke. Despite remarkable 
progress in terms of early diagnosis and prevention, CVDs remain the most 
common, serious, chronic, life-threatening illnesses in Western countries, 
causing more deaths, disability and economic costs than all other disorders.  
As estimated by the World Health Organization Report 2011, about 17.3 
million people have died from CVDs in 2008, representing 30% of all global 
deaths (www.who.int/mediacentre/factsheets/fs317) (Figure 1.1). Of 
these deaths, 7.3 million were due to coronary heart disease and 6.2 
million to stroke. It is estimated that, by 2030, almost 23.6 million people 
will die from CVDs, a number which will possibly increase because of a 
dramatic rise in the prevalence of certain risk factors – including obesity, 
overweight and diabetes. In particular, in Europe, every year 4.3 million 
people die from cardiovascular diseases (www.ehnheart.org/cvd-statistics), 
of which more than 1.8 million before the age of 75. CVDs are responsible 
for 54% of all deaths in women across Europe and of 43% of deaths in 
men, killing more people than all cancers together.  
Cardiac pathologies are not only a cause of mortality, but also of morbidity 
and therefore they have a deep impact on the society also from an 
economical point of view. CVDs cost to the EU € 192 billion every year, of 
which approximately 57% is due to health care, 21% to loss of productivity 




















Tobacco smoking, physical inactivity, unhealthy diet and the harmful use of 
alcohol are the main behavioural risk factors of CVDs. Long-term exposure 
to behavioural risk factors results in raised blood pressure (hypertension), 
raised blood sugar (diabetes), raised and abnormal blood lipids 
(dyslipidaemia) and obesity (Roger et al., 2011).  
Currently available medical and surgical therapies - including angioplasty, 
thrombolysis and bypass surgery - have profoundly modified the natural 
history of CVD and its immediate prognosis, however their applications 
suffer important limitations in a broad number of patients and their efficacy 
is often inadequate in the long term. Moreover, many pharmaceutical 
treatments such as beta-blockers, ACE inhibitors and others improve the 
patients’ conditions, but actually only counteract symptoms or slow down 
pathology progression, whereas no treatment able to stop or revert the 
disease is currently available.  
 
Figure 1.1 Distribution of major causes of death including CVDs 
Cardiovascular diseases represent ~30% of the total cause of global death. Other 
Noncommunicable diseases (NCDs) include cancer, respiratory diseases, diabetes 


















1.1.1 Atherosclerosis as risk factor 
One of the main underlying pathological processes that lead to myocardial 
infarction and stroke is atherosclerosis. This is an inflammatory process 
affecting medium- and large-size blood vessels throughout the 
cardiovascular system, which usually starts during childhood with damage 
in the innermost layer of the artery and worsens with ageing.  
The initial step of atherosclerosis occurs when LDL particles leave the blood 
and enter the arterial intima, where, if LDL levels are increased, they 
accumulate (Insull, 2009). LDLs are afterwards modified by enzymes and 
oxidized into pro-inflammatory molecules, which provoke reaction of the 
innate inflammatory system within the intima. Endothelial cells become 
activated and secrete adhesion molecules, and the smooth muscle cells 
secrete chemokines and chemoattractants (like IL-1 and TNF-), which 
draw monocytes and lymphocyte into the arterial wall (Ait-Oufella et al., 
2011). Upon entry, monocytes transform into macrophages, take up lipids 
as multiple small inclusions, and become foam cells. This in-principle 
protective function may be overwhelmed and turned into a detrimental 
disease-causing pathway when the foam cells die and leave the lipid behind 
as a soft, destabilizing, and rather inert necrotic (atheromatous) core within 
the plaque (Falk, 2006). The increasing accumulation of lipids and the 
proliferation of smooth muscle cells stimulated by many growth factors 
secreted by macrophages, such as PDGF, FGF and others, determine the 
enlargement of the necrotic plaque, which is progressively covered by a 
fibrous cap consisting of smooth muscle cells and collagen.  
Although advanced atherosclerotic lesions can lead to ischemic symptoms 
as a result of progressive narrowing of the vessel lumen, acute 
cardiovascular events that result in myocardial infarction and stroke are 
generally thought to result from plaque rupture and thrombosis.  





of inflammatory cells (Lusis, 2000). Plaque rupture exposes plaque lipids 
and tissue factor to blood components, initiating the coagulation cascade, 
platelet adherence, and thrombosis (Glass and Witztum, 2001). Rupture 
frequently occurs at the lesion edges, which are rich in foam cells, 
suggesting that factors contributing to inflammation may also influence 
thrombosis (Figure 1.2).  
Many ruptures of thin caps are clinically silent; they heal by forming fibrous 
tissue and collagen fibers but may rupture again with thrombus formation. 
These cyclic changes of rupture, thrombosis, and healing may recur as 
many as 4 times at a single site in the arterial wall, resulting in multiple 
layers of healed tissue. Calcification and neovascularization, common 
features of advanced lesions, may also influence the stability of 
atherosclerotic lesions. Intimal calcification is an active process in which 
pericyte-like cells secrete a matrix scaffold, which subsequently becomes 
calcified. Moreover, the growth of small vessels from the media may favour 
the invasion by inflammatory cells. Angiogenesis occurs in association with 
remodellng and protease activation in surrounding tissues, suggesting that 
neovascularization could contribute to plaque instability and rupture. The 
clots generated by thrombosis can cause coronary occlusions that are 
responsible of myocardial infarction. Should they move into the circulation, 
they may reach downstream arteries causing thromboembolism. In this last 
case, the most frequent consequence is brain stroke. 
Atherosclerosis risk is influenced by different non-modifiable factors, such 
as age, gender and inherited genetic disposition, as well as by a series of 
factors that can be modulate by life style (physical inactivity, tobacco 
smoking, overweight and unhealthy diet) or pharmacological therapy 



























1.1.2 Ischemic Heart Disease  
Myocardial ischemia originates from an imbalance between myocardial 
blood supply and oxygen demand. It has a variety of consequences 
depending on the severity of the reduction in coronary blood flow, the 
duration of the ischemic insult, the area of myocardium supplied by the 
occluded artery and the presence of collateral vessels from other adjacent 
vascular beds in that portion of the heart (Senter and Francis, 2009) 





Figure 1.2 Atherosclerotic plaque evolution 
A. Endothelial dysfunction: Leukocyte adhesion and migration into the intima B. 
Fatty streak formation: platelet aggregation, foam-cell formation and smooth muscle 








Some episodes of myocardial ischemia are painful, causing angina pectoris, 
while others are completely silent. The most frequent mechanism leading 
to angina is an increased oxygen demand in conditions of stress or physical 
activity; this can be relieved simply by resting or by sublingual nitroglycerin 
treatment. In contrast, plaque disruption, platelet plugging, and coronary 
thrombosis are responsible for an acute coronary syndrome, which can 












The patients suffering of an acute coronary syndrome can be divided into 
one of two main groups by electrocardiography (ECG) analysis: 1) patients 
with myocardial infarction with ST-segment elevation (STEMI); the elevated 
ST segment indicates that a relatively large amount of heart muscle 
damage is occurring because the coronary artery is totally occluded; 2) 
patients with unstable angina or non-ST-segment elevation MI 
(UA/NSTEMI). A common problem when a patient has an acute coronary 
syndrome without ST-segment elevation is discriminating whether a heart 
attack is occurring or it is an unstable angina event. An important tool to 
distinguish between these two possibilities is the measurement of the levels 
of some cardiac enzymes, markers of myocardial necrosis, such as troponin 
Figure 1.3 Myocardial 
Infarction (MI) caused by 
coronary artery stenosis 
Myocardial infarction (MI) results 
from the interruption of blood 
supply to a portion of the heart and 
consequent death of the 
correspondent myocytes. This is 
most commonly caused by a 
coronary artery occlusion generated 
by blood clots derived from 







T or I, myoglobin and creatine kinase or creatine kinase-MB, the levels of 
which are all increased after MI (Thygesen et al., 2007).  
The very early phase of myocardial ischemia is reversible. During this 
phase, one of the prominent metabolic changes is potassium loss, which 
may be related to the early increase in anaerobic glycolysis. Reversibly 
injured myocytes are edematous and swollen from the osmotic overload 
and the cell size is increased with cardiomyocytes hypertrophy and 
decrease in the glycogen content. The myocyte fibers are relaxed and 
thinned, I-bands are prominent secondary to non-contracting ischemic 
myocytes. The nuclei show mild condensation of chromatin at the 
nucleoplasm and the cell membrane (sarcolemma) is intact and no breaks 
can be identified. The mitochondria are swollen, with loss of normal dense 
mitochondrial granules and incomplete clearing of the mitochondrial matrix, 
but without amorphous or granular densities. 
When the coronary blood flow is restored after a brief interruption, the 
reversible abnormalities of the myocytes progressively disappear but, if the 
blood flow is not restored within approximately 1 hour from the occlusion 
of the coronary artery, myocardial necrosis starts to occur. Several 
biochemical and functional alterations occur during the progression to 
necrotic cell death. These include loss of mitochondrial ATP production, 
compensatory increase in anaerobic glycolysis with the deleterious 
accumulation of H+ ions and lactate, resulting in intracellular acidosis and 
impairment in fatty acid metabolism (Lopaschuk et al., 2010). Functionally, 
these changes are followed by a rapid loss of contractile function of the 
affected region and by electrical abnormalities that may result in severe 
arrhythmias. Moreover, the cytosolic and mitochondria calcium levels 
increase and lead to activation of proteases, disruption of myocytes 
ultrastructure, cell swelling, and, eventually, to the physical disruption of 





The oxygen reduction also leads to an increase in reactive oxygen species 
(ROS) production by the mitochondrial electron transport chain. These also 
contribute to lipid peroxidation, damage to the cellular cytoskeleton, loss of 
sarcolemmal integrity, and, finally, to cell death.  
Morphologically, a myocardial infarction usually starts in the 
subendocardium and proceeds towards the subepicardium. Cell death 
starts rapidly after occlusion in the subendocardium and is generally 
completed within 3-6 hours. By histological analysis, it is possible to notice 
an acute inflammation, induced by myocytes nuclear lysis and release of 
cell content, which occurs in subsequent phases during ischemic necrosis. 
In 12-72 hours, a prominent neutrophil infiltration in the infarct border 
zone is observed, followed by the invasion of the infarcted tissue; by day 5-
7, macrophages and fibroblasts begin to appear in the infarct border area. 
After 1 week, neutrophils decline, granulation tissue progressively replaces 
necrotic tissue and neocapillary invasion and both lymphocytic and plasma 
cell infiltrations are evident. Lymphocytes may be seen as early as 2-3 
days, but they are not prominent in any stage of infarct evolution, while 
eosinophils are present in the inflammatory infiltrate in only 24% of 
infarcts. By the second week, fibroblasts are mainly present; they actively 
produce and deposit collagen, forming a fibrotic infarct scar. Healing is 
usually completed in 4 weeks, but may also require 8 weeks or more, 
depending on the extent of necrosis.  
Recently, multiple evidence indicated that cardiomyocyte death following 
ischemia also involves other types of cell death, such as apoptosis and 
autophagy. These conditions are thought to lead at later stages to necrosis. 
Apoptosis is energy dependent and characterized by absence of 
inflammation. Microscopically apoptotic cells show nuclear chromatin 
condensation and formation of small dense bodies; no cell membrane 





with cell shrinkage occurring.  Lysosomes are intact inside the cells and 
neither inflammation nor fibrosis is induced, because apoptotic cells are 
phagocytosed by neighboring cells or macrophages (Takemura and 
Fujiwara, 2004). Ischemic myocytes also can undergo autophagy. This 
degradation process of endogenous proteins and organelles by the 
lysosomes is activated in conditions of energy deprivation and allows the 
recycling of proteins or organelles (Yan et al., 2005). Autophagy is also 
observed in conditions of cell death and its mechanisms are very different 
from those of necrosis or apoptosis, because the recycling of proteins by 
autophagy might rather be a survival mechanism to generate energy and 
new peptides. For these reasons, autophagy may be a long-term survival 
mechanism sustaining the viability of chronically ischemic myocardium. 
The primary cardiac response to myocardial infarction (MI) is 
cardiomyocyte hypertrophy, which initiates a genetic program culminating 
in apoptotic myocyte loss, progressive collagen replacement, and 
enlargement of the left ventricle because cardiomyocytes are not able to 
actively regenerate after injury. Usually this process, termed cardiac 
remodeling, leads the ischemic heart to a pathological condition known as 
heart failure, which results in the progressive decline of ventricular 
performance.  
 
1.1.3 Congestive Heart Failure 
Heart failure is a complex syndrome that arises from inherited or acquired 
abnormalities of cardiac structure or function, which impair the ability of 
the heart to pump blood.  
The prevalence of congestive heart failure (CHF) in developed countries is 
1-2% of the adult population, and approximately 6-10% in the elderly. In 
the US, congestive HF is responsible for more than 30,000 deaths and 





population, increasing rates of obesity and diabetes, and the availability of 
interventions that prolong survival following cardiac damage, the incidence 
of heart failure will rise over the coming decades. The costs associated with 
an increasing number of patients and specialized treatments are 
contributing significantly to the economic burden caused by this pathology. 
Common causes of HF include disorders that chronically increase cardiac 
workload, such as loss of muscle due to myocardial infarction or pressure 
overload due to hypertension (Figure 1.4). The cardiac response to these 
conditions entails complex remodeling of cardiomyocytes and the non-
myocyte cells, which could initially be adaptive but, eventually, progress to 
contractile dysfunction, ventricular dilatation, and arrhythmias (Shah and 
Mann, 2011). This condition is usually called "congestive" heart failure 
because the heart's inability to pump correctly can cause blood and fluid to 
back up into the lungs or accumulate in the lower extremities. 
Signs and symptoms of heart failure include tachycardia, venous 
congestion (edema) and low cardiac output (fatigue). HF is generally 
diagnosed by echocardiography (to evaluate left ventricular function) or 
electrocardiography (to identify arrhythmias), chest radiography (to 
diagnose pulmonary edema), angiography (to evaluate the patency of 
coronary arteries in patients with history of coronary artery disease) and 








 Figure 1.4 Congestive heart failure progression  Initial events, structural remodeling during progression of disease and clinical 


































Development and progression of HF could be summarized in three 
sequential stages (Fedak et al., 2005):  
1) Preserved function: In the first stage, the myocardium injured or 
subjected to increased load decrease its pumping capacity, therefore 
numerous adaptive compensatory mechanisms are activated, in order to 
preserve a normal cardiac function. Usually, in this phase clinical 
manifestations are absent. Irrespective of the type, extent, and duration of 
the initial injury, the majority of patients will anyway progress to the 
second stage of HF; however, the timing of progression is variable and 
unpredictable. 
2) Compensated dysfunction: In the second stage of HF, the continued 
load, injury, and adaptive compensatory mechanisms act together to 
progressively deteriorate LV function. Usually the patients in this phase 
show moderate clinical manifestations that often require treatment. They 
exhibit myocardial hypertrophy and chamber dilatation and global cardiac 
function is abnormal. Despite the treatments, the majority of patients 
inevitably evolve towards the next stage of decompensated dysfunction 
(Swynghedauw, 1999). 
3) Decompensated dysfunction: In this phase, the LV structure and size are 
grossly abnormal and characterized by wall thinning, LV dilatation, and the 
global cardiac function is severely compromised. This final stage shows 
high morbidity and mortality and cardiac transplantation is often the only 
therapeutic solution.  
The most common cause of HF is ischemic heart disease, responsible for 
more than 60% of heart failure events. After the injury, as already 
mentioned, a series of initially compensatory, but subsequently 
maladaptive mechanisms, such cardiac remodeling, are activated in order 
to preserve normal cardiac output. Ventricular remodeling plays a key role 





et al., 2009). Alterations in genome expression resulting in molecular, 
cellular, and interstitial changes, whose clinical manifestations include 
modifications in the size, shape, and function of the heart after cardiac 
damage, are the major determinants of this process (Cohn et al., 2000).  
Ventricular remodeling could be divided into an early phase (within 72 
hours) and a late phase (beyond 72 hours). The early phase is 
characterized by the expansion of the infarct zone, which may lead to 
ventricular rupture or aneurysm formation. Late remodeling involves the 
left ventricle globally, and is associated with time-dependent dilatation, 
distortion of ventricular shape, and mural hypertrophy (Figure 1.5). The 
failure to normalize increased wall stresses results in progressive dilatation, 
recruitment of border zone myocardium into the scar, and deterioration in 
















Additional changes, such as increase in end-systolic and end-diastolic 
Figure 1.5 Left ventricle post-MI remodeling 
The early phase of post-MI LV remodeling is characterized by the formation of a 
fibrous scar in the infarcted zone, which progressively becomes thinner and start to 
elongate. On the other hand, the main feature of late remodeling phase is LV 
dilation, which is driven by myocyte hypertrophy, apoptosis and collagen deposition 


















volumes with decrease in ejection fraction and shortening fraction 
(Pennock et al., 1997) are frequently observed. 
Pathological remodeling is associated with the activation of 
neuroendocrine, paracrine, and autocrine factors, which are upregulated 
after myocardial injury and in a context of hemodynamic alterations.  
The renin-angiotensin-aldosterone axis, the beta-adrenergic pathway, 
increased oxidative stress and cell death, changes in calcium transit, 
release of proinflammatory cytokines and endothelin, energy deficit and 
collagen accumulation are all contributing factors involved in the onset of 
ventricular dysfunction (Konstam et al., 2011). Cardiac remodeling can be 
considered a central target for treatment in patients with congestive HF. 
Novel therapeutic strategies able to limit it by the modulation of molecular 
and cellular factors involved in tissue repair could be essential to improve 
patients’ outcome. Therefore, a better understanding of the complex 
mechanisms underling this process is absolutely required. 
 
1.1.3.1 Compensatory and pathological hypertrophy  
Cardiac hypertrophy is the common response of the myocardium to 
different kinds of stimuli and can be easily defined as an increase in heart 
mass (Bernardo et al., 2010). Cardiomyocyte hypertrophy is an adaptive 
mechanism that improves pump function by expanding the volume of 
contractile myocytes and reduces wall stress by increasing wall thickness. 
However, when excessive or prolonged, myocyte hypertrophy is 
maladaptive and it can directly results in congestive heart failure (Fedak et 
al., 2005). 
Physiological cardiac hypertrophy (during normal postnatal growth or in 
response to exercise or pregnancy) is reversible and is characterized by 
normal or enhanced cardiac function and by normal cardiac morphology, 





cardiac fibrosis. In contrast, pathological cardiac hypertrophy results from 
stressing stimuli such as hypertension, which is the most frequent cause of 
LV hypertrophy, valvular heart disease, myocardial infarction or neuro-
hormonal activation. It could also be due familiar hypertrophic 
cardiomyopathy, a well known hereditary condition with monogenic 
inheritance. Pathological hypertrophy is typically associated with loss of 
myocytes and fibrotic replacement, reduction of capillary density, cardiac 
dysfunction, and increased risk of heart failure and sudden death. In 
addition to the mentioned structural and functional alterations, during 
pathological hypertrophy modification of cardiac metabolism also occur. In 
particular fatty acid oxidation, which is the main metabolic pathway 
responsible for generating energy, accounting for 60–70% of ATP 
production, is dramatically reduced and paralleled by an increase in glucose 
metabolism (Stanley et al., 2005). Many pathways are implicated in 
cardiomyocyte hypertrophy regulation, acting through a complex network 
























Moreover, it is now well recognized that pathological hypertrophy is 
associated with alterations in cardiac contractile proteins (a decrease in - 
and an increase in -myosin heavy chain (MHC)), increased expression of 
fetal genes like atrial natriuretic peptide (ANP), B-type natriuretic peptide 
(BNP), -skeletal actin and down-regulation of calcium-handling proteins 
like sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a). 
In response to hemodynamic overload, autocrine and paracrine factors 
including Ang II, endothelin-1, IGF-1, TGF- and cardiotrophin-1 are 
released from cardiomyocytes and activate intracellular cascades that 
trigger Ca2+ release and the consequent induction of maladaptive 
hypertrophic signaling through calcineurin–NFAT activation or calmodulin-
dependent kinase (CaMK)–HDAC inactivation. The activation of MAPK 
signaling pathways is also linked to hypertrophy. This cascade is initiated in 
cardiomyocytes by GPCRs, receptor tyrosine kinases (IGF-I and FGF 
receptors), receptor serine/threonine kinases (TGF receptors), 
cardiotrophin-1 and by stress stimuli such as stretch (Heineke and 
Molkentin, 2006). MAPK cascade ends with phosphorylation and activation 
of p38, c-Jun, JNKs and ERK that phosphorylate multiple intracellular 
targets, including many transcription factors that induce the 
reprogramming of cardiac gene expression.  
According to the complexity of the pathological hypertrophic process, it is 
absolutely required that therapeutic strategies to counteract this disease 
aim at controlling these maladaptive signaling pathways. 
Figure 1.6 Cellular processes leading to the development of cardiac 
hypertrophy 
Growth of cardiac myocytes is dependent on the initiation of several events in 
response to an increase in functional load, including activation of signaling 
pathways, changes in gene expression, increases in the rate of protein synthesis, 







1.1.4 Peripheral Artery Disease 
Peripheral artery disease (PAD) is caused by the progressive narrowing of 
arteries in lower extremities, in particular the iliac, femoral, popliteal and 
tibial arteries are the most commonly affected. PAD is a relatively common 
manifestation of atherosclerotic vascular disease, associated with 
significant morbidity and mortality (Selvin and Erlinger, 2004; Tendera et 
al., 2011). PAD affects a total of 27 million people in Western Europe and 
North America, approximately 16% of the total population of these 
countries, with an age > 55 years. In the United States, a higher 
prevalence of PAD is observed among AfricanAmerican and Hispanic 
populations.  
Similar to coronary artery disease and cerebrovascular disease, the risk 
factors that contribute to the development of PAD are advancing age, 
hypertension, dysipidemia, diabetes mellitus, smoking and obesity. 
Additional risk factors associated with PAD include chronic kidney disease, 
low serum vitamin D levels, and the presence of inflammatory biomarkers 
such as homocystein, C-reactive protein, 2-microglobulin and cystatin C 
(Lau et al., 2011). 
The clinical presentation of PAD may vary from no symptoms to 
intermittent claudication, atypical leg pain, rest pain, ischemic ulcers, or 
gangrene (Olin et al., 2011). However only 10% to 35% of patients with 
PAD present typical claudication and 1% to 2% progress to critical limb 
ischemia (CLI), while 50% of all patients with PAD are asymptomatic. 
Although therapies to improve symptoms and reduce the complications of 
PAD are available, detection and treatment rates of this disease are still low 
(Watson et al., 2006). One explanation for this low rate is the absence or 
variability of symptoms in patients with the disease, which makes PAD 
frequently underdiagnosed and thus undertreated. Cardiovascular 





are symptomatic or not. Within 1 year from diagnosis, 25% of patients with 
critical limb ischemia die of cardiovascular disorders and another 25% 
suffer major limb amputation. Even patients with stable PAD or 
asymptomatics have a 20% incidence of myocardial infarction or stroke 
and 15% to 30% of mortality in 5 years (Gandhi et al., 2011).  
The treatment of subjects with critical limb ischemia is dependent on the 
severity of the symptoms and their impact on lifestyle. Patients with a mild 
to moderate disability are traditionally treated with a regimen of risk-factor 
modification and exercise, while patients with severe symptoms are usually 
revascularized by endovascular or surgical approaches, in order to preserve 
or restore function and limb viability.  
 
1.1.5 Conventional treatments for cardiovascular disorders  
 
1.1.5.1 Acute Myocardial Infarction 
The management of patients with an acute myocardial infarction (MI) 
event includes rapid restoration of blood flow by pharmacological and 
catheter-based means, block of recurrent ischaemic events through 
antithrombotic therapies, and treatments aimed at reducing the effects of 
myocardial necrosis and preventing future events (White and Chew, 2008).  
Usually, the immediate treatment for acute MI includes oxygen, aspirin and 
sublingual nitroglycerin. Nitroglycerin has a vasodilatory effect on the 
coronary and peripheral vessels; consequently, it leads to a decrease in 
myocardial wall stress and oxygen demand (Sami and Willerson, 2010). In 
addition, pharmacological reperfusion with fibrinolysis is the principal 
treatment for improving survival, frequently associated with percutaneous 
coronary intervention (PCI), an invasive treatment with cardiac 
catheterization and angioplasty. The number of patients who need a 





but CABG could be indicated after failed PCI (Van de Werf et al., 2008).  
As already mentioned, during PCI intervention patients are usually co-
treated with anticoagulant/fibrinolytic (heparin) and antiplatelet therapy 
(aspirin, clopidogrel and GPIIb/IIIa antagonists, able to block the final 
pathway of platelet aggregation). Other pharmacological therapies for the 
treatment of acute MI entail the use of -blockers (Baker et al., 2011). 
These drugs, which are used both during and after an acute MI, act by 
competitively blocking the effects of catecholamines on the cardiomyocyte 
membrane beta-receptors, reducing myocardial contractility, sinus node 
rate, and AV node conduction velocity. All these effects lead to a decrease 
in cardiac work and myocardial oxygen demand (Anderson et al., 2007). 
 
1.1.5.2 Long-term management of cardiovascular disease and 
heart failure 
Coronary heart disease is a chronic condition, and patients who have 
recovered from a MI are at high risk for new events and premature death. 
From 8 to 10% of post-infarction patients have a recurrent infarction within 
a year after the first event, and mortality after discharge remains much 
higher than in the general population. Control of risk factors of 
cardiovascular diseases has a favourable effect on the incidence of later 
cardiovascular events. In particular, prevention by controlled lifestyle, 
physical exercise and the use of drugs to improve cardiac functionality are 
the most common approaches for this class of pathologies. 
The pharmacological interventions for the management of patients affected 
by ischemic CVD and HF entail the use of different classes of drugs (Jessup 
and Brozena, 2003) (Figure 1.7): 
- Antiplatelet and anticoagulant: long-term administration of 
antiplatelet agents like aspirin leads to 25% reduction in the risk of plaque 





2002). The most commonly used agent is aspirin, but also other drugs with 
similar efficacy but greater cost are available, like the adenosine 
diphosphate receptor inhibitors clopidogrel, prasugrel and ticlopidine. 
- -blockers: several trials and meta-analyses have demonstrated that 
-blockers reduce mortality and reinfarction by 20–25% in those patients 
who have recovered from an infarction (Fonarow, 2005). The primary 
action of -blockers as -adrenergic receptor antagonists is to counteract 
the harmful effects of endogenous catecholamines like epinephrine, 
norepinephrine and other stress hormones, exerting an antihypertensive 
and antiarrhythmic effect. They are used for treating hypertension, angina, 
myocardial infarction, arrhythmias and heart failure. The first generation of 
-blockers (alprenolol, propranolol, etc.) was non-selective, meaning that 
they blocked both 1 and 2 adrenoceptors, while the second generation 
(atenolol, metopronol, etc.) is now more selective for the 1 receptor 
(Frishman and Saunders, 2011). Evidence from all available studies 
suggests that -blockers should be used indefinitely in all patients who 
have recovered from a STEMI and do not have any major contraindication. 
- Angiotensin-converting-enzyme (ACE) inhibitors: they induce 
vasodilation and reduce the activity of the renin-angiotensin-aldosterone 
system by inhibiting the formation of angiotensin II. This vasoconstrictor is 
formed by the proteolytic action of renin, released by kidney, acting on 
circulating angiotensinogen to form angiotensin I. Angiotensin I is then 
converted to angiotensin II by ACE, therefore its inhibition leads to a 
decrease in blood pressure. Moreover ACE inhibitors block the breakdown 
of bradykinin, promoting vasodilatation. Another class of drugs that share 
many common features with ACE inhibitors is the angiotensin II receptor 
blockers (ARBs). Commonly used for patients intolerant to ACE inhibitors, 
ARBs may offer more complete angiotensin II inhibition by interacting 





Controversy concerns the use of ARBs in patients with chronic heart failure 
who are already receiving ACE inhibitors; in patients at high risk for 
vascular events the combination of the two drugs was associated with 
more adverse events, without an increase in benefit (Yusuf et al., 2008). 
- Aldosterone antagonists: patients with heart failure produce an 
excess of adolsterone that can lead to coronary inflammation, cardiac 
hypertrophy, myocardial fibrosis, ventricular arrhythmias, and necrotic 
lesions. Aldosterone antagonists act as diuretics; they antagonize the 
binding of adolsterone to the mineralcorticoid receptor and therefore 
decrease the reabsorption of sodium and water and the secretion of 
potassium, reducing edema and cardiac workflow (Nappi and Sieg, 2011).  
- Statins: this class of drugs blocks the HMG-CoA reductase and, as a 
consequence, the cholesterol synthesis pathway, therefore they decrease 
the LDL cholesterol levels. Statins highly reduce the mortality of patients 
with pre-existing cardiovascular disease acting on cholesterol synthesis, but 
also modulating inflammatory response, endothelial function and increasing 
atherosclerotic plaques stability (Shanes et al., 2007). 
Beside pharmacological treatments also invasive interventions could be 
considered as therapeutic options for long-term management of existing 
vascular diseases. The three most common procedures are the already 
mentioned coronary artery bypass graft (CABG), percutaneous coronary 
intervention (PCI) and PCI with stent. CABG consists in the placement of 
grafts from the saphenous vein, but recently more often from internal 
mammary artery, to bypass stenosed coronary arteries. The main indication 
for CABG is for patients with left main coronary artery stenosis or multiple 
coronary arteries stenosis with reduced LV function, mainly among 
diabetics. The main indication for PCI is instead for low-risk patients with 
single or double vessel disease and poor response to medical treatment. 



















Despite the improvements in acute care and the impact of primary and 
secondary prevention, coronary artery disease remains the leading cause of 
death worldwide. The improved survival of infarcted patients treated with 
the common therapies and surgery has moreover led, in the last decades, 
to a dramatic increase in the number of patient with compromised LV 
function and suffering from heart failure (Davis et al., 2002; Stewart et al., 
2001). Considering the guidelines 2009 of the American Heart Association 
for treatments of HF (Hunt et al., 2009; Jessup et al., 2009), it is clearly 
evident that despite the availability of numerous drugs for the management 
of this pathology long-term prognosis associated with HF remains poor, 
indicating the need for new therapies. The current recommended 
treatments have been mainly developed more than 20 years ago thus novel 
treatments, able to counteract HF symptoms and also to directly impact on 
cardiomyocyte viability and function, are absolutely required. 
 
Figure 1.7 Main targets for 
heart failure treatment 
Treatment options for patients 
with HF target more than one 
organ system involved in HF 







1.2 BIOLOGICAL THERAPEUTICS AS NEW TREATMENTS 
FOR CARDIOVASCULAR DISEASE 
 
Current therapies for cardiovascular pathology essentially aim at either 
counteracting symptoms or slowing disease progression, whereas no 
treatment able to stop or revert the disease is available so far. Despite this 
lack of curative therapies, however notable progresses have been recently 
achieved in understanding the cellular and molecular mechanisms leading 
to cardiac disorders. Some of these mechanisms appear common to several 
forms of degenerative conditions (for example those involved in the 
regulation of cell apoptosis), whereas others seem to be more specific for a 
particular disease. It can thus be expected that biological therapeutics, able 
to interfere with different mechanisms of disease onset and progression, 
might offer novel, exciting therapeutic opportunities by interacting with 
both common and specific mechanisms of disease.  
Starting with insulin in the 1980s, over 350 biotechnological drugs have 
now gained clinical approval and over 400 have entered clinical trials 
(Rader, 2008; Walsh, 2006). These drugs also bear an important value 
from an economic point of view; in 2007, total recombinant protein-based 
drug sales were $54.5 billion, and are expected to increase to over $75 
billion in 2012 (Pavlou and Reichert, 2004). Typical biological therapeutics 
that have been successfully introduced into clinical practice include blood 
coagulation factors (Factor VIII and Factor IX), thrombolytic agents (tissue 
plasminogen activator), hormones (insulin, glucagon, growth hormone, 
gonadotropins), vaccines (hepatitis B surface antigen and human papilloma 
virus L1 capsid antigen), monoclonal antibodies, various growth factors and 
cytokines and, more recently, nucleic acid–based products.  
The delivery of nucleic acids for human therapy includes the use of coding 





biological therapeutics, including oligonucleotides, short RNA and DNA 
molecules with catalytic function, short RNAs with regulatory function 
(siRNA and microRNA), decoy RNA or DNA molecules and aptamers. 
Many of the mentioned classes of biological therapeutics have been 
explored in order to identify novel treatments for cardiovascular disorders 
and in particular recombinant proteins administration, cell and gene 
therapy approaches, so far offer the most promising therapeutic 
perspective in this field. According to the 2011 report from the 
Pharmaceutical Research and Manufacturers of America (PhRMA) 
(www.phrma.org) nowadays biopharmaceutical research companies are 
developing nearly 300 new treatments for cardiovascular diseases and the 
number is doomed to increase in the future. 
 
1.2.1 Recombinant protein administration
Recent evidence indicates that different cytokines and growth factors have 
a marked effect on cardiomyocyte viability and contractility in animal 
models of myocardial infarction and HF. In particular, factors able to 
stimulate therapeutic angiogenesis and therefore to increase the perfusion 
of the ischemic region, represent a novel and promising treatment for 
ischemic heart disease, mainly for patients who are not candidates for 
current methods of revascularization. Angiogenic growth factors, such as 
fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), 
insulin growth factor (IGF), hepatocyte growth factor (HGF) and others 
have demonstrated to promote in vivo new vessel formation and to exert 
beneficial effects in ischemic conditions, that are also broader when they 
are administered in combination (Kano et al., 2005; Lu et al., 2007). 
The members of the FGF family bind to various spliced isoforms of the FGF 
receptors and the activation of these receptors, which are expressed on 





proliferation of these cell types. In particular, FGF-1 and FGF-2 are highly 
angiogenic and may act synergistically with VEGF (Losordo and Dimmeler, 
2004). FGF-1 angiogenic properties have been widely described and it has 
been shown that its administration induces the development of new 
vascular structures in the ischemic human heart (Schumacher et al., 1998). 
Similarly, the administration of FGF-2 in patients with severe CHD was 
shown to improve myocardial perfusion, enhancing the development of 
collateral vessels (Laham et al., 2000; Udelson et al., 2000). These 
suggestions of therapeutic efficacy were tested in a double blind phase II 
trial, but, awfully, the results from the FGF-2 Initiating Revascularization 
Support Trial (FIRST) revealed that a single intracoronary infusion of 
recombinant FGF-2 did not improve exercise tolerance or myocardial 
perfusion but showed trends toward symptomatic improvement at 90 (but 
not 180) days, in patients with CAD (Simons et al., 2002). 
Hepatocyte growth factor (HGF) is another protein that, among its many 
functions, exerts also high proangiogenic activity. It acts through the 
receptor c-met, which is expressed on a variety of cells, including 
endothelial cells and hematopoietic stem cells (Morishita et al., 1999). In 
addition HGF is a potent anti-fibrotic factor, which plays an important role 
in the pathogenesis of fibrotic cardiovascular disease, like cardiomyopathy. 
Insulin-like growth factor I (IGF-I) also exhibits attractive therapeutic 
profile for the treatment of cardiac disorders. This molecule was described 
as a cardioprotective agent for the first time during the ‘90s (Buerke et al., 
1995), demonstrating that pre-treatment with this growth factor reduced 
myocardial necrosis, apoptosis, and neutrophils accumulation in a rat 
model of myocardial ischemia followed by reperfusion. IGF-I is a growth 
factor very similar to insulin, which is synthesized by various cell types, 
including cardiomyocytes (Ren, 2002). The IGF-I effects on the 





synthesis after the interaction of IGF-I with its specific receptors on 
endothelial cells (vascular function and regeneration) and cardiomyocytes 
(myocardial function and survival) (Conti et al., 2004). Many authors have 
extensively described the potential cardioprotective role of recombinant 
human IGF-I; however the temporal window and duration of IGF-I 
administration were demonstrated to be critical issues in determining the 
beneficial effects of this molecule. Indeed, persistent expression of IGF-I in 
a transgenic mouse model initially induced a physiologic hypertrophy, 
characterized by increased cardiac mass and improved systolic 
performance; however, later on this hypertrophy progressed to a 
pathological condition characterized by decreased systolic performance and 
increased interstitial fibrosis (Delaughter et al., 1999). Recombinant human 
IGF-I administration actions on cardiovascular system were studied both in 
health and disease conditions, with particular attention to HF (Donath et 
al., 1998; Duerr et al., 1995). However, no placebo controlled trial based 
on recombinant IGF-I administration has so far been conducted, neither in 
patients with acute atherothrombosis nor in patients with chronic ischemic 
heart disease. 
The proangiogenic factor most extensively studied is VEGF; the mammalian 
family of the vascular endothelial growth factor includes five structurally 
related proteins: VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth 
factor (PIGF). The biological effects of this class of molecules are mediated 
by cell surface tyrosine-kinase receptors (RTKs). In particular, VEGF-A and 
its splice variants preferentially activate VEGFR-1 and VEGFR-2, VEGF-B 
only VEGFR-1, whereas VEGF-C and VEGF-D stimulate VEGFR-2 and 
VEGFR-3, thereby contributing to lymphangiogenesis (Ferrara et al., 2003; 
Henry et al., 2003; Matsumoto and Claesson-Welsh, 2001). VEGF-A, usually 
referred to as VEGF tout court (Ferrara and Henzel, 1989), was discovered 





factor enhances migration, increases permeability and promotes survival of 
endothelial cells (ECs) (Zachary and Gliki, 2001). VEGF also exerts a variety 
of pleiotropic effects, which include a cardioprotective effect during acute 
ischemic conditions (Hausenloy and Yellon, 2009; Luo et al., 1997), by 
acting on cardiomyocyte survival. 
Successful therapeutic angiogenesis has been reported with VEGF protein 
in numerous preclinical models (Lopez et al., 1998; Pearlman et al., 1995). 
Initial clinical trials using intracoronary and intravenous recombinant VEGF 
protein demonstrated safety, tolerability, and encouraging clinical results 
(Hendel et al., 2000; Henry et al., 2001), leading to the VIVA (Vascular 
endothelial growth factor in Ischemia for Vascular Angiogenesis) trial 
(Henry et al., 2003). This trial did not reach some primary endpoints, such 
as exercise treadmill time or myocardial perfusion improvement (except for 
the high-dose VEGF group), revealing the main challenges of this 
therapeutic approach. The most obvious limitation of protein therapy is 
indeed the demand to maintain therapeutic concentration sufficient to 
induce the desired angiogenic response for an adequate time in the specific 
target tissue. More in general, a main obstacle for cardiac therapy based on 
recombinant proteins is clearly the way by which these are delivered. Oral, 
intravenous, intrarterial, or intramuscular routes for protein administration 
are not always as effective as desired, and the therapeutic protein can be 
metabolized or cleared before it can enter the target tissue. 
Gene transfer to the myocardium is nowadays considered the most 
promising alternative strategy to achieve prolonged local expression of 
angiogenic proteins in the target tissue. This technology will be described 








1.2.2 Cell Therapy 
Cell therapy could be defined as the transplantation of human or animal 
cells to replace or repair a damaged tissue. This concept appears certainly 
appealing in particular for cardiovascular pathologies, for which the 
possibility to regenerate or repair nonviable myocardium by delivery of 
stem or progenitor cells from many different sources could open novel, 
intriguing therapeutic perspectives.   
Traditionally, the heart was considered a post-mitotic organ and the 
possibility to obtain cardiac regeneration has been intensely investigated 
for more than 150 years (Carvalho and de Carvalho, 2010; Laflamme and 
Murry, 2011). However, recent evidence raises the possibility that a natural 
system of myocytes repair exists; around 45% of human cardiomyocytes 
are exchanged during life span, but of course this percentage is not 
sufficient to guarantee an adequate repair upon an ischemic insult 
(Bergmann et al., 2009).  
In both preclinical and clinical studies, the potential of various stem cell 
populations for cardiac repair has been analyzed (Figure 1.8): 
- Bone marrow-derived cells (BMCs): This heterogeneous cell 
population has been the most studied over the last 15 years in order to 
define cell therapy strategies for cardiovascular disorders. Initially this 
approach has been considered as a new opportunity to enhance cardiac 
performance by the possibility to induce trans-differentiation of the injected 
cells into cardiomyocytes (Orlic et al., 2001). Starting from this original 
evidence, several clinical studies, for both chronic ischemic disease and 
acute myocardial infarction, were initiated (Murry et al., 2005). Most of the 
trials for chronic myocardial ischemia, confirmed the safety of the 
procedure and a beneficial effect of the treatment on LV function after long 
follow up (Perin et al., 2003; Strauer et al., 2010; Tse et al., 2007; van 





involved patients with acute myocardial infarction. Several of these studies 
have demonstrated long-term (>3 years) improvement of ventricular 
performance after stem cell therapy, resulting in an increase in ejection 
fraction and decreased infarct size (Beitnes et al., 2009; Meyer et al., 2009; 
Schachinger et al., 2004; Schachinger et al., 2006; Strauer et al., 2002; 
van der Laan et al., 2008). The increase in cardiac performance, however, 
turned out to be modest in all these studies. This rather disappointing 
finding, together with the subsequent demonstration that BMCs actually do 
not differentiate into cardiomyocytes once injected in the heart (Balsam et 
al., 2004; Murry et al., 2004) has now markedly lowered the enthusiasm 
for BMCs transplantation. The modest, beneficial effect these cells exert 
might be explained by their paracrine secretion of growth factors, 
especially those stimulating angiogenesis (Du et al., 2008; Kocher et al., 
2001; Molina et al., 2009).
Bone marrow includes many different cell populations that possess the 
ability to proliferate, migrate and differentiate into various mature cell 
types including the aforementioned haematopoietic stem cells (HSC), but 
also endothelial progenitor cells (EPC), mesenchymal stem cells (MSC), 
multipotent adult progenitor cells and “side-population” cells. All these cells 
have been identified by specific surface markers and individually studied in 
order to characterize their beneficial potential after transplantation in 
ischemic hearts. Of these cell populations, a positive effect on cardiac 
function has been well established in particular for MSCs. Similar to the 
case of HSCs, the ability of MSCs to transdifferentiate into cardiomyocytes-
like cells is also controversial (Shi and Li, 2008; Toma et al., 2002; Wang et 
al., 2006). Clinical experience of cardiac cell therapy with MSCs is limited to 
date. The first published clinical trials (Chen et al., 2004; Hare et al., 2009; 
Yang et al., 2010) reported that these cells are very well tolerated after 





deaths reported during follow-up, and no induction of arrhythmias. 
Because of the promising efficacy data from the above-mentioned trials, 
the interest towards this therapeutic approach remains high and many 
clinical trials such as PROMETHEUS (NCT00587990) or POSEIDON 
(NCT01087996) are currently ongoing both for both MI and HF. 
- Cardiac progenitor cells: Several investigators have reported the 
presence of resident populations of cardiac progenitor cells (CPCs) in 
postnatal hearts, which were identified by the expression of specific surface 
markers such as c-Kit or Sca-1 (Beltrami et al., 2003; Matsuura et al., 
2004; Oh et al., 2003). CPCs expressing c-kit are the most extensively 
studied of these cells.  After isolation from rat and human hearts, c-kit+ 
cells have been reported to give origin to cardiomyocytes, smooth muscle 
cells and endothelial cells. Some studied indicated that, when transplanted, 
these cells induce extensive regeneration of myocardial infarction (Bearzi et 
al., 2007), whereas others suggest smaller-scale regeneration (Tang et al., 
2010). A clinical trial (NCT00474461) based on intracoronary infusion of 
this cell population is ongoing, but preliminary results of the phase I trial 
seem very encouraging (Bolli et al., 2011). Another CPCs population 
currently in clinical trial (NCT00893360) is cardiosphere-forming cells (CSs) 
(Barile et al., 2007; Messina et al., 2004). These cells grow as clusters, 
migrate from cultured cardiac tissue fragments and give rise to 
cardiomyocytes and vascular cells (Chimenti et al., 2010). However, the 
stemness of these cells has been recently questioned and it has been 
suggested that they could be mainly cardiac fibroblasts and that 
spontaneously beating CSs consist of contaminating myocardial tissue 
fragments (Andersen et al., 2009). So far, the randomized phase I trial 
confirmed the safety of intracoronary infusion of CSs in infarcted patients 
and highlighted an increase in viable myocardium after treatment (Makkar 





- Embryonic stem cells (ESc): This class of pluripotent cells is able to 
generate virtually all different cell types and tissues in the organism. 
Multiple evidence show that ESc can differentiate into cardiomyocytes and 
improve contractile function upon transplantation into the infarcted 
myocardium (Kehat et al., 2001). However, the risk of teratoma formation 
prevents the direct inoculation of these cells in vivo, and demands the 
complete in vitro differentiation of these cells into cardiomyocytes before 
transplantation (Nussbaum et al., 2007). Other problems preventing clinical 
translation of ESc are their allogenic origin, which can induce a strong 
immune response in target tissues (Saric et al., 2008), and of course the 
still opened ethical concerns related to this type of cells. 
 
- Induced pluripotent stem cells (iPSCs): The possibility to generate 
a population of pluripotent stem cells, with plasticity similar to that of ESc, 
by nuclear reprogramming of somatic cells, has recently opened completely 
new possibilities for cell therapy (Hochedlinger and Jaenisch, 2006; Yu et 
al., 2007). This approach could overcome the ethical issues related to the 
use of embryos to obtain ESc and could also allow to generate patient-
specific stem cells, avoiding problems related to immune rejection. Initially 
iPSCs were generated by retroviral vector delivery of four genes coding for 
transcription factors regulating “stemness” into skin fibroblasts (Takahashi 
and Yamanaka, 2006). More recently, many different strategies have been 
attempted to reduce the number of genes (now Oct4 seems to be the only 
one necessary for reprogramming) and to avoid the use of viral vectors 
(Kim et al., 2009; Okita et al., 2008). Some publications have 
demonstrated the ability of iPSCs to differentiate into functional 
cardiomyocytes and to exert beneficial properties in models of myocardial 
infarction (Mauritz et al., 2008; Nelson et al., 2009). Nevertheless, several 
problems related to the number of cardiomyocytes that can be generated 





solved before proceeding towards clinical translation for cardiac 
regeneration. 
 
- Adipose tissue-derived cells and umbilical cord-derived cells have 
been also reported to be able to prevent left ventricle dilatation and to 
enhance cardiac function after MI (Moelker et al., 2007; Planat-Benard et 
al., 2004). In particular the facilitation of access to fat and its abundance 
make adipose tissue-derived cells an appealing source for cell based 























































Figure 1.8 Cell therapy: features of different cell types 
In the picture the features of many cell types considered as candidates for cell 






1.2.3 Gene therapy approaches for cardiovascular disorders 
The growing knowledge of the underlying molecular mechanism of 
myocardial diseases has led to the definition, in the last decades, of novel 
potential therapeutic targets, such as genes coding for calcium handling 
proteins, sarcomeric and cytoskeletal proteins, angiogenic or antiapoptotic 
factors and many other important regulators involved in damaged heart 
protection or regeneration.  
In addition, an essential element for the development of effective gene 
therapy approaches for cardiovascular disorders is the identification of the 
best vector and gene delivery system for each pathological condition. In 
this direction many headway have been achieved in these years, in order to 
optimize strategies able to guarantee a high efficacy of myocardial gene 
transfer and a prolonged expression of the therapeutic gene in the target 
tissue. 
 
1.2.3.1 Targeting the heart: gene delivery strategies 
Nowadays a number of vectors and delivery strategies for gene transfer in 
the myocardium are available. Of course the pathological features of the 
disease, the timing of intervention and the role of the therapeutic gene, 
exert an essential role for the definition of the most effective one. 
While the choice of the transgenes can be easily modified with increasing 
knowledge in molecular biology and physiology, obtaining efficient and 
long-term delivery of the therapeutic genes seems to be the most critical 
point in clinical gene therapy approaches attempted so far (Muller et al., 
2007). 
In order to choose the best delivery option for cardiac gene therapy, it is 
important to consider that a vector has to overcome several physical 
barriers to reach the target cells and that these barriers can influence its 




















In particular, viral vectors need to escape neutralizing antibodies in the 
bloodstream, because a potential interaction can cause immune activation. 
Another barrier to cross whether the vectors are not directly injected into 
the myocardium is the endothelial cell barrier in the capillary wall (Di 
Pasquale and Chiorini, 2006). Once the vector reaches the interstitial 
space, it has to take advantage of the naturally occurring endocytosis and 
intracellular trafficking pathways and release the genetic material into the 
nucleus.  
As previously mentioned, the definition of an optimal gene delivery 
method, which allows the vector to overcome these barriers, is absolutely 
essential for successful gene therapy. Several routes have been used to 
administrate the therapeutic gene to the myocardium (Figure 1.10). 
Intracoronary delivery is usually the preferred way for global myocardial 
diseases, such as heart failure and cardiomyopathy. However, the barrier 
Figure 1.9 Delivery barriers for cardiac gene transfer 
Representation of different strategies to pass the cellular barriers and reach the 
nucleus: a) transvascular approach (intravenous, intraarterial, retroinfusion); b) 
intramyocardial injection; c) endothelial penetration mediated by viral vector; d) 
ultrasound mediated vector delivery; e) receptor mediated viral entry; f) DNA 
penetration of cell membrane by intramyocardial injection, liposome or ultrasound 














imposed by the coronary endothelium membrane may limit the diffusion of 
the vectors and the consequent distribution and uptake of the therapeutic 
transgene; moreover this route of administration could also lead to 
significant collateral organs gene delivery. In contrast, intramyocardial 
injection could be a desirable method for gene transfer to specific areas of 
myocardial disease and this approach has been extensively exploited to 
deliver angiogenic and cytoprotective genes to ischemic myocardium 
(Isner, 2002; Schwarz et al., 2000). With this strategy, however, transgene 
expression is restricted to the area near the site of injection, and multiple 
injections are often required to treat the damaged tissue and to induce a 
therapeutic effect. Anyway the direct gene delivery approach was the first 
one that allowed to establish the efficacy of cardiac gene therapy and it has 
been successfully used both in experimental models and in Phase I/II 
clinical trials, demonstrating its therapeutic relevance (Kornowski et al., 












In addition, a variety of catheters have been developed both for 
intracoronary and intramyocardial delivery (Sylven et al., 2002; Vale et al., 
2001). As already mentioned, antegrade intracoronary injection is one of 
Figure 1.10 Delivery routes 
of a therapeutic gene to the 
heart 
The five routes most commonly 
used for the administration of 
therapeutic genes into the 
heart include: intramyocardial 
and epicardial direct injection, 
intracoronary infusion using 
catheters, intraventricular 
delivery or retroperfusion (Melo 














the most direct way to deliver vectors to the myocardium (Kawase et al., 
2008), while another strategy less commonly used is the retrograde 
injection into the coronary sinus or cardiac vein (Raake et al., 2004). 
Recently, a novel technique that allows a closed recirculation of vector 
genomes in the cardiac circulation using cardiopulmonary bypass (MCARD) 
has been developed. This approach efficiently isolated the heart from the 
systemic circulation in vivo and resulted in global cardiac-specific LV gene 
expression (White et al., 2011). A direct injection of the vector into the 
myocardium, on the other hand, can be achieved surgically or 
percutaneously, by direct or catheter-based ventricular delivery or by 
pericardial delivery (Fromes et al., 1999; Katz et al., 2011; Ly et al., 2007). 
 
1.2.3.2 Cardiac gene targets  
As mentioned in the previous paragraph a significant evolution in the 
understanding of the pathophysiology of cardiovascular disorders has been 
reached over the past 20 years and several genes have emerged as 
potential targets for gene therapy approaches. Strategies for rescuing the 
failing myocardium included the delivery of genes coding for proangiogenic 
growth factors, in order to promote neovascularization of ischemic 
myocardium or, in the post-infarction period, the inhibition of genes 
involved in regulation of ventricular remodeling such as the matrix 
metalloproteinases (MMPs) that participate in extracellular matrix 
degradation. In addition, potential strategies for rescuing contractile 
function include over-expression of the sarcoplasmic reticulum calcium 
ATPase (SERCA2a), -adrenergic receptor, and adenylate cyclase. 
Moreover, many approaches to obtain cardiac protection have been 
described, such as the overexpression of cytoprotective and pro-surviving 





inhibition of genes expressing pro-inflammatory proteins. These 
approaches are briefly described below. 
 
Angiogenic gene therapy 
Genes coding for factors able to induce therapeutic angiogenesis are 
certainly the most explored in these years, with numerous clinical trials 
already completed (Giacca and Zacchigna, 2012; Yla-Herttuala and Alitalo, 
2003). Therapeutic blood vessel growth into an ischemic tissue can be 
achieved by gene transfer, either as single vectors or in combinations, of 
members of the VEGF family, FGF family, by HGF, IGF-I, PDGF, 
angiopoietins, hypoxia inducible factor–1 (HIF-1) and also by several 
other “less popular“ molecules, currently under investigation. 
Traditionally, new blood vessel formation in the adult life occurs through 
capillary sprouting from pre-existing vessels. The process starts with the 
proliferation and migration of endothelial cells, paralleled by a wide 
extracellular matrix remodeling. Afterwards, the new capillaries 
progressively mature by the addition of mural cells (pericytes and smooth 
muscle cells) allowing proper functionality, and a vascular network formed 
by arterioles and venules is formed (Risau, 1997).  
In physiological conditions, the main regulator of angiogenesis is hypoxia. 
In situations of low oxygen, the transcription factor HIF-1 (Hypoxia 
Inducible Factor–1) activates the expression of many genes such as the 
vascular endothelial growth factor (VEGF) and its receptors, which are 
essential for the angiogenetic process (Giacca, 2007). Thanks to its 
prominent role in promoting neovascularization, VEGF has been the most 
investigated molecule for the promotion of therapeutic angiogenesis. As 
already mentioned, the VEGF family is composed of five members (VEGF-A, 
B, C, D and PlGF), with different isoforms arising from alternative splicing 





four main isoforms of 189, 165, 149 and 121 amino acids and among them 
VEGF-165 is the most potent in promoting new blood vessels formation 
(Giacca, 2010; Rissanen and Yla-Herttuala, 2007).  
In addition to the results obtained by recombinant VEGF administration 
(described in section 1.2.1), also the in vivo overexpression of VEGF by 
viral vectors has been shown to stimulate excellent angiogenesis, 
remodeling of the capillary network and consequent perfusion increase, 
both in ischemic and healthy skeletal muscle and myocardium (Giacca and 
Zacchigna, 2012). VEGF-165 gene therapy mediated through plasmids or 
adenoviral vectors in rats induced significant neovascularization and 
improved fractional shortening after infarction (Hao et al., 2007; Schwarz 
et al., 2000). In porcine and dog models of MI, VEGF-165 increased 
myocardial blood flow, improved wall thickening (Jacquier et al., 2007), 
increased ejection fraction and myocardial viability (Ferrarini et al., 2006) 
thereby leading significant benefits to cardiac function. Also in models of 
hind limb ischemia, VEGF-165 delivery as naked DNA or by adenoviral 
vector gene transfer induced capillaries and arterioles sprouting and 
augmented development of collateral vessels (Rissanen et al., 2005; 
Takeshita et al., 1996; Tsurumi et al., 1996).  
Another important member of the VEGF family, which is emerging as a 
major cytoprotective factor, is VEGF-B. This factor selectively binds VEGF 
receptor (VEGFR)-1, a receptor that does not mediate angiogenesis; 
therefore it exerts its cardioprotective action upon AAV-mediated gene 
delivery in infarcted myocardium by limiting apoptotic cell loss and delaying 
the progression toward heart failure (Pepe et al., 2010; Zentilin et al., 
2010). 
 
Beside VEGF, another gene extensively studied for the induction of 
therapeutic angiogenesis is FGF. The FGF family actually includes 22 





(Itoh and Ornitz, 2011). These factors are potent endothelial cell mitogens 
and also act as ligands for other cell types including vascular smooth 
muscle cells and fibroblasts. FGF-1 (aFGF) and FGF-2 (bFGF) are the 
prototypic members of the family and they were the first that were shown 
to induce new blood vessel growth both after plasmid mediated 
transduction (Ishii et al., 2004; Kondoh et al., 2004) or by viral gene 
transfer (Muhlhauser et al., 1995). Also FGF-4 and FGF-5 showed peculiar 
angiogenic properties when administered by adenoviral vectors into 
ischemic skeletal muscle (Giordano et al., 1996; Rissanen et al., 2003). 
HGF has been also studied as pro-angiogenic factor. Human HGF gene 
transfer induced angiogenesis in rats and swine after MI (Aoki et al., 2000; 
Wang et al., 2006). Additionally, it has been shown that HGF improves 
remodellng and contractility of the heart (Jin et al., 2004), decreases 
apoptosis and fibrotic scar formation after injury (Ahmet et al., 2002). 
Moreover the role of platelet-derived growth factors (PDGFs), especially 
PDGF-B, in the recruitment of pericytes to growing vessels makes them 
attractive candidates for combined use with VEGFs, in order to obtain a 
better microvascular maturation and collateral growth, resulting in a 
significant gain in perfusion and muscle function (Kupatt et al., 2010). 
 
Besides endothelial cell sprouting, functional new blood vessel formation 
also requires other factors that act at later time points to promote vessel 
maturation. Among these, an essential role is played by the angiopoietins. 
Angiopoietin-1 and -2 (Ang-1 and Ang-2) form an agonist–antagonist pair 
of molecules that modulate the maturation of blood vessels via binding to 
Tie-2 receptor. Ang-1 is anti-inflammatory and acts stabilizing vessels, and 
counteracting VEGF-induced vascular permeability (Arsic et al., 2003; 
Thurston et al., 2000). Ang-2 is the natural antagonist of Ang-1; it binds to 





angiogenesis in the absence of VEGF (Lobov et al., 2002). 
In addition to the genes mentioned above, other candidate therapeutic 
genes, currently under investigation to induce therapeutic angiogenesis, 
include HIF-1 (Patel et al., 2005), eNOS (Namba et al., 2003), Del-1 
(Zhong et al., 2003), IGF-I and IGF-II (Su et al., 2003), netrins (Wilson et 
al., 2006), stromal cell derived factor-1 (Hiasa et al., 2004), Sonic 
hedgehog (Kusano et al., 2005) and various transcription factors like zinc 
finger transcription factors, which could induce simultaneous expression of 
many growth factors and cytokines, leading to a more natural angiogenic 
response (Yamamoto et al., 2010).  
 
Gene therapy to rescue contractile function 
Rescue of contractile function is another potential target for cardiac gene 
therapy. The failing myocardium is characterized by alterations in calcium 
handling, decreased myofilament sensitivity, excessive catecholamine 
release, and adrenergic receptor down-regulation and desensitization, 
leading to a decrease in contractility (Towbin and Bowles, 2002). The 
genetic manipulation of these therapeutic targets represents a potential 
strategy for HF treatment. 
A hallmark of HF is the presence of alterations in cardiac -adrenergic 
signaling, which is mediated by the 1 (the most abundant) and 2 
adrenergic receptors (-ARs). These alterations, including receptors down-
regulation, up-regulation of -AR kinase and increased inhibition of Gi 
protein function, lead to -ARs desensitization and decreased signaling 
through their pathway. Overexpression of -AR was initially tested as a 
simple way to overcome its downregulation, but transgenic mice 
overexpressing the human 1 receptor gene in the heart suffered from 
severe cardiomyopathy (Engelhardt et al., 2004), although this did not 





On the contrary, the overexpression of 2-AR led to an improvement in LV 
function in different animal models (Maurice et al., 1999; Shah et al., 
2000), suggesting a potential benefit of 2-AR enhancement. The two 
receptors activate the same pathway (AC-cAMP-PKA pathway), but 2-AR is 
coupled to both Gs and Gi and probably this is the reason of the different 
phenotype caused by their individual overexpression (Hata et al., 2004).  
Other possible gene therapy approached are based on the inhibition of G-
protein-coupled receptor kinases (GRKs), which regulate the receptor 
activity and are usually overexpressed in HF (Dzimiri et al., 2004; Penela et 
al., 2010), or on the activation of cardiac adenylyl cyclase VI activity, often 
downregulated in failing hearts (Phan et al., 2007). Both strategies have 
demonstrated their efficacy in a large number of preclinical studies 
(Rebolledo et al., 2006; Williams et al., 2004). 
Ca2+ plays a crucial role in contraction and relaxation of the cardiac muscle; 
therefore gene therapy strategies for normalization of myocardial cytosolic 
calcium transients also have shown promising results in experimental 
models of heart failure. Usually, an action potential at the cell membrane 
induces Ca2+-influx through sarcolemmal L-type calcium channel and this 
triggers further Ca2+ release from the sarcoplasmic reticulum (SR) to the 
cytosol via the major SR Ca2+-release channel ryanodine receptor (RyR2). 
Ca2+ then binds troponin C on the myofilament, triggering the contraction 
process, while muscle relaxation occurs when Ca2+ detaches from the 
troponin complex and is either taken up into the SR by 
sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA2a) (responsible 
for 75% of Ca2+ removal in humans) or removed by the sarcolemmal 
Na2/Ca2+ exchanger (NCX) (Bers, 2008). 
A decrease in SERCA2a activity has been observed in HF, therefore 
different gene therapy approaches has been developed, aimed at 





delivery of Adv-SERCA2a in a rat model of HF showed improvement in LV 
function and survival rate 28 days after treatment (del Monte et al., 2001). 
Similar results were obtained by AAV1-SERCA2a administration through 
epicardial coronary artery infusion in pigs with mitral valve impairment 
(Kawase et al., 2008). Starting from these results, a clinical trial based on 
AAV1-SERCA2a gene delivery to the myocardium of patients with HF was 
initiated, which will be described in section 1.2.3.3 (Hajjar et al., 2008; 
Jaski et al., 2009). 
Another interesting gene therapy target is phospholamban (PLN), a protein 
implicated in regulation of SERCA2a activity. When unphosphorylated, PLN 
inhibits SERCA2a, while PLN phosphorylation relieves its inhibitory effect 
and results in increased SERCA2a activity with improved Ca2+ handling. In 
order to act on PLN in experimental HF models, PLN inhibitory or dominant-
negative molecules have been developed. In the first case, a mutant form 
of PLN with a mutation at serine-16 (S16E), the site of PKA action, 
generated and used to promote SERCA2a activity. AAV-mediated 
overexpression of PLN-S16E prevented post-MI cardiac dysfunction in both 
hamsters and rats models of HF (Hoshijima et al., 2002; Iwanaga et al., 
2004) and intracoronary administration of an AdV-PLN-S16E in a sheep 
model of cardiomyopathy led to a clear improvement in cardiac activity 
(Kaye et al., 2007). Moreover, an RNAi therapeutic approach based on 
rAAV9-shPLB intravenous administration was tested in a rat model of HF, 
showing a restoration of LV function (Suckau et al., 2009).  
Other critical players in this process are the protein phosphatase 1 (PP1), a 
serine/threonine phosphatase that dephosphorylates PLN in the heart and 
its inhibitor phosphatase inhibitor protein 1 (I-1). The inhibition of PP1 and 
the activation of I-1 have been shown to enhance cardiac function in 






Gene therapy for myocardial protection 
Oxidative injury plays a critical role in several cardiovascular diseases 
including myocardial infarction, myocardial ischemia/reperfusion (MI/R) 
injury, atherosclerosis, hypertension, cardiomyopathies and HF (Abrescia 
and Golino, 2005; Levonen et al., 2008). Reoxygenation of the ischemic 
myocardium increases the formation of reactive oxygen species (ROS), 
which cause lipid peroxidation, protein oxidation and affect Ca2+ handling 
proteins, such as RYR2 and SERCA2a. Gene therapy aimed at increasing 
antioxidant activity or inducing the expression of cytoprotective genes has 
therefore been devised as a promising strategy against I/R injury. This 
novel concept of preventive gene therapy may potentiate the native 
protective response of the myocardium, rendering it resistant to future 
ischemic insults and thereby minimizing the need for acute intervention 
(Wu et al., 2009).  
In this perspective, viral vector-mediated overexpression of most 
antioxidant enzymes, such as superoxide dismutase (SOD), glutathione 
peroxidase (Gpx), catalase or hemeoxygenase-1 (HO-1) has been tested in 
different animal models of myocardial I/R injury. Extracellular superoxide 
dismutase (Ec SOD) overexpression in rats and rabbits infarcted hearts was 
shown to improve LV ventricular function, decrease infarct size and prolong 
survival (Agrawal et al., 2004; Li et al., 2001). Similar results were obtained 
by AAV-mediated HO-1 transduction in a model of rat myocardial infarction 
(Liu et al., 2007; Melo et al., 2002). Significant protection from ROS-
induced injury was also achieved by overexpression of other antioxidant 
enzymes such as Cu/Zn SOD (Woo et al., 1998), catalase, and glutathione 
peroxidase (Shiomi et al., 2004).  
Additional strategies to obtain myocardial protection from ischemic damage 
have been devised targeting genes involved in cell death pathways. For 





of the anti-apoptotic protein Bcl-2 reduced the rate of cardiomyocyte 
apoptosis and preserved heart function (Chatterjee et al., 2002).  
Another gene therapy target is the heat shock proteins family (HSPs); 
adenoviral-mediated HSP-70 gene delivery to the rabbit heart before MI 
decreased infarct size (Okubo et al., 2001), and similar results were 
obtained by gene transfer of HSP-20 in rat myocardium, 4 days before an 
acute I/R injury (Zhu et al., 2005). Cardiac protective properties of 
numerous genes have been described over time in various preclinical 
models, among these, are the pro-survival genes Akt (Cittadini et al., 
2006), kallikrein (Agata et al., 2002), cardiotrophin-1 (Ruixing et al., 2007) 
TGF-1 (Dandapat et al., 2008), leukemia inhibitory factor (Berry et al., 
2004) and others.  
A potential strategy for protection from I/R injury may also entail the 
inhibition of proinflammatory genes activated by damage. A decoy 
oligonucleotide inhibiting the action of NF-B has been shown to reduce MI 
size in rats (Morishita et al., 1997); besides, approaches based on in vivo 
delivery of NF-B inhibitors (IBs) were able to obtain comparable 
beneficial effects on injured myocardium (Squadrito et al., 2003). In 
addition, TNF- is a pro-apoptotic cytokine and the delivery of its 
antagonist, the soluble TNF- receptor-1 gene, reduced infarct size and 
improved cardiac function after MI in mice (Sugano et al., 2004). 
From the results described above it is possible to conclude that the long-
term overexpression of anti-oxidant enzymes and/or cytoprotective genes 
in the myocardium provides a promising strategy for enhanced protection 
from cardiac injury. In the future, further understanding of molecular 
apoptosis and autophagy pathways, could therefore define novel, 
interesting targets for therapeutic gene therapy approaches aimed at 






1.2.3.3 Clinical trials for therapeutic cardiovascular gene therapy 
Among cardiovascular gene therapy trials, the vast majority was designed 
to induce therapeutic blood vessel growth using growth factors, mainly 
VEGF (Atluri and Woo, 2008; Zachary and Morgan, 2011). 
As previously reported, after the identification of VEGF and FGF as powerful 
inducers of angiogenesis, various clinical trials were conducted delivering 
these factors as recombinant proteins, but despite the brilliant results 
obtained in preclinical models, the administration of these proteins 
produced only modest or no result at all in the treated patients. To 
overcome the limitations associated with this approach several clinical trials 
based on VEGF or FGF gene transfer, were started in the last 15 years, 
initially based on naked plasmid DNA delivery. The first pilot trials were 
based on the administration of plasmid DNA encoding human VEGF165 for 
treatment of hind limb ischemia (Baumgartner et al., 1998; Isner et al., 
1996); these studies reported the resolution of rest pain and an increase in 
collateral vasculature after treatment. A series of over 20 clinical trials 
followed, which entailed the injection of naked plasmids encoding VEGF to 
the myocardium by different routes of administration. In many trials the 
treated patients exhibited an improvement of clinical status, myocardial 
perfusion, collateral growth and LV function (Losordo et al., 1998; Sarkar et 
al., 2001; Vale et al., 2001). Most of these procedures were well tolerated, 
with few major adverse cardiac events and without complications related to 
gene expression. However, these results should be interpreted with 
caution, considering the uncontrolled, open-label design of the trials. 
Indeed, a double-blinded, placebo-controlled experimentation performed 
few years later (the Euroinject One trial) failed to show any significant 
difference between injection of a plasmid encoding VEGF165 and placebo 





trial, also involving VEGF-165 plasmid delivery, did not show any 
improvement in perfusion in patients with angina (Stewart et al., 2009). 
Other ongoing clinical trials, also based on naked plasmid DNA gene 
transfer, take advantage of a plasmid encoding FGF-1. After a phase II, 
double-blind, randomized, placebo-controlled trial in patients with critical 
limb ischemia, no improvement in wound healing was observed, however 
the treatment significantly reduced the risk of amputation and might thus 
lower mortality rates (Nikol et al., 2008). Finally, two additional trials used 
naked DNA for gene transfer in patients with PAD; the first was based on 
the delivery of HGF (Powell et al., 2008), while the second was based on 
the administration of a plasmid encoding the angiomatrix protein Del-1 
(developmentally regulated endothelial locus 1) and both showed not 
significant clinical efficacy (Rajagopalan et al., 2004). 
Despite the relative ease of production of naked plasmid DNA, the clinical 
success obtained by their direct injection has been generally poor, mainly 
because of the low efficiency of tissue transfection and transgene 
expression. Given these limitations, other clinical trials exploited adenoviral 
vectors to deliver therapeutic genes.  
In the REVASC trial, the administration of Ad-VEGF121 via intramyocardial 
injection in patients with severe angina resulted in increased exercise time 
and improved anginal symptoms at 26 weeks of follow up (Stewart et al., 
2006). The same vector was also tested in the RAVE trial, a phase II study 
designed to test efficacy and safety of intramuscular delivery of this vector 
in subjects with PAD. In this study however a single intramuscular 
administration of Ad-VEGF121 was not associated with improved exercise 
performance or quality of life, and did not support further experimentation.  
Two trials assessed the efficiency of an adenovirus expressing VEGF165 or 
of a plasmid expressing the same gene delivered in a liposome formulation 





trial). Both the adenovirus and liposome formulations were reported to 
increase the collateral vessels of the treated limbs 3 months after therapy 
and to enhance myocardial perfusion in the CAD patients 6 months after 
therapy (Hedman et al., 2003; Makinen et al., 2002). 
The angiogenic gene therapy (AGENT) trials have addresses the safety and 
efficacy of delivery of an adenoviral vector expressing FGF-4 (Ad5FGF4) in 
patients with stable angina. These trials established that intracoronary 
administration of this vector was safe, and that a single dose could provide 
an anti-ischemic effect up to 12 weeks of evaluation (Grines et al., 2002; 
Grines et al., 2003). These preliminary results led to a phase II/III trials, 
but unfortunately, the obtained preliminary data clearly indicated that the 
trial, as designed, would provide insufficient evidence of efficacy, and 
further recruitment was stopped in 2004 (Henry et al., 2007). 
Despite the initial highly positive results, therefore, the overall outcome of 
the subsequent randomized trials has been much more disappointing. 
Certainly novel vectors and improved delivery methods are needed before a 
real clinical success might be reached. The only viral vector system that, at 
present, appears suitable for gene therapy of cardiovascular disorders is 
based on AAV. As discussed in chapter 1.3, these vectors display many 
appealing features for gene transfer to the heart and skeletal muscle and, 
for this reason, they probably will play a central role in the clinical 
cardiovascular gene therapy experimentation in the next future. 
As already mentioned, most of the ongoing clinical gene therapy trials 
target the revascularization of the ischemic myocardium, as chronic HF is 
most commonly caused by myocardial infarction. However, HF can also be 
due to a variety of causes that cannot be managed by angiogenesis. 
Taking into account the molecular pathways involved in HF, few other gene 
candidates, identified and characterized in extensive preclinical studies, are 





Based on a large amount of data in preclinical models, the first phase I 
clinical trial (CUPID) was recently started in HF patients, through 
intracoronary infusion of AAV1-SERCA2a. This trial exploited, for the first 
time, AAV vectors-mediated delivery strategies to express the therapeutic 
gene in the heart. The results of this study demonstrated a good safety 
profile and improvements at 12 months of LV functional parameters (Jaski 
et al., 2009). The safety profile of this phase I study led to the approval of 
a double-blind placebo-controlled randomized trial of AAV1-SERCA2a. At 6 
months, the AAV1-SERCA2a–treated patients demonstrated improvement 
or stabilization in many functional parameters, demonstrating that 
SERCA2a is a critical target in the pathogenesis of HF.  
Two other clinical trials targeting SERCA2a are currently enrolling patients. 
The first trial is in patients with advanced HF and who will receive either 
AAV6-SERCA2a or saline. A second, Phase II double-blind randomized 
placebo-controlled, parallel study will be performed, with the primary 
objective to investigate the impact of AAV6-CMV-SERCA2a on cardiac 
remodeling parameters in patients with severe HF.  
In a recent randomized, double-blind phase I/II clinical trial, which is still 
enrolling patients, the safety and efficacy of adenoviral gene transfer of 
human adenylyl cyclase type 6 (AC6) will be assessed in patients with 
congestive HF (trial NCT00787059). An additional trial is then examining 
the effects of Stromal Cell-derived Factor-1 (SDF-1) intramyocardial 











1.3 ADENO-ASSOCIATED VIRAL VECTORS (AAVs)  
 
1.3.1 Molecular biology of Adeno-Associated Virus  
The Adeno-Associated Virus (AAV) is a small non-enveloped, single 
stranded (ss) DNA virus with a diameter of 18–25 nm, belonging to the 
family Parvoviridae and the genus Dependovirus. The members of this 
genus, in contrast to those belonging to the other genus (erythroviruses) of 
the Parvoviridae family, are incapable of autonomous replication and 
depend on the superinfection of the cells with another virus to complete 
their replicative cycle, hence the name. The AAV name derives from its 
original isolation as a contaminant of cell cultures infected with adenovirus 
(Atchison et al., 1965). In the absence of helper virus (adenovirus, but also 
herpesvirus), AAV (serotype 2) can establish latency by integrating into 
chromosome 19q13.4, representing the only mammalian DNA virus capable 
of site-specific integration (Daya and Berns, 2008).  
The members of the Dependovirus genus are very diffuse in nature; twelve 
human serotypes ad more than 100 AAV variants from nonhuman primates 
have been discovered to date, and new serotypes are continuously 
identified (Gao et al., 2005). Although all AAV serotypes share a similar 
structure, size and genome organisation, each serotype has a specific 
tissue tropism, essentially determined by the capacity to bind different cell 
surface receptors. Despite the high seroprevalence of AAV in the human 
population (approximately 80% of humans are seropositive for AAV2) the 
virus has not been linked to any human pathology. 
 
1.3.1.1 Genome organization and structure of virions 
The AAV has a linear single-strand DNA genome of about 4.7 kb and 
contains two open reading frames, corresponding to the genes rep and 





The rep region codes for replication-related proteins while the cap region 
codes for the three structural proteins VP1, VP2, and VP3 that together 
form the viral capsid (Srivastava et al., 1983). Through the use of two 
different promoters, (p5 and p19) and the inclusion or not of an exon, the 
rep gene codes for 4 protein isoforms (Rep78, 68, 52 and 40) (Figure 
1.11). The larger Rep proteins (Rep78 and Rep68) are transcribed from 
the P5 promoter, whereas Rep52 and Rep40 from the P19 promoter. 
Rep78 and Rep68 are important regulatory proteins that act in trans in all 
phases of the AAV life cycle; indeed they regulate AAV gene expression and 
are required for DNA replication and integration. Rep52 and Rep40 instead 
are involved in the accumulation of single-stranded viral genomes from 
double-stranded replicative intermediates, for packaging within AAV capsids 
(Chejanovsky and Carter, 1989). All four Rep proteins have helicase and 
ATPase activity and Rep78 and Rep68 possess also strand- and site-specific 
endonuclease activity and site-specific DNA binding activity.  
The structural proteins VP1, VP2 and VP3 are generated from the cap gene 
from a single promoter (p40), but using three different start sites for 
translation. All the AAV transcripts have the same polyadenylation site, 
located at the 5' of the genome. VP1, VP2 and VP3 together assemble into 
the capsid shell, with icosahedral symmetry (T=1), a diameter of 18-25 nm 
and which is composed by 60 subunits, with a ratio of 1:1:18 for the three 
proteins (each virion has 3, 3 and 54 VP1, VP2 and VP3 proteins 
respectively). The capsid includes the viral genome, a single stranded DNA, 
having either positive or negative polarity; usually, in any AAV preparation, 
about half of the virions have a DNA with positive polarity and the other 
half a DNA with negative polarity. Moreover, VP1 protein contains a 
phospholipase A2 (PLA2) motif that seems to be required between the 
translocation of the AAV genome into the nuclear compartment and the 





Recently, it has been shown that AAV encodes another protein required for 
capsid formation by means of a nested, alternative ORF of the cap gene. 
This protein, designated assembly-activating protein (AAP), is localized in 
the host cell nucleolus, where AAV capsid morphogenesis occurs. AAP 
targets newly synthesized capsid proteins to this organelle; this event 




















As mentioned above, the coding region of the viral genome is flanked by 
two ~145 nucleotides (nt) long inverted terminal repeats (ITRs), of which 
first 125 nt constitute a palindrome, which folds upon itself forming a T-
shaped hairpin structure, identical at the two viral ends (Bohenzky et al., 
Figure 1.11 Organization of the AAV genome 
Rep and cap genes flanked by the ITRs. The different Rep and Cap transcripts are 






1988). The ITRs provide a free 3’ hydroxyl group essential for the initiation 
of viral DNA replication by a mechanism of self-priming single-strand 
displacement, involving leading-strand and double-stranded replicative 
intermediates synthesis (Berns, 1990). The virus does not encode a 
polymerase and exploits cellular polymerase activities to replicate its DNA 
(Ni et al., 1998). For viral genome replication and integration, the presence 
of the Rep68 or Rep78 proteins is also essential. These proteins specifically 
bind the Rep binding element (RBE), a sequence within the ITR, and cleave 
in a site- and strand-specific manner at the terminal resolution site (TRS) 











In addition, the ITRs play a key role in viral genome integration into the 
host genome as well as in the subsequent rescue of viral DNA from the 
integrated state. A 33 bp sequence spanning the chr19 RBE and the TRS 
homology element, called AAVS1, is present in human chromosome 
19q13.4 and represents the minimal sequence necessary and sufficient for 
AAV site-specific integration (Kotin et al., 1990; Samulski et al., 1991). The 
AAVS1 region is located in a centromeric position with respect to the genes 
Figure 1.12 AAV2 Inverted Terminal Repeats (ITRs)  
AAV2 ITR secondary structure showing the Rep binding element (RBE) and the 






coding for the slow skeletal muscle troponin T (TNNT1) and cardiac 
troponin I (TNNI3), located 15 and 26 kb apart respectively (Dutheil et al., 
2000). Recently novel hotspots near consensus RBE were identified on 
chromosome 5p13.3 (AAVS2) and on chromosome 3p24.3 (AAVS3), 
demonstrating that targeted AAV integration is not as strictly specific for 
AAVS1 as previously assumed (Huser et al., 2010). 
The ITRs are the only sequences preserved during AAV vectors generation, 
while a transcriptional cassette (composed by a promoter, the therapeutic 
gene and the polyadenylation site) substitutes the rep and cap genes. 
 
1.3.1.2 AAV life cycle  
As described in the previous paragraph, the AAV life cycle strictly depends 
on the presence or absence of host cell co-infection with a helper virus 
(Figure 1.13). In the presence of helper virus (adenovirus or herpesvirus), 
a lytic stage ensues and AAV undergoes productive infection characterized 
by genome replication, viral gene expression, and viral particles production. 
Adenovirus and herpesvirus provide different genes for helper function, but 
they both regulate cellular gene expression, providing a permissive 
intracellular environment for AAV productive infection.  
On the other hand, under non-permissive conditions, the AAV genome 
mainly integrates into the AAVS hot spots regions, where it establishes a 
latent infection for indefinite periods of time. The viral components that are 
required for target integration have been identified. These include the 
already mentioned ITRs and Rep78 and Rep68 proteins, but also a 138-bp 
sequence, the integration efficiency element (IEE), located within the P5 
promoter in cis (Feng et al., 2006; Philpott et al., 2002).  
When a latently infected cell is super-infected with a helper virus, the AAV 
gene expression program is re-activated, leading to the AAV Rep-mediated 





and packaging of the viral DNA. The lytic phase of AAV life cycle can also 
be induced in the absence of a helper virus, though with less efficiency, 
when the host cell is subjected to DNA damaging agents such as UV or -



















1.3.1.3 AAV infection 
Viral infection is a process that requires virions to pass through different 
steps (receptor binding, cell entry, intracellular trafficking, endosomal 













































Figure 1.13 AAV life cycle  
Permissive conditions allow the AAV replicative cycle, which ends with the release of 
novel viral particles from the host cell. On the contrary, under non-permissive 
conditions, the viral DNA undergoes site-specific integration into the AAVS1 region 







release, viral uncoating and nuclear entry) before delivering the genome 
into the nucleus for replication. A detailed understanding of this process is 
pivotal to overcome limitations and to optimize the efficiency and safety of 















Cell membrane attachment. The first step in AAV infection consists in 
the binding of the virus to specific receptors, which mediates its entry 
inside the cell. Heparan sulphate proteoglycan (HSPG) has been identified 
as one of the primary attachment receptors for AAV2 (Summerford and 
Samulski, 1998), but after virus binding the interaction with a coreceptor 
seems to be necessary for internalization of the virus. So far at least six 
coreceptors are known, including v5 integrins (Summerford et al., 1999), 
FGFR-1 (Qing et al., 1999), HGFR (Kashiwakura et al., 2005), v1 integrin 
(Asokan et al., 2006), and 37/67 kDa laminin receptor (Akache et al., 
2006). The laminin receptor has been also indicated as the primary 
attachment receptor for AAV8. HSPG has also been reported to represent 
Figure 1.14 AAV intracellular trafficking 
AAV infection is a multistep process. After the entry of the virus trough receptor-
mediated endocytosis, the trafficking of the viral particles to the nucleus involves 
different pathways, leading to endosomal release, viral uncoating and nuclear entry 






the binding receptor for AAV3, while sialic acid is the primary attachment 
receptor for AAV4 and AAV5. AAV5 primarily uses N-linked sialic acid for 
binding and platelet-derived growth factor receptor has been identified as 
its coreceptor (Di Pasquale et al., 2003; Walters et al., 2001), whereas 
AAV4 preferentially uses O-linked sialic acid for attachment (Kaludov et al., 
2001). AAV1 and AAV6, whose capsid proteins differ in only six amino 
acids, both uses N-linked sialic acid for binding (Wu et al., 2006), while 
recently has been shown that N-linked glycans with terminal galactosyl 
residues represent the primary receptors for AAV9 (Shen et al., 2011).  
Endocytosis and intracellular trafficking. After receptor binding, 
internalization is the next step in the AAV viral entry pathway. AAV2 is 
internalized through clathrin-coated pits (Bartlett et al., 2000), while AAV5 
seems to use both coated pits and caveolae during this process (Bantel-
Schaal et al., 2009). In the first case, viral endocytosis is dependent from 
dynamin, a 100 kDa cytosolic GTPase that regulates the pinching off of 
clathrin-coated vesicles from the cell membrane (Duan et al., 1999).  
The cellular events that mediate AAV trafficking post-entry are not 
completely characterized. The endocytosis process has been associated 
with many signaling pathway molecules; because integrins are known AAV 
coreceptors, their pathways have been extensively analyzed. The activation 
of the GTP-binding protein Rac1 and its downstream molecule PI3K is 
essential for intracellular movement of AAV2 to the nucleus via both 
microfilaments and microtubules (Sanlioglu et al., 2000). 
For a successful AAV infection to occur, the viral particles need to escape 
from these endocytic vesicles. The lowering of the pH inside these 
compartments during their maturation from early to late endosomes, 
triggers conformational changes of the viral capsid leading to exposure of 
previously hidden regions; this process seems to be essential for virus 





As already mentioned, the phospholipase A2 (PLA2) motif at the N-terminal 
of VP1 has been reported to exert a critical role in this phase, probably 
inducing pore formation in the endocytic vesicles (Stahnke et al., 2011; 
Zadori et al., 2001). However, on the basis of studies performed in AAV2, 
AAV5 and canine parvovirus, at least five potential trafficking pathways 
have been postulated, involving multiple types of endosomes, lysosomes 
and the Golgi apparatus (specifically for AAV5), as shown in Figure 1.14 
(Ding et al., 2005).  
Nuclear translocation. Once AAV has escaped from the endosomes 
some of the virions are ubiquitinated and degraded by the proteasome, 
while others traffic to the nucleus. Experimental studies have shown that 
inhibition of the proteasome leads to an accumulation of AAV genome into 
the nucleus, in the case of AAV2 and other different serotypes, such as 
AAV7 and AAV8. These findings suggest that proteasome-mediated 
degradation may represent a significant limitation of AAV-mediated 
transduction in certain cell types (Yan et al., 2004).  
For a long time, the process of AAV nuclear translocation has been 
considered slow and inefficient. In most studies, only a small portion of 
internalized AAV can be found in the nucleus at short time points post-
infection, with a prominent accumulation of viral particles in the perinuclear 
compartment (Bartlett et al., 2000). However, following the movement of 
free virus in the cytoplasm and the nucleus by real-time imaging of 
fluorescent AAV, it was suggested that ATP-dependent molecular motors 
on tubular networks probably facilitate this traffic that seemed much faster 
than previously observed (Seisenberger et al., 2001). Relatively little is still 
known on the processes that control the nuclear translocation of the virus 
across nuclear pores. Theoretically, the 26-nm diameter capsids of the 
parvoviruses should be able to pass through the nuclear pore complex 





indicates that the viruses might not enter the nucleus through the NPC, 
despite the NLS- targeting sequences in the N- terminus of VP1 that are 
exposed during entry. Disruption of the nuclear envelope has been 
observed indicating a pore-independent mechanism of AAV nuclear entry 
(Cohen et al., 2006).  
Uncoating. Viral uncoating is believed to occur in the nucleus; 
consistently, several investigators have reported the presence of 
fluorescent capsids inside cell nuclei (Sanlioglu et al., 2000; Seisenberger et 
al., 2001). Moreover, nuclear injection of antibody against intact capsids 
dramatically reduced viral transduction (Sonntag et al., 2006). On the 
contrary, other studies using GFP labelled viruses concluded that the entry 
of intact AAV capsids into the nucleus is inefficient and favoured the 
occurrence of viral uncoating before or during nuclear entry (Lux et al., 
2005). A recent study has demonstrated that AAV2 virions enters the 
nucleus and accumulates in the nucleolus, whereas empty capsids are not 
able to reach the nucleus. The subsequent mobilization of the virions from 
the nucleolus permits uncoating and subsequent gene expression or 
genome degradation (Johnson and Samulski, 2009). Viral uncoating is 
considered a rate-limiting step of transduction. Recently, it was reported 
that the rate of viral uncoating is serotype- and cell-specific (Sipo et al., 
2007). 
Genome processing and viral particles release. After virion uncoating, 
the free AAV ssDNA genomes must be converted into dsDNA to be 
transcribed. As mentioned in the previous paragraph, the AAV DNA, during 
the lytic phase, undergoes second-strand synthesis, using the ITR 3’ OH 
free end as a primer for the host-cell DNA polymerases. This conventional 
replication scheme requires de novo synthesis of the complementary DNA 
strand, but an alternative mechanism, involving the annealing of 





(Nakai et al., 2000).  
It is known that AAV viral particles contain both sense and antisense ss 
genomes at equivalent numbers. Therefore, when multiple viral genomes 
transduce the same cell, the two strands could potentially anneal. These 
two possible mechanisms are not mutually exclusive and their relative 
contribution to AAV transduction has been investigated through the use of 
modified ss AAVs that are able to package only one polarity of the vector 
genome, thus precluding the process of complementary strand annealing 
(Zhong et al., 2008; Zhou et al., 2008). Single-polarity vectors transduce 
different cell types with the same efficiently as conventional ss AAV, 
supporting the hypothesis that second-strand DNA synthesis is a primary 
pathway in dsDNA conversion.  
Once the second strand has been generated, the fate of the input viral 
genome is still under the control of host cell factors. As mentioned before, 
under non-permissive conditions, the viral genome enters a latent cycle 
and integrates into the host cell DNA in a site-specific manner. On the 
contrary, whether the infection process is productive, at the end of the 
replication process two viral genomes are generated, with complementary 
polarity and both of them are packaged inside the virions at equal 
efficiency. In a few hours, every cell produces 5x105-1x106 viral particles; 
the infected cells eventually are lysed and the virions released outside.  
It is still largely unclear which are the molecular determinants governing 
cell permissivity to productive AAV replication. A number of treatments 
increase the efficiency this process, including co-infection with adenovirus, 
DNA-damaging agents (ultraviolet, !-irradiation, X-radiation, alkylating 
agents, radiomimetic drugs, etc.), agents that inhibit DNA synthesis 
(hydroxyurea), thereby suggesting that DNA damage repair (DDR) 
mechanisms may be involved in transduction (Alexander et al., 1994). In 





AAV genome. Indeed, the AAV genome, similar to damaged cellular DNA, is 
single-stranded and bears imperfectly paired DNA sequences at the level of 
its terminal hairpins (Cervelli et al., 2008; Zentilin et al., 2001). These 
proteins block replication of the genome by impeding its conversion to a 
double-stranded form. Once the cell is treated with chemical or physical 
agents, the DDR proteins are recruited to other sites of cellular DNA 
damage, thus permitting the AAV genome to complete its replication. 
 
1.3.2 Recombinant AAV vectors  
The characteristics of AAV life cycle, including its defectiveness and ability 
to persist in infected cells as a latent viral genome, early suggested that 
this virus could be an excellent tool for in vivo gene transfer (Tratschin et 
al., 1984). In the early 1980s, pioneering work on the successful cloning of 
AAV established the foundation of recombinant AAV vectors capable of 
expressing foreign genes in mammalian cells (Coura Rdos and Nardi, 
2007).  
AAV vectors are usually obtained starting from the AAV2 genome, cloned in 
a plasmid form, by removing all the viral sequences (rep and cap ORFs) 
with the exception of the two 145 bp ITRs (Hermonat and Muzyczka, 
1984). Between the ITRs, an expression cassette is cloned containing the 
therapeutic gene and its regulatory elements (Figure 1.15). The ITR 
sequences of the parental virus are the only required cis elements for viral 
genome replication and its packaging into viral particles, while the excised 
structural and non-structural proteins can be provided in trans, by an 
helper plasmid. In contrast to retroviruses, the replicative cycle of which 
involves the generation of both RNA and DNA genomic forms and in which 
the choice of the promoter is thus critical to determine the vector 
efficiency, AAV replication only involves DNA intermediates. As a 





therapeutic gene, without interfering with the production of vectors. This 
includes strong constitutive, inducible or tissue-specific promoters.  
The only strict requirement is that the transcriptional cassette cloned 
















As already mentioned, site-specific integration of AAV genome is dependent 
on the Rep proteins. The rep gene is removed from the vector DNA 
genome, therefore the current generation of AAV vectors persists inside 
non-dividing cells mainly as extrachromosomal DNA; many studies have 
confirmed the long-term role of the DNA episomes in transgene expression 
(Nakai et al., 2001; Schnepp et al., 2005). Although rAAV episomes are the 
main actors in long-term transduction, viral integration could occur as well, 
but this event is very rare. In this case, given the absence of Rep, the 
vector genome integrates in a random manner (Miller et al., 2005). Recent 
studies have demonstrated that AAV vectors exhibit a preference for 
targeting DNA palindromes of at least 20 bp arm-length, near gene 
regulatory sequences (Inagaki et al., 2007; Nakai et al., 2005). Given the 
lack of homology between vector sequences and chromosomal junction 
points, non-homologous recombination is probably the mechanism 
responsible for integration (Rutledge and Russell, 1997). 
Figure 1.15 Recombinant AAV vectors structure 
A rAAV vector is constructed from its wild type counterpart by replacing the Rep and 
Cap genes with an expression cassette, containing the therapeutic gene and its 













1.3.2.1 rAAV vector production and purification 
Traditionally, rAAV production was based on co-transfection of the vector 
plasmid together with a second plasmid, supplementing the rep and cap 
gene functions, into Adenovirus-infected cells (usually HEK293 or Hela 
cells) (Merten et al., 2005). In this case, the resulting viral preparation was 
contaminated with adenoviral particles that could easily induce a relevant 
host immune response. To avoid this problem, adenovirus co-infection was 
afterwards substituted by the co-transfection of a third helper plasmid 
providing the adenoviral sequences (E2A, E4, VA), necessary for AAV 
replication (Xiao et al., 1998). Nowadays, a single packaging/helper 
plasmid containing both the AAV2 rep and cap genes and the adenoviral 
helper genes is the most exploited system for AAV2 vector generation; in 
this case, the production of vectors involves cell transfection with only two 
plasmids (Grimm et al., 1998b). For the other serotypes, a separate Cap 
expressing plasmid is transfected along with the vector and a helper 
plasmids. Since the transfection method has been often considered 
unsuitable for large-scale production, many efforts have been attempted in 
the past in order to overcome the dependency on transient transfection, 
establishing packaging cell lines stably expressing the rep and cap genes 
(Liu et al., 2000). Nonetheless, these efforts have met very limited success 
so far, mainly due to the cellular toxicity caused by a constitutive Rep 
protein expression (Saudan et al., 2000). For these reasons, transient 
transfection still remains the method of choice to obtain AAV vector 
preparations. 
After 48 hours from transfection, the cells start to show a cytopathic effect, 
due to viral replication, and a large number of virions are present both in 
the supernatant and in cell lysates. AAV genomes are very resistant to 
treatment with chemical and physical agents; thus, they can easily be 





chromatography (O'Riordan et al., 2000; Zolotukhin et al., 1999), for large-
scale production. The obtained viral preparations are pure and the titers 
can reach or surpass 1x1014 viral particles/ml, achieving concentrations 
higher than those obtained from either VSV-G-pseudotyped retroviral 
vectors or adenoviral vectors. 
A standard AAV production protocol entails utilization of the AAV2 ITRs in 
conjunction with the AAV2 rep and cap genes. However, the capsid 
proteins corresponding to any AAV serotype can recognize the AAV2 ITRs 
and mediate packaging of the AAV2 genome inside the virions. By this 
strategy, it is possible to obtain chimeric viral particles simply by using, 
during production, an expression vector for any desired cap gene 
(Rabinowitz et al., 2002).  
 
1.3.2.2 Properties of AAV-based vectors 
This increasing interest on AAV vectors for in vivo gene transfer is justified 
by their characteristic features that distinguish them from others viral 
vector systems.  
Based on a widely diffused, non-pathogenic virus, AAV vectors retain less 
than 10% of the original viral genome; they maintain only the viral 
sequence corresponding to the ITRs, which greatly improves their safety 
for human clinical applications by reducing the risk of recombination with 
wild-type virus. These vectors do not express any viral protein, therefore 
they are not immunogenic and do not cause inflammation. As a 
consequence, therapeutic gene expression usually lasts for years after 
transduction; this represent a major requirement for many gene therapy 
approaches and constitutes one of the most distinguishing features of AAV 
vectors.  
AAV vectors transduce particularly well post-mitotic tissues such as brain 





and pigment epithelium cells) and skeletal muscle (myofibers). In these 
tissues they persist in an episomal form, probably as head-to-tail or head-
to-head extrachromosomal concatamers, therefore avoiding the problem of 
insertional mutagenesis typical of retroviral vectors. 
Finally, AAV vectors can be generated at high titers and exhibit a high 
multiplicity of infection, thus allowing the simultaneous expression of 
different genes from the same cells or tissues. This property could be of 
great importance in light of the possibility to deliver in vivo multiple growth 
factor coding genes, which represent one of the main point of this Thesis.  
 
1.3.2.3 rAAV vector optimization 
Several novel technologies have recently been developed to optimize 
different properties of AAV vectors, with the aim to improve the therapeutic 
potential of this class of vectors. In particular, these concern the 
development of innovative approaches to overcome the limitations imposed 
by the AAV genome size and the conversion of the genome to a dsDNA 
format. 
AAV vectors with increased genome capacity 
The small packaging capacity of AAV vectors is one of their main 
limitations, since, in some instances, it excludes the possibility to deliver 
therapeutically important genes or large regulatory elements. Taking 
advantage of the ability of the AAV genomes to form head-to-tail 
concatamers in the target cells through intermolecular recombination in the 
ITRs, a system based on the split of a long transgene between two AAV 
vectors able to recombine was developed (Yan et al., 2002; Yan et al., 
2000). Transcription from the recombined molecules is followed by trans-
splicing of the ITR sequences, resulting in a functional gene product 
(Figure 1.16). Although this approach has allowed the delivery of almost 





was lower than using rAAV vectors encoding a full-length transgene. More 
recently, the strategy to generate these vectors has undergone revision 
















Enhanced gene expression 
AAV is a ssDNA virus, but both wild type AAV genes and rAAV-mediated 
transgene expression require the conversion of ss to dsDNA before 
transcription. By mutating one of the ITRs, it is possible to generate 
vectors that exclusively package self-complementary AAV (scAAV) DNA 
genomes; these vectors can fold upon themselves, immediately forming 
transcriptionally competent dsDNA, which results in greater and more rapid 
in vivo transduction (McCarty et al., 2003). The main disadvantage of this 
approach, however, is the need to limit the transgene size to approximately 
Figure 1.16 Trans-splicing strategy 
A large gene is divided into two AAV vectors. One of them contains a promoter, the 
5' half of the gene and a splice donor site (SD), while the other a splice acceptor 
sequence (SA), the 3' portion of the gene and a polyadenylation signal. Both the 
cassettes are cloned between ITRs sequences. Intermolecular recombination 
between the two vectors restores the full-length gene and results in the synthesis of 
the desired protein after the splicing of the ITR sequences from the primary 



















AAV serotypes and molecular engineering of the capsid 
Nowadays, at least 12 different serotypes, and over 100 AAV variants, have 
been isolated from adenovirus stocks and tissues of human, nonhuman 
primate, and other animal sources. All these viruses share a similar 
structure, genome size and genetic organization and only differ in the 
amino acid forming the capsid proteins (Gao et al., 2005). Despite the 
isolation of such a wide variety of AAV variants, AAV2 still represents the 
best-characterized AAV serotype; its cellular entry, trafficking and 
replication have been extensively described and therefore its genome 
constitutes the starting point for the generation of recombinant AAV 
vectors. However, AAV-2 vectors are rather inefficient at transducing some 
tissues such as liver and, in addition, gene transfer might be hampered by 
neutralizing anti-AAV-2 antibodies, which are highly prevalent in the human 
population.  
Figure 1.17 Structure of scAAV vectors 
Comparison between classical rAAV (on the left) and self-complementary AAV 





In recent years, significant efforts have been made on isolating new AAV 
serotypes and engineering AAV capsids, in order to increase the efficiency 
of vectors transduction and also to target non-permissive cells. Since the 
capsid is an essential vector component for cell infection, starting from the 
natural serotypes, capsid mutant have been generated by different 
strategies.  
As reported above, the most exploited approach has been the generation 
of pseudo-typed AAV vectors, combining the AAV2 genome with different 
capsid serotypes. Each of the currently available serotypes exhibits a 
specific profile of transduction efficiency and tissue tropism (Figure 1.18). 
Recombinant AAV2 infects a broad number of tissues, such as skeletal 
muscle, heart, brain and kidney, while rAAV1, rAAV6 and rAAV7 are more 
specific for the muscle (Blankinship et al., 2004; Louboutin et al., 2005). 
Retinal epithelium is efficiently transduced by rAAV4 (Weber et al., 2003) 
and rAAV5 and the latter exhibits strong tropisms also for the lung 
(Auricchio et al., 2002). Regarding the central nervous system, rAAV 
serotypes 1, 2, 4, 5, 7, and 8 have been found to be efficient transducers 
of neurons in different regions of the brain (Burger et al., 2004; Taymans 
et al., 2007). Recombinant AAV8 and rAAV9 are able to pass through the 
endothelial blood barrier so, when systemically administered by 
intraperitoneal or intravenous injection, they transduce a wide number of 
tissues throughout the body. AAV9 appears to be the most naturally 
cardiotropic serotype (Bish et al., 2008; Pacak et al., 2006). As mentioned 
above however, although extremely high levels of cardiac expression are 
observed after rAAV9 administration, other organs (including liver, skeletal 
muscle, and pancreas) also display high levels of transduction (Inagaki et 
al., 2006; Prasad et al., 2011). AAV8 and AAV9 exhibit also the higher level 
of hepatocyte transduction (Sands, 2011).  Serotypes 10 and 11 resemble 





lung and AAV10 targets also the liver (Mori et al., 2004). AAV12 targets 
muscle and nasal epithelium, however, little is still known about its cell 















In addition to investigations on the naturally occurring serotypes, many 
efforts are underway to modify AAV capsids for designer tissue tropism or 
immune system evasion (Kwon and Schaffer, 2008). “Mosaic” AAV vectors, 
for example, have been generated mixing VP capsid subunits from different 
serotypes. The advantage of this technique is the ability to combine 
selective features from different sources that synergistically enhance 
transgene expression (Hauck et al., 2006; Rabinowitz et al., 2004).  
Another exploited approach has been the adsorption of receptor ligands to 
the AAV capsid surface. For example AAV-specific antibodies able to 
interact with receptors expressed from non-permissive cells have been 
used, such as a bispecific F(ab’!)2 antibody with specificity for AAV2 capsid 
Organ Serotype 
Liver AAV8, AAV9
Skeletal muscle AAV1, AAV7, AAV6, AAV8, 
AAV9, AAV2, AAV3
CNS AAV5, AAV1, AAV4, AAV2
Eye Retinal 
epithelium






Figure 1.18 AAV serotype tropism 





and the surface receptor IIb3 expressed by non-permissive megakaryocyte 
cells (Bartlett et al., 1999). Another study utilized biotinylated viruses able 
to react with a bispecific fusion protein, composed by avidin and FGF or 
EGF, in order to target the AAV vectors towards cells expressing FGFR or 
EGFR (Ponnazhagan et al., 2002). As an alternative to attaching molecules 
to the capsid surface, another described approach has been the molecular 
engineering of the capsid by direct modification into the cap gene. An 
example of this technique is the generation of “chimeric” AAV vectors, 
containing capsid proteins that have been modified by domain- or amino 
acid-exchange between different serotypes. By exploiting the sequence 
homology between AAV serotypes to induce recombination, it has been 
possible to rescue infectious or target phenotypes in mutant virions 
(Bowles et al., 2003). This approach allows also the insertion of a foreign 
epitope into the capsid sequence. Of course, the success of this strategy 
requires a site on the capsid that is tolerant to the insertion, ensuring that 
assembly and DNA packaging within the mutant remains efficient. 
Modifications of the cap gene have been achieved by insertion of peptide 
sequences on the basis of known ligand–receptor interactions (Wu et al., 
2000), or have selected for peptides in phage-display libraries (Work et al., 
2006). Another strategy has been to insert random sequences of amino 
acids, followed by in vitro selection of the best performing capsids (Perabo 












1.4 GHRELIN: A GROWTH HORMONE (GH)-RELEASING 
PEPTIDE WITH PROMISING BENEFICIAL EFFECTS ON 
THE MYOCARDIUM 
 
The work described in this Thesis, which was focused on the selection of 
novel secreted factors able to defend the myocardium from ischemic 
damage, led to the identification of ghrelin as a powerful cardioprotective 
factor.  
In the last decade, the identification of ghrelin (GHRL) (Kojima et al., 
1999), a gastric polypeptide displaying strong growth hormone (GH)-
releasing activity by activation of the type 1a GH secretogogue receptor 
(GHS-R1a) located in the hypothalamus-pituitary axis, has introduced novel 
perspective in neuroendocrine and metabolic research. 
The major active product of the ghrelin gene is a 28-amino acid peptide, 
which becomes acylated at Ser3 position with an octanoyl group (C8:0). 
The same gene can also generate other bioactive molecule besides ghrelin, 
mainly obestatin and des-Gln14-ghrelin, obtained from alternative splicing. 
In addition, a vast part of ghrelin in the body remains non-acylated (des-
acyl ghrelin). Although the receptors for these other peptides have not yet 
been identified, the biological activity of these molecules suggests the 
existence of a complex system composed by multiple effectors. 
 
1.4.1 The discovery of ghrelin 
It is well established that GH release is stimulated by hypothalamic GH-
releasing hormone (GHRH) and inhibited by somatostatin (Anderson et al., 
2004). More recently, however, another pathway regulating GH release 
was identified from studies involving the GH secretagogues (GHSs). 
Synthetic GHSs are a family of synthetic, peptidyl and non-peptidyl, 





stimulating GH release, working through a G protein-coupled receptor 
(GPCR), the GHS-receptor 1a (GHS-R1a) (Korbonits et al., 1999). GHSs are 
artificial compounds and do not exist naturally. Therefore, it was assumed 
that an endogenous ligand that binds to GHS-R1a and exerts functions 
similar to GHSs must exist.  
To discover this natural ligand, the orphan receptor (GHS-R1a) was 
overexpressed in a cell line system and used to identify tissue extracts able 
to stimulate the receptor as monitored by a second messenger (Ca2+) 
activation. Several groups unsuccessfully tried to isolate the endogenous 
GHS-R1a ligand from extracts of brain, pituitary, or hypothalamus, the 
known sites of GHS-R1a expression. Unexpectedly, however, it was finally 
identified and purified through four steps of chromatography from the rat 
stomach in 1999 (Kojima et al., 1999; Kojima et al., 2001). This small 
peptide was called “ghrelin”, from “ghre”, the Proto-Indo-European root of 
the word grow, and “relin” that refers to its GH-releasing activities. 
The purified ligand was a peptide of 28 amino acids, mainly synthesized 
and secreted by X/A-like cells in the stomach (Ariyasu et al., 2001). Later 
on, ghrelin mRNA was also found in other tissues, such as gut, brain, small 
intestine, pancreas, heart, lung and others (Gnanapavan et al., 2002). The 
serine 3 residue of the peptide was n-octanoylated and this modification 
was observed to be essential for its GH-releasing activity. Although they 
share common functions, there was no structural homology between 
ghrelin and GHSs, such as GHRP-6 or hexarelin. 
The discovery of ghrelin clearly constituted an example of “reverse 
pharmacology”, starting with the synthesis of synthetic analogs, then 
leading to the isolation of a natural receptor and finally to the discovery of 







1.4.2 Ghrelin gene structure and derived-peptides 
The human ghrelin gene is located on chromosome 3p25-26; it consists of 
five exons and three introns (the short first exon is only 20 bp long and 
encodes for part of the 5’ untranslated region), and encodes for a 
transcript of 511 bp, corresponding to a 117 amino acids precursor called 
pre-proghrelin (Figure 1.19). This precursor contains a signal peptide and 
the pro-ghrelin protein, coding for the two mature peptides ghrelin and 
obestatin. As it enters the ER, pre-proghrelin is processed to pro-ghrelin by 
a cleavage, which removes the 23 aa sequence corresponding signal 
peptide-corresponding sequence. Pro-ghrelin is further processed to ghrelin 
by the enzyme pro-hormone convertase 1/3, which cleaves after arginine-
28 of pro-ghrelin, generating the mature 28 aa peptide (Zhu et al., 2006). 
Before this last cleavage, a post-translational modification occurs, which 
consists in the esterification of a fatty acid, usually n-octanoic acid, on the 
third amino acidic residue, which correspond to a serine (Ser3). As already 
mentioned, only acylated-ghrelin is able to bind the GHS-R1a, therefore 
this modification is considered essential for ghrelin biological activity. The 
enzyme responsible for the acylation has been recently discovered and 
named ghrelin-O-acyltransferase (GOAT) (Yang et al., 2008). GOAT is 
encoded by the MBOAT4 gene and is highly conserved in vertebrates. The 
relative tissue distribution of GOAT mRNA matches that of ghrelin and it is 
highest in stomach, but, recently, low levels of GOAT expression have also 
been observed in other tissues, including the heart (Lim et al., 2011). 
A mechanism of alternative splicing of the ghrelin gene transcript can 
trigger the production of a minor active isoforms of the molecule called 
des-Gln14-ghrelin, identical to the main form of the molecule, except for the 
deletion of glutamine in position 14. Des-Gln14-ghrelin undergoes the same 
process of acylation as ghrelin (Hosoda et al., 2000).   





ghrelin with acyl chains of 10 or 11 C has also been reported (Hosoda et 
al., 2003). These peptides showed lower calcium mobilization activity and 
GH-release than octanoylated ghrelin.  
In addition to Ghrelin, from the pro-ghrelin precursor another small peptide 
of 23 amino acids named obestatin is also generated (Seim et al., 2011). 
Obestatin seems to exert opposite effects to ghrelin on food intake, acting 
on a different G protein-coupled receptor (GPR39) (Zhang et al., 2005). 
Although this effect remains debated, other biological functions of obestatin 
have also been described, such as memory improvement, activation of 
cortical neurons and modulation of sleep (Carlini et al., 2007) 
Des-acyl ghrelin, lacking O-n-octanoylation at serine 3, is also produced in 
the stomach and constitutes the major molecular form secreted into the 
circulation. Plasma des-acyl/acyl ghrelin ratio ranges from 3:1 to 10:1 in 
different metabolic conditions (Garcia et al., 2005; Yoshimoto et al., 2002). 
However, des-acyl ghrelin does not bind GHS-R1a, and thus does not exert 
the same physiological function as ghrelin. While des-acyl ghrelin was 
originally considered inactive, it is now clear that this peptide exerts a 
number of autonomous functions, which will be described later. Most likely, 
these activities are mediated by an additional, not-yet identified, receptor, 
































Ghrelin is highly conserved in vertebrates (Figure 1.20).  Rat and human 
sequences, for example, differ in only two residues, and the 10 amino acids 
in the N-terminus of the protein, containing the acylated Ser3, are identical 
among all mammalian ghrelins. 
Studies dealing with the minimal sequence needed to activate GHS-R1a 
showed that the entire sequence is not necessary for ghrelin activity: short 
N-terminus tetra- or penta-peptides including the first Gly-Ser-Ser(n-
octanoyl)-Phe amino acids seem to constitute the “active core”, able to 
activate GHS-R1a (Bednarek et al., 2000). The n-octanoyl group of ghrelin 
is one of the principal structural features determining its potency on GHS-
R1a, which requires bulky hydrophobic groups at the side chain of Ser3. 
Figure 1.19 Human ghrelin gene 
The ghrelin gene is located on chromosome 3, it is composed of five exons and 
generate a 511 bp mRNA. The pre-proghrelin precursor contains a signal peptide 
and the proghrelin protein, which gives origin to the two mature peptides: ghrelin 


















1.4.3 Ghrelin receptors 
Since its discovery and characterization as a GH-releasing and orexigenic 
factor, acyl ghrelin has been demonstrated to be a pleiotropic molecule, 
displaying many different functions, which do not necessarily require the 
presence of the GHS-R1a. An increasing number of reports on the presence 
of specific binding-sites recognized by both acyl and des-acyl ghrelin 
(Bedendi et al., 2003) have suggested that GHS-R1a is not the only ghrelin 
receptor, but most likely one of the ghrelin receptor subtypes.  
 
1.4.3.1 Type 1a GHS Receptor (GHS-R1a) 
The ghrelin receptor, or GHS-R, is a typical GPCR with seven 
transmembrane domains (7-TM). The human GHS-R gene is located on 
chromosome 3q26.2, and is highly conserved across species (Camina, 
2006). This gene is composed of two exons (the first one encodes TM-1 to 
TM-5 and the second TM-6 and TM-7). Alternative spicing of the pre-mRNA 
generates two transcripts, designed GHS-R type 1a (GHS-R1a) and GHS-R 
type 1b (GHS-R1b) (Howard et al., 1996) (Figure 1.21).  
Figure 1.20 Ghrelin sequences comparison among vertebrates 
Ghrelin sequence is highly conserved among species and the N-terminus with the 
acyl-modification in the third serine (marked with as asterisk) is perfectly conserved 





The human full-length GHS-R1a is a polypeptide of 366 amino acids with 7-
TM domains, which exhibits high affinity for GHSs and ghrelin. Molecular 
modelling and site direct mutagenesis were exploited to identify the ligand-
binding pocket of GHS-R1a. Ghrelin and synthetic GHSs share common 
binding at TM-3, while other contact points in TM sites are specific for 
different GHSs (Feighner et al., 1998). Recently, it was shown that ligand 
binding and activation of GHS-R1a by ghrelin requires the ligand to interact 
with one pocket formed by polar amino acids and one formed by non-polar 
amino acids present in TM2/TM3 and TM5/TM6, respectively (Pedretti et 
al., 2006). Acylation at Ser3 of the ghrelin peptide is essential for GHS-R1a 
activation; however, short peptides composed only by the first four or five 
residues of ghrelin were found to activate GHS-R1a about as efficiently as 
full length ghrelin; only the segment Gly-Ser-Ser-(n-octanoyl)-Phe 
appeared to constitute the ‘active core’ required for receptor binding 
(Bednarek et al., 2000). 
On the other hand, the GHS-R1b transcript is encoded by one exon and 
gives origin to a truncated peptide of 289 amino acids, only containing 5-
TM domains with additional 24 amino acids at the C-terminus. GHS-R1b 
fails to bind either GHSs or ghrelin and its functional activity has to be 
clearly determined to date. A recent hypothesis is that it could play a role 
in modulating other GPCRs, including GHS-R1a, through GPCR homo- 
and/or hetero-dimerization (Chu et al., 2007). GHS-R1a/1b 
heterodimerization has been already described; by this interaction, GHS-
R1b could attenuate the GHS-R1a-mediated PLC activation. GHS-R1b may 
act as a dominant-negative regulator of GHS-R1a by reducing the cell 
surface expression of the receptor and, therefore, reducing its constitutive 
signaling (Leung et al., 2007). 
GHS-R1a is a member of a subfamily of G-protein coupled receptors, whose 





This family is composed of receptors for neurotensin and neuromedin U 
(30-35% homology), motilin (52% homology) and other GPCRs, including 
GPR39 (27-32% homology), which was initially described as the obestatin 
receptor (Holst et al., 2004). The thyrotropin-releasing hormone receptor 













GHS-R1a is highly expressed in the hypothalamus and pituitary, consistent 
with its metabolic functions. However, its expression has also been 
reported in different areas of the CNS like the hippocampus, substantia 
nigra, cortex and others, in the vagal nodose ganglion and in multiple 
peripheral organs, such as stomach, intestine, pancreas, thyroid, gonads, 
kidney, heart and vasculature, bone and various tumors and cell lines 
(Gnanapavan et al., 2002).  
This broad expression of the receptor is fully in agreement with the rising 
spectrum of actions of ghrelin. GHS-R1a, as its ligand ghrelin, is highly 

























GHS-R1a protein (366 aa)
Putative GHS-R1b protein (289 aa)
Figure 1.21 Growth Hormone Secretogogue Receptor (GHS-R) gene 
structure 
GHS-R gene and its transcripts GHS-R type 1a and type 1b. Black boxes represent 





conserved among vertebrates, highlighting its important physiological 
functions. 
Signal transduction from the ghrelin receptor 
Two endogenous GH-releasing peptides have been identified, ghrelin and 
GHRH. GHRH acts on GHS-R1a to activate adenylate cyclase and increase 
intracellular cAMP, which in turn activates protein kinase A. This clearly 
demonstrates that GHS-R1a is coupled to a Gs subunit. On the other hand, 
the binding of ghrelin to GHS-R1a activates the protein kinase C (PKC) 
system and induces an increase in intracellular Ca2+ concentration, 
indicating that the receptor is also coupled to a Gq subunit. In particular, 
the ghrelin/GHS-R1a interaction induces phospholipase C to hydrolyze 
phosphatidyl-inositol-4,5-biphosphate, stored in the plasma membrane, to 
give both diacylglycerol (DAG) and inositol-triphosphate (IP3). IP3 binds to 
its receptor on the endoplasmic reticulum and induces Ca2+ release from 
intracellular storage, while DAG activates PKC that, through tyrosine 
phosphorylation, inhibits the potassium channel, causing depolarization and 
the opening of voltage-dependent L-type Ca2+ channels. A possible 
crosstalk between Gs and Gq might be responsible of the multiple 
described effects of GHS-R1a. Additionally, different ligands could also 
induce different conformations of the receptor, favouring coupling to 
different G proteins and activation of various signaling pathways (Maudsley 
et al., 2005).  
Another important feature to underline is that, besides the activation upon 
ligand-receptor interaction, GHS-R1a is constitutively highly active, also 
signaling at approximately 50% of the ghrelin-induced activity in the 
absence of agonists (Holst et al., 2004). It has been suggested that this 
high level of constitutive activity may be of physiological importance in its 






The interaction between GHS-R1a and its ligands results in rapid 
desensitization, due to the uncoupling of the receptor from heterotrimeric 
G proteins and to receptor internalization, mediated by clathrin-coated pits, 
from the cell surface to intracellular compartments. Once the ligand-
receptor complex is internalized into vesicles, it is sorted into endosomes 
where the complex is dissociated and the receptor is then recycled to the 
membrane (Camina et al., 2004). The recycling of GHS-R1a requires 
approximately one hour, while surface binding reaches normal levels after 
3-6 hours. 
 
1.4.3.2 Non-type 1a GHS Receptors 
Even if the formation of heterodimeric receptor complexes may partially 
account for the GHS-R1a alternative signaling in response to ghrelin, it is 
likely that other, yet unidentified receptors exist (Figure 1.22). Many 
studies demonstrated that ghrelin is active also in tissues or cell lines not 
expressing GHS-R1a, giving strength to the hypothesis that GHS-R1a is not 
the only receptor for this peptide (Filigheddu et al., 2007; Gauna et al., 
2006; Thompson et al., 2004). Besides the mentioned GPCR homologues of 
GHS-R1a and its splicing variant GHS-R1b, many reports have confirmed 
the existence of alternative receptors binding either acyl and des-acyl 
ghrelin or specific for the latter. In addition, an unidentified obestatin 
receptor must also exist. 
Since des-acyl ghrelin does not bind GHS-R1a, acylation at Ser3 being 
essential for receptor activation, the described effects induced by this 
peptide should be mediated by other receptors. Recently, an increasing 
number of ghrelin sensitive tissues or cell lines have been shown to be 
responsive also to des-acyl ghrelin, sometimes with different functional 
profiles. Both acyl and des-acyl ghrelin are able to prevent cell death of 





Akt pathways (Baldanzi et al., 2002) and to improve survival and 
proliferation of cells of pancreatic islets (Granata et al., 2007). They also 
induce neurogenesis in rat fetal spinal cord (Sato et al., 2006), increase 
osteoblasts proliferation (Delhanty et al., 2006), promote adipogenesis 
(Thompson et al., 2004) and inhibit isoproterenol-induced lipolysis (Muccioli 
et al., 2004). This evidence clearly demonstrates that at least one receptor 
exists, different from GHS-R1a or 1b, which is shared by the acylated and 
non-acylated forms of ghrelin.  
Moreover, the existence of receptors able to discriminate between acyl and 
des-acyl ghrelin derives from the observation that, in some cells, the two 
peptides exert opposite functions (Gauna et al., 2005). In addition, it was 
reported that des-acyl ghrelin, when centrally administered, is able to 
stimulate food intake in GHS-R1a knockout mice, thus revising the concept 
that GHS-R1a is the only mediator of this function (Toshinai et al., 2006). 
Obestatin was initially reported to be the endogenous ligand of the orphan 
receptor GPR39, which shares homology with GHS-R1a. However, recent 
reports have challenged this conclusion by showing that, in GRP39 
expressing cells, there is neither specific binding of the peptide nor 
activation of a signal transduction pathway, which is, in contrast, activated 
by Zn2+ (Lauwers et al., 2006).  
Finally, there is also evidence for the existence of receptors only specific for 
the GHSs. Among these, the only one identified so far is CD36, a class B 
scavenger receptor expressed in many tissues such as vascular 
endothelium, skeletal and smooth muscle cells, monocytes and 
macrophages, which is activated by hexarelin and others structurally 



























1.4.4 Ghrelin physiology 
Ghrelin is a pleiotropic hormone, with a wide spectrum of biological actions. 
Although it was initially discovered as an endogenous GH-releasing peptide, 
very soon it became clear that it exerts a wide range of different functions, 
which are briefly summarized in this paragraph. 
  
GH-releasing activity  
As already mentioned, acylated-ghrelin stimulates GH release in a dose-
dependent and GHS-R1a-mediated manner. Intravenous injection of this 
Figure 1.22 Ghrelin peptides and receptors 
Acyl-ghrelin binds GHS-R1a, while both acyl and des-acyl ghrelin are believed to also 
act through a yet unidentified alternative receptor. Moreover, the existence of 
receptors specific for des-acyl ghrelin has been hypothesized. The receptor for the 





molecule induces potent release of GH both in rats and in humans. Ghrelin 
stimulates this release from primary pituitary cells, thus acting at pituitary 
and hypothalamic level; a prominent role of the vagus nerve in mediating 
this action has been described (Popovic et al., 2003). In addition, high 
doses of ghrelin in humans also increase the circulating levels of ACTH, 
prolactin, and cortisol (Takaya et al., 2000). 
The GH-releasing function of ghrelin is linked with age; indeed it increases 
at puberty, remains constant during adulthood and decreases in elderly 
people (Broglio et al., 2003). It has been hypothesized that the decline of 
GH secretion during lifespan would reflect age-related decrease in ghrelin 
levels and/or GHS-R activity/expression levels. 
Feeding regulation  
A balance of stimulating and inhibiting forces in the hypothalamus 
regulates feeding. However, the regulatory mechanisms of this process are 
not only in the central nervous system, but also involve appetite-regulating 
humoral factors secreted from peripheral tissues. Leptin is a known 
feeding-inhibitor produced by the adipose tissue, while acyl ghrelin is the 
only known gastrointestinal peptide able to stimulate appetite and 
increases meal size, among dozens of factors secreted by the 
gastrointestinal tract in response to food in the lumen. Fasting induces the 
elevation of ghrelin in mice and rats, whereas re-feeding restores it (Guo et 
al., 2008). In humans, pre-prandial increase and post-prandial fall in 
ghrelin levels (Natalucci et al., 2005) support the idea that ghrelin has a 
role in meal initiation. When injected into the cerebral ventricles of rats, 
ghrelin stimulates food intake and in particular enhance fat ingestion, 
inducing an increase in the fat body mass (Nakazato et al., 2001). A similar 
effect has been observed also after intravenous or subcutaneous 
administration of ghrelin. 





(Otto et al., 2001), obesity and cardiac cachexia (Nagaya et al., 2004), has 
been analyzed. Ghrelin was found at high concentrations in patients 
suffering from anorexia nervosa and at low concentrations in obese 
subjects. These observations suggest that ghrelin plays a substantial role in 
long-term energy homeostasis. Despite this, ghrelin-/- mice have display 
growth rate, feeding behaviour and body composition comparable to 
ghrelin+/+ mice, implying that ghrelin is not an essential orexigenic factor or 
that it function can be compensated for by other mechanisms (Sun et al., 
2003). 
Ghrelin exerts its feeding-promoting activity on the hypothalamic arcuate 
nuclei (ARC) in the central nervous system, stimulating the neuropeptide Y 
(NPY)/agouti-related protein (AgRP) producing neurons and, as a 
consequence, inducing the release of the corresponding orexigenic 
peptides (Morton and Schwartz, 2001). Within the ARC, another ghrelin-
responsive cell group is the population of neurons identified by the co-
expression of POMC (proopiomelanocortin) and CART (cocaine- and 
amphetamine-regulated transcript), which is often referred to as an 
anorexigenic population. Ghrelin stimulation of NPY/AgRP neurons also 
induces the release of the inhibitory neurotransmitter GABA, which acts on 
the POMC/CART neurons, blocking their anorexigenic activity. The action 
on these classes of neurons is mediated by GHS-R1a, which is bound by 
both hypothalamic ghrelin and the peripheral produced peptide that reach 
the hypothalamus trough the bloodstream or via afferent vagal fibers (Date 
et al., 2002). Leptin also acts on ARC exerting effects opposite to ghrelin 

























Gastrointestinal effects  
Available data suggest that ghrelin affects many aspects of gastrointestinal 
function; indeed intravenous administration of the peptide increases gastric 
acid secretion and motility (Masuda et al., 2000). Ghrelin induces motor 
activity of the gastrointestinal tract both by a central mechanism (mediated 
by vagus nerve and NPY neurons) and by a peripheral effect similar to 
motilin. Ghrelin may also stimulate cell proliferation and differentiation of 
the gastrointestinal epithelium.  
Des-acyl ghrelin, on the contrary, does not influence gastric secretion while 
it inhibits gastric emptying without altering small intestinal transit. This 
function is probably due to des-acyl ghrelin direct activation of brain 
receptor CRF-2 by crossing the blood-brain barrier and not by the 
activation of vagal pathways (Chen et al., 2005).  
Figure 1.23 Ghrelin and leptin action on the hypothalamus 
Both ghrelin and leptin are peripheral hormones with central functions. They act on 
the hypothalamic arcuate nuclei (ARC) in the central nervous system stimulating 





Glucose metabolism  
The first report showing an effect of ghrelin on glucose homeostasis 
demonstrated that this peptide acutely inhibits insulin secretion in humans 
after intravenous injection, despite increased glucose levels (Broglio et al., 
2001). The same metabolic effects are not induced by synthetic GHS or by 
des-acyl ghrelin, which seems to exert exactly the opposite effect, 
increasing insulin concentration. The observation that insulin levels in the 
blood were suppressed despite the increase in glucose concentration led to 
the hypothesis that ghrelin could differentially modulate glucose 
metabolism and insulin secretion. In the first case, ghrelin seems to exert a 
direct effect on hepatic glucose handling (Gauna et al., 2005), while the 
influence on insulin production has been more debated; ghrelin may act 
regulating pancreatic -cells function by inhibiting glucose-stimulated 
insulin secretion. In conclusion, despite the controversial data about the 
direct effect of ghrelin on insulin release, ghrelin modulates circulating 
glucose levels, increasing insulin resistance and stimulating 
gluconeogenesis.  
Lipid metabolism  
Ghrelin has also been implicated on the regulation of lipid metabolism, with 
effects in the liver, skeletal muscle and adipose tissue. As mentioned 
above, ghrelin favours lipid accumulation. The observed tendency to 
increase body fat in ghrelin-treated animals seems to be independent from 
changes in food intake or weight gain (Tschop et al., 2000). The increase 
in respiratory quotient following both central and peripheral administration 
of ghrelin is likely to reflect reduced whole body lipid oxidation.  
In fat tissue, both ghrelin and des-acyl ghrelin promote adipogenesis and 
inhibit lipolysis, and both peptides also modulate lean tissue fat distribution 
and metabolism. Subcutaneous injection of acyl ghrelin in rats induces 





favouring triglyceride deposition in liver over skeletal muscle (Barazzoni et 
al., 2005). These results supported the hypothesis that ghrelin is involved 
in adaptive changes of lipid distribution and metabolism in the presence of 
caloric restriction and loss of body fat.  
Moreover, both acyl and des-acyl ghrelin inhibited isoproterenol-induced 
lipolysis in rat adipocytes, therefore confirming the existence of a not yet 
identified receptor, different from GHS-R1a, specific for both peptides and 
mediating the ghrelin actions on lipid metabolism (Muccioli et al., 2004).        
 
Bone formation 
Ghrelin and its receptor are synthesized in bone cells, such as chondrocytes 
and osteoblasts. Both acyl and des-acyl ghrelin stimulate osteoblasts 
proliferation and differentiation, increase osteoblastic markers like 
osteocalcin and bone alkaline phosphatase, and repress osteoblasts 
apoptosis via phosphatidylinositol 3-kinase and mitogen-activated protein 
kinase signaling (Delhanty et al., 2006). 
Immunomodulation 
Many studies have revealed that ghrelin regulates immune cell proliferation 
and activation and secretion of pro-inflammatory cytokines. Human 
monocytes, neutrophils, B and T lymphocytes express ghrelin. In general, 
the effects of ghrelin are anti-inflammatory and immune-enhancing. For 
example, it acts through GHS-R1a to specifically inhibit the expression of 
cytokines such as interleukin 1 and 6, TNF-, and nuclear-factor kappa B 
(Dixit et al., 2004) and stimulates proliferation of thymic epithelial cells and 
T lymphocytes. Ghrelin also suppresses neutrophil and macrophage 
migration. In contrast, des-acyl ghrelin has no role in immunomodulation. 
Cell proliferation  
Numerous studies have demonstrated that both acyl and des-acyl ghrelin 





cortical and brainstem neurons, osteoblasts, endothelium, cardiomyocytes, 
and adipocytes (Baldanzi et al., 2002; Chung et al., 2008; Granata et al., 
2007; Kim et al., 2005; Kui et al., 2009). The observation of several cell-
cycle effects induced by either acyl or des-acyl ghrelin has raised the 
possibility of the involvement of both GHS-R1a and non-GHS-R1a receptor 
pathways. 
Behavioural effects  
In addition to the described central and peripheral actions, ghrelin seems 
to be involved also in behavioural functions, such as sleep-wake regulation, 
memory improvement and stress adaptation (Steiger et al., 2011). 
 
1.4.5 Ghrelin effects on the cardiovascular system  
Widespread expression of ghrelin and GHS-R1a is observed in the 
cardiovascular system (Gnanapavan et al., 2002). The mRNA encoding 
GHS-R1a was detected in myocardium and aorta, of course in a much 
lower amount compared to the pituitary. Furthermore, several groups have 
confirmed the presence, in the heart, of the previously mentioned putative 
ghrelin receptor distinct from GHS-R1a, exhibiting the same affinity both 
for acyl and des-acyl ghrelin (Baldanzi et al., 2002) or a receptor specific 
for des-acyl ghrelin (Lear et al., 2010). This receptor might be responsible 
of the opposing metabolic properties exhibited by acyl and des-acyl ghrelin 
in glucose and fatty acid uptake observed in cardiac cells. 
Some of the so far described effects exerted by either acyl or des-acyl 
ghrelin on the cardiovascular system and mediated by GHS-R1a or by yet 
unidentified putative alternative receptors, are summarized below. 
Vasoactive function 
Acyl ghrelin has direct vasodilatatory, endothelium-independent, effects in 





volunteers induced a decrease in blood pressure without changing the 
heart rate (Nagaya et al., 2001a). This effect appeared to occur through an 
action on the nucleus of the solitary tract (NTS), by which ghrelin 
suppresses sympathetic activity (Lin et al., 2004). Similarly, des-acyl 
ghrelin, upon injection into the NTS, reduced arterial pressure and heart 
rate, suggesting that it also contributes to cardiovascular regulation and 
that a receptor other than GHSR-1a exists in NTS (Tsubota et al., 2005).  
Another possible mechanism that could explain the vasodilatatory effect of 
ghrelin is its antagonistic action on the vasoconstrictor endothelin-1, 
observed in isolated mammary arteries (Wiley and Davenport, 2002). 
Cardiotropic effects 
Several studies have suggested a role of ghrelin as an inotropic regulator; 
however it was difficult to establish whether the enhancement of cardiac 
output observed in these conditions is due to a direct effect on cardiac 
contractility, rather than on vasodilation and reduced after-load, or 
secondary to increased secretion of GH. Recently, a few studies suggesting 
inotropic effects reported an improvement of systolic function in the 
absence of decreased peripheral resistance, thus excluding a vasodilatatory 
effect (Enomoto et al., 2003). However, experiments to investigate the 
effect of ghrelin on isolated papillary muscle contractility have 
demonstrated a reduction of contractile force upon both acyl and des-acyl 
ghrelin administration. This action was dependent on NO synthesis, on 
endocardial endothelium integrity and independent from the receptor GHS-
R1a, therefore reinforcing the hypothesis of a direct effect of the peptides 
on cardiac contractility, with a mechanism totally independent from GH 
release (Soares et al., 2006).  
Ghrelin is effective in improving cardiac performance in pathological cardiac 
conditions, such as chronic HF. Rats with HF treated with acyl ghrelin, 





treated animals; furthermore ghrelin increased posterior wall thickness, 
inhibited LV enlargement and increased fractional shortening (Nagaya and 
Kangawa, 2003; Nagaya et al., 2001b).   
Similar beneficial effects upon ghrelin administration were also observed in 
patients with HF. Repeated administration of the peptide improved LV 
function, exercise capacity, and muscle wasting in these patients (Nagaya 
et al., 2004). Cardiac cachexia, a catabolic state characterized by weight 
loss and muscle wasting, occurs frequently in patients with end-stage HF 
and is a strong risk factor for mortality. Plasmatic ghrelin level is increased 
in cachectic patients, probably as a compensatory mechanism in response 
to anabolic- catabolic imbalance. 
Protective effects on myocardial ischemia 
Recently, it was observed that acyl ghrelin peptide administration for two 
weeks after rat myocardial infarction (MI) prevents an increase in cardiac 
sympathetic tone, improves cardiac remodeling, LV function and reduces 
mortality (Soeki et al., 2008). Interestingly, similar protective effects were 
observed also after early treatment, when ghrelin was administered <2 
hours after the infarct (Schwenke et al., 2008). Although further 
investigations are needed to establish whether the described beneficial 
effects of ghrelin also provides long-term benefit for improving cardiac 
function, taken together, these data suggest the potential usefulness of 
this peptide as a new cardioprotective hormone early after MI. In addition, 
ghrelin and GHS-R1a in the myocardium are up regulated during 
isoproterenol-induced myocardial injury. A protective effect of both acyl 
ghrelin and des-acyl ghrelin against isoproterenol-induced myocardial injury 
and fibrosis has been described, which suggests that both the peptides 
could represent endogenous cardioprotective factors in ischemic heart 
disease (Li et al., 2006).  





the cardiac beneficial functions of ghrelin. Its protective effect against 
cardiac ischemia could be partially explained by an inhibitory activity of the 
molecule on cardiomyocytes cell death. A possible direct effect of ghrelin in 
inhibiting apoptosis has been demonstrated on primary adult and H9c2 
cardiomyocytes and endothelial cells in vitro (Baldanzi et al., 2002). These 
effects are regulated via a MAPK- and Akt-dependent pathway. Des-acyl 
ghrelin is similarly active. Moreover, H9c2 cardiomyocytes do not express 
the ghrelin receptor, again suggesting that another receptor is involved.  
Many reports further confirmed the antiapoptotic effect of ghrelin in 
different cell types through similar signaling pathways. Recently it was 
demonstrated that, in mouse cardiomyocyte cell line HL-1, des-acyl ghrelin 
also recognizes specific binding sites and that both acyl and des-acyl 
ghrelin exert antiapoptotic activities, despite their opposite metabolic 
effects. Indeed, acyl ghrelin inhibited insulin-induced glucose uptake and 
had no effect on fatty acid uptake, whereas des-acyl ghrelin reversed the 
inhibitory effect on glucose uptake and increased fatty acid uptake and 
glucose transporter-4 translocation to the cell membrane (Lear et al., 
2010). 
In a model of doxorubicin induced cardiac damage it was shown that 
ghrelin not only reduces apoptosis and markers of oxidative stress but also 
increases anti-oxidative enzyme activity and preserves mitochondrial 
membrane potential and energy metabolism through the TNF-/NF-kB 
pathway (Xu et al., 2008). Accordingly, ghrelin was previously found to 
counteract cytokine-induced apoptosis and to reduce inflammation. The 
ability of ghrelin to reduce endoplasmic reticulum stress after I/R injury 
was confirmed both in vitro and in vivo (Zhang et al., 2009). 
The recently identified ghrelin gene-derived peptide obestatin was also 
described as a protective molecule against apoptosis in several cell types, 





appears to be mediated by the PKC, PI3K, and ERK1/2 pathways. Despite 
these results, to date the physiological role of obestatin is still largely 


























Figure 1.24 Ghrelin action on the cardiovascular system 
The interactions between GHRH, ghrelin, and obestatin with the CNS and the 





1.5 INSULIN-LIKE PEPTIDE 6: A NOVEL MEMBER OF THE 
RELAXIN FAMILY 
 
Another factor that was identified in the course of this Thesis work as a 
powerful cardioprotective molecule was Insulin-Like Peptide 6 (INSL6), a 
member of the relaxin family of proteins.  
Frederick L. Hisaw discovered relaxin in 1926, when he reported the 
relaxation of the interpubic ligament of female guinea pigs following 
injection of serum from pregnant guinea pigs or rabbits. Relaxin was first 
isolated in 1930 from extracts of porcine ovary, however, the interest 
towards this molecule increased only in the ‘80s after peptide purification, 
which allowed the identification of its amino acidic sequence (Fields and 
Larkin, 1981). Afterwards, the genes coding for two human molecular 
forms of relaxin with high sequence homologies (95%), designed H1 and 
H2 relaxins, were identified (Hudson et al., 1984).  
Relaxin was originally described as a pregnancy hormone, produced in the 
reproductive tract of many mammals during pregnancy and primarily 
secreted by the corpus luteum, even if the main source of relaxin varies 
among species. Recent research has revealed that relaxin is also produced 
by non-reproductive organs and acts through endocrine, paracrine and 
autocrine mechanisms on a wide range of tissues (Sherwood, 2004).  
INSL6 was originally identified in the testis of humans and rats (Lok et al., 
2000) and found to be a member of the relaxin family of proteins.  
 
1.5.1 The relaxin family peptides and their receptors 
Relaxin belongs to the insulin/relaxin superfamily that includes the insulin 
family (insulin, IGF-I and IGF-II), that diverged early in vertebrate 
evolution from the relaxin family, composed by relaxin-1, relaxin-2, relaxin-





INSL4, INSL5 and iNSL6 (Wilkinson et al., 2005) (Figure 1.25).  
Despite the overall sequence identity of these peptides is low, they are all 
synthesized as pro-hormones, comprising a signal sequence and a B-C-A 
domain configuration. Afterwards, the removal of the C chain and the 
formation of three disulfide bridges between six invariant cysteine residues 
found on the A and B chains, produces the active protein. The B domain is 
responsible for the primary interaction with the receptors, whereas the A 
chain is essential for the maintenance of the correct three-dimensional 
conformation of the peptides (Bathgate et al., 2006). The amino acid motif 
Arg-X-X-X-Arg-X-X-Ile, located in the middle of the B chain, is required for 
relaxin bioactivity and is therefore conserved among species (Bullesbach 
and Schwabe, 2000) 
Relaxin-1 is found only in humans and the great apes and its gene 
expression is limited to decidua, placenta, endometrium and prostate. 
Relaxin-2 is the major circulating form of the relaxin in humans, and the 
relaxin-1 equivalent in non-primates. The major source of relaxin-2 is the 
corpus luteum of the ovary, from which it is secreted into the bloodstream; 
however, relaxin-2 is not merely a hormone of pregnancy, but has a 
number of other roles in vivo, such as the regulation of collagen 
metabolism and the actions on receptors located in the vasculature and in 
the brain (discussed in the next section). Relaxin-2 is also locally produced 
and acts as a paracrine/autocrine factor in the endometrium, mammary 
gland, placenta, prostate and heart. Relaxin-3 shows, on the contrary, 
brain specific expression and has putative actions as a neuropeptide. It has 
a role in mediating stress response and appetite regulation (McGowan et 
al., 2009; Smith et al., 2010). The gene coding for relaxin-3 is highly 
conserved among species, therefore it is considered the ancestral relaxin 
gene. INSL3, or relaxin-like factor (RLF), is expressed in testis and ovary 





survival (Kawamura et al., 2004), while INSL5 is widely found in kidney and 
colon, as well as in the brain and pituitary. INSL4 and INSL6 are mainly 
expressed in the placenta and testis, respectively, and their functions are 












Given the structural similarity between relaxin and insulin, the relaxin 
receptor was thought to be a tyrosine kinase receptor, similar to the insulin 
one. However, it was finally demonstrated in 2002, that two orphan G 
protein-coupled receptors, LGR7 and LGR8, are activated by relaxin-2 and 
INSL3, respectively (Hsu et al., 2002; Kumagai et al., 2002). The leucine- 
reach-repeat containing GPCR (LGR) family consists of three class of 
receptors: class A, composed by the luteinizing hormone receptor (LHr), 
thyroid stimulating hormone receptor (TSHr) and follicle stimulating 
hormone receptor (FSHr); class B, which includes the orphan receptors 
LGR4, LGR5 and LGR6 and class C, composed of the relaxin receptors LGR7 
and LGR8. These receptors, now termed relaxin family peptide receptor-1 
(RXFP1) and RXFP2, have a widespread distribution throughout the body.  
The binding of relaxin-2 and INSL3 to their receptors mainly stimulates the 
Gs-cAMP-PKA-dependent signaling pathway, but there is evidence that 
Figure 1.25 Relaxin family evolution  


















relaxin-2 also causes tyrosine kinase phosphorylation and can also acts 
through the MAPK pathway in different cell types (Van Der Westhuizen et 
al., 2007). In addition relaxin-2 can act by increasing the activity of nitric 
oxide synthase (NOS) (Failli et al., 2002). 
Subsequently, other two GPCRs, GPCR135 and GPCR142 (now termed 
RXFP3 and RXFP4), were identified as the specific receptor for relaxin-3 
and INSL5, respectively (Liu et al., 2003; Liu et al., 2005). According to its 
ligand expression, the relaxin-3 receptor RXFP3 is mainly present in the 
brain, while RXFP4 is also expressed in numerous peripheral tissues. 
Although these four receptors are all Type I GPCRs, they are very distantly 
related and, in particular, RXFP3 and RXFP4 are coupled to cAMP inhibition, 
exerting opposite functions of RXFP1 and RXFP2.  
INSL4 and INSL6 do not interact with any of the RXFP receptors and their 
native receptors are currently unknown.  
 
1.5.2 Biological functions of relaxins  
In the past 30 years it has been established that relaxin is essential for 
numerous aspects of pregnancy, including the modification of the pelvic 
girdle in many mammalian species, as show by the initial studies by Hisaw 
and collaborators. However, it has become evident that relaxin also affects 
non-pregnant animals, exerting many functions on different tissues, 
including the male reproductive organ. 
A role for relaxin in protecting several organs from the progression of 
fibrosis was confirmed by studies with relaxin knockout mice, which display 
a number of changes, including increased lung, renal and ventricular 
collagen deposition with age (Du et al., 2003; Samuel et al., 2004b) and 







1.5.2.1 Effects on reproductive organs 
As already mentioned, relaxin has been traditionally viewed as a hormone 
of pregnancy and parturition, able to induce lengthening of the interpubic 
ligament and softening of the birth canal’s tissue by induction of collagen 
remodeling, in order to facilitate the fetus passage. However, in contrast to 
the elevated relaxin serum levels observed during the third trimester of 
pregnancy in guinea pigs and other mammals, H2 relaxin functions 
differently in higher primates and humans, where the highest plasma levels 
are observed during the first three months of pregnancy (Parry and 
Vodstrcil, 2007). This finding suggested that, in humans, relaxin might 
facilitate embryo implantation rather than being involved in maintenance of 
pregnancy and parturition. Indeed, in both humans and other primates 
relaxin has been associated with endometrial angiogenesis, thickening and 
bleeding (Goldsmith et al., 2004). In addition, relaxin is important in the 
development of mammary nipple and mammary gland of a number of 
species, including humans (Sherwood, 2004). 
Slower progress has been made towards the understanding of the role of 
endogenous relaxin in males. Relaxin is not a circulating hormone in males, 
but it is locally expressed by the prostate. In addition, the observation that 
both relaxin gene knock-out (M1RKO) and relaxin receptor knock-out 
(LGR7KO) male mice display underdeveloped testis, underdeveloped 
reproductive tract, and reduced fertility provide evidence that relaxin plays 
a role in the development of the male reproductive system (Samuel et al., 
2003). So far, other relaxin family peptides have been associated to male 
reproductive organ development; in particular, the expression of INSL5 and 
INSL6 was described in testis, while INSL3 was reported to be a major 







1.5.2.2 Effects on other organ systems 
Relaxin also exerts important actions on non-reproductive organs both 
during pregnancy and in non-pregnant females and males, where it is 
produced by numerous cell types to act in a paracrine or autocrine manner. 
As mentioned above, relaxin promotes tissue remodeling by increasing 
collagen turnover during pregnancy but, in addition, it exerts the same 
function also in other relaxin-expressing tissues, as demonstrated by the 
observation that relaxin knock out mice develop a progressive fibrosis in 
many organs, such as heart, lung, kidney and skin, with aging.  
The use of the relaxin peptide to limit collagen production was effective in 
restoring normal functions in numerous models of organ fibrosis (Lekgabe 
et al., 2005; Mookerjee et al., 2006). It was shown that relaxin acts directly 
on TGF--stimulated human dermal fibroblasts, lung and cardiac fibroblasts 
(Samuel et al., 2004a) to reduce type I and type III collagen synthesis, and 
to increase matrix metalloproteinases (MMPs) expression. Moreover, relaxin 
successfully modifies the extracellular matrix in dermis, lung, liver and 
kidney (Samuel and Hewitson, 2006; Tang et al., 2009). Interestingly, in all 
of these experimental conditions, relaxin only affects aberrant collagen 
deposition, induced by pro-fibrotic stimuli, but has little effect on normal 
collagen levels.  
Another relaxin property that was shown to involve both reproductive and 
non-reproductive organs is its ability to induce blood vessels dilation. This 
activity, which determines hypotension, is consequent to the ability of 
relaxin to dilate not only microvessels such as arterioles, but also capillaries 
and postcapillary venules in numerous sites throughout the body. Relaxin 
exerts its vasodilatatory action through the stimulation of nitric oxide (NO) 







1.5.2.3 Effects on the cardiovascular system 
It has been demonstrated that relaxin protects the cardiac tissue against 
myocardial injury caused by ischemia and reperfusion (IR) or myocardial 
infarction. When relaxin is present during IR, it reduces the areas of 
damage, ventricular arrhythmias, mortality, neutrophils accumulation, and 
morphological features of myocardial cell injury in rats (Bani et al., 1998). 
This effect could be partially ascribed to the mentioned vasodilatatory and 
anti-fibrotic activities of the peptide (Figure 1.26). Moreover, in a rat 
model of myocardial infarction it was shown that relaxin might influence 
the perfusion of ischemic sites by inducing VEGF-A and FGF-2, thus 
augmenting collateral vessel formation (Unemori et al., 2000). Relaxin may 
also mediate its cardioprotective effects through inhibition of inflammatory 
cell activation (Masini et al., 2004), or counteracting cell death, oxidative 
stress and calcium overload (Moore et al., 2007). 
The evidence for a local production and release of relaxin by 
cardiomyocytes suggests that this peptide may act as an autocrine or 
paracrine physiological regulator of cardiac function. It has been reported 
that expression of both H1 and H2 relaxin genes is increased in failing 
cardiac tissue, and that plasma concentrations of relaxin correlates 
positively with the severity of congestive heart failure (Dschietzig et al., 
2001), a finding that is however controversial (Fisher et al., 2003). 
A phase II clinical trial (Pre-RELAX-AHF), based on the intravenous 
administration of recombinant relaxin protein in acute heart failure (AHF) 
patients, was recently completed. The results of this trial demonstrated 
that the infusion of relaxin improved prognosis in patients with AHF, 
without significant safety concerns. A phase III clinical trial (RELAX-AHF-1) 






















1.5.3 Insulin-like peptide 6 (INSL6) 
 
1.5.3.1 Identification and characterization of INSL6 
Insulin-like peptide 6 (INSL6) is a member of the insulin/relaxin 
superfamily. The factor was identified for the first time in 2000 from an 
Expressed Sequence Tag (EST) database, searching for proteins containing 
the insulin family B-chain cysteine motif (Lok et al., 2000). Afterwards, 
using a probe derived from the EST sequence, a 790 bp rat and a 717 bp 
human cDNA encoding INSL6 were isolated from testis cDNA libraries. 
INSL6 exhibits the hallmark of the family, comprising a signal peptide, B- 
and A- cysteine domain and an intervening C-domain (Figure 1.27). The 
prohormone of human INSL6 has longer C- and A- domains than rat INSL6 
and an open reading frame of 213 vs 188 amino acids. Within the B- and 
A- domains, the two INSL6 exhibit 55% identity. 
Figure 1.26 Relaxin beneficial effects in heart failure 
One of the main properties of relaxin consists in the modulation of vascular tone. In 
HF condition, relaxin relieves systemic and renal vasoconstriction inducing 
vasodilation both by NO production and also activating the endothelin B (ET-B) 
receptor on endothelial cells. In addition, relaxin counteracts inflammation, 
decreases fibrosis and induces the expression of pro-angiogenic factors, such as 





In humans, INSL6 maps to chromosome 9p24, the same position where 
the gene coding for INSL4, another family member associated with 
reproductive tissues, is also located. This region also harbours an 
autosomal testis-determining factor locus (TDFA). Failure of testis 
development was associated with rearrangement of the 9p24.1 region, 
demonstrating that this chromosome portion is important for reproductive 
function (Ion et al., 1998). In mice, both INSL6 and relaxin map to 
chromosome 19, which is syntenic to human chromosome 9. 
Initially, human INSL6 expression was only detected in the germ cells of 
the testis (in spermatocytes and spermatidis, but not in either Leyding or 
Sertoli cells), while, in the rat, INSL6 transcripts were also detected in the 
prostate. INSL6 mRNA expression was detectable at low levels at 
embryonic day 14.5 and 17.5, and the level of expression remained low 
until postnatal day 20, when there was a 40- to 50-fold increase in mRNA 
abundance with maximum levels attained by day 40 and maintained up to 
day 90 of age (Lu et al., 2006). Later, the INSL6 mRNA was also detected 
in other tissues in mice, such as kidney, small bowel, heart, thymus, brain, 
intestine, uterus, ovary, spleen, lung and liver (Brailoiu et al., 2005; Kasik 
et al., 2000). However, the level of expression in these tissues was only 1-
8% of that observed in the testis. Pro-protein convertase 4 (PC4), a furin-
like protease expressed only in testis, is believed to be involved in INSL6 
protein maturation from its prohormone precursor. In addition to 
prohormone processing, INSL6 undergoes other post-translational 
modifications, such as disulfide bond formation between the B- and A- 


























1.5.3.2 Functions of INSL6  
Given the predominant expression on INSL6 in the testis, INSL6-deficient 
mice have been generated in order to elucidate the role of this molecule in 
germ cell development (Burnicka-Turek et al., 2009). INSL6 resulted to be 
not essential for embryogenesis and gonadal differentiation, while it turned 
out of be required for spermatogenesis. INSL6-/- mice exhibited a clear 
impairment of this process, which was arrested at the stage of late 
pachytene spermatocytes because of a failure in completing meiosis. 
Immature germ cells were released, with a consequent significant decrease 
in the number of spermatozoa, which also had a reduced motility. Thus, 
the INSL6 deficiency appeared to lead to an arrest in the development of 
most germ cells at the end of meiotic prophase; enhanced apoptosis was 
Figure 1.27 Murine INSL6 protein  
The signal peptide, the A-, B- and C- domains and the location of disulfide bonds 





demonstrated to cause germ cell depletion after the arresting step.  
Recently, INSL6 was reported to have a function in skeletal muscle (Zeng 
et al., 2010). Exploiting a model of cardiotoxin (CTX) induced injury, Zeng 
and co-workers showed that INSL6 is a muscle-derived factor that is up 
regulated by damage; the same effect was also observed after induction of 
Akt signaling in skeletal muscle-specific, conditional Akt1 transgenic mice. 
In contrast, the other insulin-like family members did not change their level 
of expression in these conditions. When expressed in the muscle by an 
adenoviral vector or in transgenic mice overexpressing the transgene from 
a muscle-specific promoter, INSL6 was able to activate satellite cells and 
accelerate the muscle regeneration process after damage, promoting 
muscle progenitor cell proliferation and survival.  
The receptor mediating INSL6 actions both in testis and other tissues has 
















2. AIM OF THE STUDY 
 
 
The overall purpose of this study was the development of an innovative 
functional selection procedure (FunSel), based on the in vivo gene transfer 
and selection of a collection of secreted factors cloned into AAV, aimed at 
identifying new potential therapeutic molecules providing benefit to 
degenerative disorders. In particular, this Thesis work was aimed at 
developing a pilot project to assess the feasibility of FunSel and 
establishing the technology required. 
The direct, in vivo selection of factors exerting a beneficial effect against 
tissue degeneration has never been attempted before and, basically, it is 
now rendered possible by the property of AAV vectors to be produced at 
high titers, infect tissues at high multiplicity of infection (MOI), persist in 
the transduced cells for prolonged periods of time and express their 
transgenes at high efficiency in vivo.  
 
The specific objectives of the Thesis work were: 
1. To establish a theoretical background supporting the feasibility of the 
FunSel in vivo selection approach based on pooled AAV gene 
transfer;  
2. To construct of an arrayed collection of AAV vectors, corresponding 
to 100 secreted factors, which were arbitrarily chosen among the 
mouse secretome cDNA collection. 
3. To experimentally test FunSel using such an AAV collections in a 
mouse model of hind limb ischemia and a mouse model of 
isoproterenol-induced myocardial damage, in order to identify 
secreted molecules protecting against these conditions. 
4. To individually verify the capacity of the selected molecules in 
exerting a cardioprotective effect after myocardial infarction.




3. MATERIALS AND METHODS 
 
 
3.1 MOLECULAR BIOLOGY PROTOCOLS 
 
3.1.1 Generation of the plasmids collection 
The RIKEN Mouse Secretome cDNAs Collection was provided by S. 
Gustincich (SISSA, Trieste) in collaboration with P. Carninci (RIKEN 
Institute, Japan) and the FANTOM Consortium. 
The cDNAs were obtained from the original cloning plasmids (modified 
pBluescript SK (+)/modified Bluescript1 and pFlcI) by PCR with specific 
primers to insert the Xho I (CTCGAG) and Not I (GCGGCCGC) restriction 
sites at the 5' and 3' ends of each cDNA. The annealing temperatures of 
the two sets of primers were respectively 65ºC for the modified pBluescript 
SK (+) and 66ºC for the pFlcI plasmids. 
PRIMER pBluescript FW:  
5' - CTG TCC GCT CGA GCC AGT GAA TTG TAA TAC GAT - 3'  
PRIMER pB/pF REV (common for both):  
5' - ATA AGA ATG CGG CCG CCT AAA GGG AAC AAA AGC - 3'  
PRIMER pFlcI FW:  
5' - CTG TCC GCT CGA GTA CGA AGT TAT GGA TCA GGC - 3' 
The amplified cDNAs were individually sub-cloned into the Multiple Cloning 
Site of the pZac2.1 AAV-backbone plasmid by the restriction sites Xh oI and 
Not I. This vector is specific for AAV vectors generation indeed it contains 
two Inverted Terminal Repeat sequences (ITRs), a CMV IE promoter, a 
multiple cloning site (MCS), and an SV40 polyA site (Fig. 3.1). PZac2.1 is a 
small vector, only 4543 bp long, and it allows the cloning of cDNAs longer 
than 3000 bp without any interference during the viral particles 
encapsidation process. 




3.1.2 PCR amplification of the pooled viral genomes 
After the individual cloning of a subset of cDNAs in pZac2.1, homogeneous 
pools of plasmids were mixed in equimolar amount to obtain the 
correspondent pools of AAV vectors. Viral genomes, recovered from each 
pooled AAV preparation, were submitted to a PCR amplification step carried 
by a pair of primers annealing on the common pZac2.1 vector sequence 
and spanning the MCS. The sequences of the primers, with annealing 
temperature of 58°C, are: 
PRIMER pZac2.1 FW: 5' - GTG TCC ACT CCC AGT TCA AT - 3'  
PRIMER pZac2.1 RV: 5' - GTG GTT TGT CCA AAC TCA TC - 3' 
AAV vector genomes recovered from skeletal muscle or heart after each 
cycle of in vivo functional selection, were amplified using these primers and 
then visualized on a 1% agarose gel, in order to evaluate the obtained 
pattern of bands corresponding to each genome and to identify eventually 














 Figure 3.1 Map of the pZac2.1 AAV-backbone plasmid 




3.1.3 Production and purification of rAAV vectors  
The rAAV vectors used in this study were produced by the AAV Vector Unit 
at ICGEB Trieste (www.icgeb.org/avu-core-facility). Infectious AAV2 and 
AAV9 vector particles were generated in HEK 293 cells, cultured in 150-
mm-diameter Petri dishes, by co-transfecting each plate with 20 µg of each 
vector plasmid together with 45µg of the packaging/helper plasmid, pDG 
(provided by J.A. Kleinschmidt, Heidelberg, Germany), expressing AAV and 
adenovirus helper functions. Viral stocks were obtained by CsCl gradient 
centrifugation (Arsic et al., 2003; Zacchigna et al., 2008) and rAAV titers 
were determined by measuring the copy number of viral genomes in 
pooled, dialyzed gradient fractions using Real-Time PCR.  
The vectors used in this study express the cloned cDNAs under the control 
of the constitutive CMV immediate early promoter and all the viral stocks 



































Collect and dialyze fractions




3.1.4 DNA and RNA extraction and Reverse Transcription 
(RT) 
Total DNA was extracted from skeletal muscle and cardiac tissue using the 
DNeasy Blood and Tissue kit (Qiagen), according to the suppliers' protocol. 
Total RNA from the same tissue samples was extracted using TRIzol 
reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s 
instructions, digested by DNAse I and reverse-transcribed using hexameric 
random primers.  
 
3.1.5 Quantification of nucleic acids by Real-Time PCR 
Quantification of gene expression was performed by Real-Time PCR; the 
cDNA was used as template to analyze the transgene expression levels of 
candidate factors like ghrelin and iNSL6 in skeletal muscle and heart, as 
well as -MHC, -MHC, SERCA2a, RYR2, ANF, BNP and PGC1, IL1-, IL6, 
TNF-, miR21 and MMP-2 expression in the LV myocardium. The murine 
housekeeping gene GAPDH (the U6 promoter for miRNA quantification) 
was used to normalize the results. All the amplifications were performed on 
BIORAD (CFX96 real-time system), using predeveloped and custom-
designed assays (Applied Biosystems, Foster City, CA, USA) or SYBRGreen 
(Bio-Rad Laboratories, Hercules, CA, USA). 
Q-PCR was used also for the detection of vector specific DNA in muscle ad 
heart samples with the aim to calculate the ratio between viral particles 
coding for different factors. The amount of each vector was quantified by 
SYBRGreen assay and compared with the total viral DNA content 
respectively in pool of plasmids, viral lysates and muscles transduced with 
the correspondent pools of vectors. A Taqman probe and primers that 
specifically recognize CMV promoter, which is common to all the AAV 
vectors in the study, was used to quantify the total viral genomes. 
 




Below the sequences of primers and probes; the efficiency of each single 
couple of primers have been tested and normalized. 
Primers for viral DNA quantification: 
Mouse D11 (Gast): F: 5’-GTGGACAAGATGCCTCGACT-3’ 
 R: 5’-TGTTCCAGGTCCTCATTGGT-3’ 
Mouse E2 (Ghrl): F: 5’-GCCCAGAGCACCAGAAAG-3’ 
 R: 5’-TGATCTCCAGCTCCTCCTCT-3’ 
Mouse C12 (INSL6): F: 5’-AACCCTCACCCTTCTTCCTC-3’ 
 R: 5’-GCTCCCAAGTGTGTGTTCCT-3’ 
Mouse G4 (Ccl7): F: 5’-CCCAAGAGGAATCTCAAGAGC-3’ 
 R: 5’-AGCCTCCTCGACCCACTTCT-3’ 
Mouse F8 (Pomc): F: 5’-CACTGAACATCTTTGTCCCCA-3’ 
 R: 5’-CGACTGTAGCAGAATCTCGG-3’ 
Mouse H2 (Cxcl9): F: 5’-CCGCTGTTCTTTTCCTCTTG-3’ 
 R: 5’-GCATCGTGCATTCCTTATCA-3’ 
Mouse G5 (Vip): F: 5’-TTCACCAGCGATTACAGCAG-3’ 
 R: 5’-GTGTCGTTTGATTGGCACAG-3’ 
Mouse 2E4 (Plgf): F: 5’-CTGCTGGGAACAACTCAACA-3’ 
 R: 5’-CCTCATCAGGGTATTCATCCA-3’ 
Mouse F2 (Afp): F: 5’-CCAAAGCATTGCACGAAAAT-3’ 
 R: 5’-CTTCCGGAACAAACTGGGTA-3’ 
Mouse 1D12 (Tgfbi): F: 5’-ATCACCAACAACATCCAGCA-3’ 
 R: 5’-CCAGCACGGTATTGAGTCCT-3’ 
Mouse 1F6 (Btd): F: 5’-ATCAGCAGGAGGCGGGACGAG-3’ 
 R: 5’-AGCGCAGAACAGCCGAGGAA-3’ 
Mouse 2C12 (Ces2a): F: 5’-GCCTGACCTCATCTCTGACACTT-3’ 
 R: 5’-TTACTCTTTGCTCTCAGGCAGTGGA-3’ 
Mouse 4A3 (Cyp2c55): F: 5’-AGCTTGATGGCCACTGTAACC-3’ 




 R: 5’-ACGTGATCGATCTCTGCCTG-3’ 
Mouse 4C10 (Spon2): F: 5’-ACTCGCTGGTGTCCTTCGTGGT-3’ 
 R: 5’-TCGGTCCCTGCATCGTGTG-3’ 
Mouse 1D3 (C8b): F: 5’-ACCAAACGCTTCGCCCACACT-3’ 
 R: 5’-GCAGGCTCTTGACCCTCTGA-3’ 
Mouse 2C11 (Ces2e): F: 5’-TGGAGTGGGGTGAGGGATGGG-3’ 
 R: 5’-CCTCATGGGCATGGGCTG-3’ 
Mouse 1C9 (Mau2): F: 5’- GCCTGCTCCCTTGTGCTGCT-3’ 
 R: 5’- CATGGCGTTCCCACATGC-3’ 
CMV DNA:  F: 5’-TGGGCGGTAGGCGTGTA -3’ 
 R: 5’-GATCTGACGGTTCACTAAACGAG-3’ 
Primers for gene expression: 
Mouse IL1-:  F: 5’-GCTGTGGCAGCTACCTGTGTCTT-3’ 
 R: 5’-GGGAACGTCACACACCAGCAGGT-3’ 
Mouse TNF-:  F: 5’-CCACCACGCTCTTCTGTCTAC-3’ 
 R: 5’-TTGGGAACTTCTCATCCCTTT-3’ 
Mouse MMP-2:  F: 5’-GGATGCCGTCGTGGACCTGC-3’ 
 R: 5’-GCTCAGCAGCCCAGCCAGTC-3’ 
Mouse miR21:  F: 5’- -3’ 
 R: 5’- -3’ 
Mouse -MHC:  F: 5’-TCCGCAAGGTGCAGCACGAG-3’ 
 R: 5’-CACGGGCACCCTTGGAGCTG-3’  
Mouse -MHC:  F: 5’-ATGTTAAGGCCAAGGTCGTG-3’ 
 R: 5’-CACCTGGTCCTCCTTTATGG-3’  
Mouse Serca2a:  F: 5’-CGCTACGGTGCCTGGCTCTG-3’ 
 R: 5’-TGCCCACACAGCCGACGAAA-3’  
Mouse RYR2: F: 5’-AAGGCGAGGATGAGATCCAGTTCCT-3’ 
 R: 5’-ATCCTTCTGCTGCCAAGCACAGCT-3’  




Mouse ANF:  F: 5’-TCCAGCTGCTTCGGGGGTAGG-3’ 
 R: 5’-CCGCAGCTCCAGGAGGGTGT-3’  
Mouse BNP:  F: 5’-GTCCTTCGGTCTCAAGGCAGCAC-3’ 
 R: 5’-GGGGAAAGAGACCCAGGCAGAGTC-3’  
Mouse PGC1:  F: 5’-CAACCGCAGTCGCAACATGCTCA-3’ 
 R: 5’-CCCTTGGGGTCATTTGGTGACTCTG-3’  
Taqman probes (assay): 
Mouse Ghrl:  Mm00445450_m1 
Mouse INSL6:  Mm01964671_s1 
Mouse IL6:  Mm00446190_m1 
CMV:  (FAM)-TGGGAGGTCTATATAAGC-  
 
 
3.2 CELLULAR BIOLOGY PROTOCOLS 
 
3.2.1 Culture of neonatal rat cardiomyocytes 
Isolation  
Ventricular myocytes from 1 to 2 days-old Wistar rats were prepared 
according to a previously detailed protocol, yielding 90% purity (Collesi et 
al., 2008). The hearts were retrieved, the ventricles isolated from atria and 
vessels and minced in small pieces with diameter of about 2-3 mm.  
The fragments were dissociated in CBFHH (calcium and bicarbonate-free 
Hanks with Hepes) buffer containing 2 mg/ml of trypsin and 20 Ag/ml of 
DNase II, repeating the digestion in fresh buffer approximately 10 times for 
10 minutes each with slow stirring, preceded by 10 times up and down 
gentle pipetting of tissue pieces. After each cycle the supernatant was 
collected into a solution containing calf serum (10% v/v) to neutralize the 
action of trypsin.  
At the end of the cycles of digestion the collected cells were centrifuged for 




10 minutes at 1,200 rpm and the cellular pellet was resuspended in DME 
containing 5% bovine calf serum (HyClone).  
Cells were preplated for 2 hours into 100-mm dishes, in order to allow the 
engraftment on the plate of fibroblasts. By this procedure stromal cells 
were separated from unattached myocytes that were then plated in dishes 
for primary cells. 
 
Culture and treatments 
Neonatal rat ventricular myocytes were plated at low density in DME/4.5g 
glucose containing 5% bovine calf serum, vitamin B12 (2 mg/ml) and 
penicillin-streptomycin (100 U/ml) and cultured as described previously 
(Deng et al., 2000). Cardiomyocytes were plated at a density of 500 
cells/mm2 into multi-well plates (Costar) and incubated at 37°C, 5% CO2.  
For cardiomyocyte transduction using AAV vectors (AAV9-LacZ and AAV9-
Ghrl), neonatal rat cardiomyocytes were infected with MOI 104 the day 
after plating and, 12 hours later, the culture medium was changed. After 
additional 12 hours apoptosis was stimulated treating the cells with 2 
different chemical compounds either (-)-Isoproterenol hydrochloride 10=M 










 Figure 3.3 Drugs chemical structures  
(A) (-)-Isoproterenol hydrochloride (B) Doxorubicin hydrochloride  
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3.2.2 Cell viability assay 
To quantify neonatal rat cardiomyocytes viability after pro-apoptotic drugs 
stimulation we used the LIVE/DEAD Viability/Cytotoxicity Kit (Invitrogen), 
following manufacturer’s instructions. After the staining cells were fixed in 
3% PFA and 2% sucrose in PBS and their fluorescence was analyzed by the 
ImageXpressMICROTM microscope and by the software MetaXpressTM, 
both from Molecular Devices. 
 
 
3.3 IN VIVO EXPERIMENTAL PROTOCOLS 
Animal care and treatment were conducted in conformity with institutional 
guidelines in compliance with national and international laws and policies 
(EEC Council Directive 86/ 609, OJL 358, December 12th 1987). CD1 mice, 
C57/Bl6 mice and Wistar rats were obtained from Harlan and maintained 
under controlled environmental conditions. 
 
3.3.1 AAV vectors in vivo administration 
Tibialis anterior muscles of C57/Bl6 mice (1 month old) were transduced by 
direct injection of 50 µl (titer of 1012 vg/ml) of AAV vector preparation 
(AAV2-Pool25, AAV2-Pool50, AAV2-Pool100, AAV2-E2, AAV2-C12) for AAV 
genomes in vivo maintenance analysis.  
For the in vivo selection in the hind limb ischemia model 30 µl of pooled 
AAV2 vectors (AAV2-PoolA+B+C; titer of 1012 vg/ml) were bilaterally 
delivered to tibialis anterior muscles of adult CD1 mice, 5 days before the 
surgical intervention of unilateral femoral artery ligation.  
For the in vivo selection in the model of isoproterenol-induced cardiac 
damage three days old C57/Bl6 mice were injected intraperitoneally (i.p.) 
with 30 µl of pooled AAV9 vectors (AAV9-PoolA to AAV9-PoolL) 
preparations (titer of 1012 vg/ml). 




In the myocardial infarction model 30l (titer of 1012 vg/ml) of recombinant 
AAV vectors (AAV9-Control, AAV9-Ghrl or AAV9-INSL6) were administered, 
immediately after LAD coronary artery ligation, in three separate injections 
into the infarct-bordering zone. 
 
3.3.2 Animal model of hind limb ischemia 
Before femoral artery ligation, CD1 mice were anesthetized with an 
intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg), 
injected intraperitoneally and placed on a warming pad to maintain core 
body temperature between 36.8 and 37.8°C. 
Unilateral hind limb ischemia was induced, by resecting a 2.5 cm segment 
of the left femoral artery (Arsic et al., 2004). Animals were sacrificed 15 
days later and total DNA was extracted, as previously described, from both 
ischemic and non-ischemic transduced skeletal muscle for subsequent 
analysis of the viral genomes content in the tissue. 
 
3.3.3 Animal model of isoproterenol-induced cardiac fibrosis 
Three weeks after AAV vector pools administration in neonatal mice, a 
single high dosage (200 mg/kg) of (-)-Isoproterenol hydrochloride (Sigma) 
was administered by intraperitoneal injection in C57/Bl6 mice to determine 
an acute damage, consisting in coagulative myocytolysis and myofibrillar 
degeneration (Milei et al., 1978). After 15 days mice were sacrificed and 
the hearts retrieved. Total DNA was extracted, as previously described, 
from both Iso-treated and untreated transduced hearts for subsequent 
analysis of the viral genomes content in the tissue.  
The proper Isoproterenol concentration for the in vivo functional selection 
was previously set up comparing the cardiac damage induced by three 
different dosages (100, 200 and 300 mg/kg) of (-)-Isoproterenol 
hydrochloride. 




3.3.4 Animal model of myocardial infarction (MI) 
Myocardial infarction was produced in CD1 mice (8-10 weeks old), by 
permanent left anterior descending (LAD) coronary artery ligation, as 
described previously (Michael et al., 1999). 
Mice were anesthetized with ketamine (100 mg/kg) and xylazine (10 
mg/kg), placed on a warming pad to maintain body temperature at 37°C 
and endotracheally intubated and connected to a rodent ventilator (Model 
131, Nemi scientific Inc.). The beating heart was accessed via a left 
thoracotomy; after removing the pericardium the heart was exposed and 
the descendent branch of the LAD coronary artery was visualized by a 
stereomicroscope and ligated with an 8-0 silk suture. Ligation was 
considered successful when the anterior wall of the LV turned pale.  
As already mentioned, immediately after LAD coronary artery ligation 50 =l 
of recombinant AAV vectors (AAV9-Control, AAV9-Ghrl or AAV9-INSL6) 
were administered in three separate injections into the myocardium 
bordering the infarct zone, using a tuberculin syringe (30G) (Roche).  
The chest was closed and the mice moved to a prone position and kept on 
the heating pad until they recovered spontaneous breathing.  
 
3.3.5 Echocardiography analysis 
To analyze LV function and dimension, transthoracic two-dimensional 
echocardiography was performed 2, 7, 30, 60 and 90 days after myocardial 
infarction, in mice sedated with 5% isoflurane, using the Vevo 770 
Ultrasound (Visualsonics), equipped with a 30-MHz linear array transducer. 
M-mode tracing were used to measure left ventricular anterior and 
posterior wall thickness and internal diameter at end-systole and end-
diastole, fractional shortening and ejection fraction. 
 
 





After echocardiography analysis (either at day 2 after myocardial infarction 
for apoptosis and inflammatory cells infiltration evaluation or after 3 
months, at the end of the LV functional follow up) the animals were 
sacrificed, hearts were collected and washed in PBS. For histological 
analysis, tissue samples were snap frozen or fixed in 4% formaldehyde and 
embedded in paraffin. In both cases they were finally cut in 5Dm thick 
slices for subsequent analysis. Heart’s frozen sections recovered at day 2 
post-MI were used for TUNEL assay (described in the next paragraph), 
while paraffin embedded sections were stained with hematoxylin-eosin 
(H&E) for inflammatory cells infiltration analysis (quantified in 5 random 
fields per slide at 200x power, using ImageJ software). The samples 
collected 90 days after the infarct were submitted to Azan’s trichrome 
staining (Bio-Optica), according to manufacturer protocol. Infarct size was 
measured on the stained sections as the percentage of (endocardial + 
epicardial circumference of infarct area) / (endocardial + epicardial 
circumference of LV). 
Azan’s trichrome staining was used also to evaluate the extent of mice 
cardiac fibrosis after high dosage (-)-Isoproterenol hydrochloride 
intraperitoneal injection. 
 
3.3.7 TUNEL assay for apoptotic cells detection 
TUNEL (TdT-mediated dUTP nick-end labelling) assay was performed on 
frozen sections (5Dm thick) of LV infarcted hearts, collected 2 days after 
MI. The sections were fixed with 4% paraformaldehyde and permeabilised 
with 1% Triton X100 for 30 minutes. After 1 hour in blocking solution (2% 
BSA in PBS) at 37°C, the primary monoclonal antibody anti-sarcomeric -
actinin (EA-53, Abcam, Cambridge MA, USA) was used and diluted 1:100 in 
blocking buffer. Alexa Fluor 488 donkey anti-mouse was used as secondary 




antibody. Apoptotic cells were visualized by in situ cell death detection kit, 
TMR red (Roche Diagnostics, Mannheim, Germany), according to 
manufacturer’s instructions. Nuclei were stained with DAPI (H-1200, Vector 
laboratories, CA).  
All images were acquired by a DMLB upright fluorescence microscope 
(Leica Mycrosystems, Wetzlar, Germany) equipped with charge coupled 
device camera (CoolSNAP CF, Roper Scientific, Trenton, NJ, USA) using 
MetaView 4.6 quantitative analysis software (MDS Analytical Technologies, 
Toronto, Canada). At least 10 high-magnification fields were counted for 
each experimental condition.  
 
3.3.8 Enzyme Immunoassay (EIA) analysis 
The levels of acyl and des-acyl ghrelin peptides in the LV after AAV9-
Ghrelin intracardiac injection was assayed by a specific EIA kit from 
Phoenix Pharmaceuticals (Belmont, CA), according to the protocol provided 
by the supplier.  
 
 
3.4 STATISTICAL ANALYSIS 
One-way ANOVA and Bonferroni/Dunn’s post hoc test were used to 
compare multiple groups. Pairwise comparison between groups was 












The overall design of the FunSel approach, based on the iterative selection 
of secreted factors upon in vivo gene transfer using AAV vectors, is 
described and schematically illustrated in the Thesis Synopsis. The specific 
purpose of the work described in this thesis was to demonstrate the 
feasibility of FunSel in the cardiovascular system using a pool of 100 AAV 
vectors each one expressing a different secreted factor from the mouse 
secretome.  
 
The results described in this Thesis can be divided into five main points, 
representing the essential steps of this project: 
1. Development of an in vivo functional selection strategy: 
mathematical considerations  
We wanted to support the feasibility of the in vivo, AAV based, FunSel 
functional selection strategy by generating a mathematical model that 
takes into account the parameters influencing in vivo selection of genes 
after gene transfer. These parameters include variables such as 
transduction efficiency, multiplicity of in vivo infection, effects of the 
unwanted co-selection of non transduced cells, efficiency of selection the 
transduced cells, complexity of vectors pools and number of selection 
cycles. Applying the developed model over a range of possible conditions 
permitted to identify those that support the feasibility of the iterative 
selection approach. 
 
2. Generation of an arrayed library of AAV vectors corresponding 
to secreted genes  
We generated a collection of 100 AAV vector plasmids, each one 
expressing a secreted factor. The construction of this collection of clones 




FANTOM Project mouse secretome collection and enriched in growth 
factors and hormones, into an AAV-backbone plasmid under the control of 
the constitutive CMV IE promoter.  
 
3. Validation of the AAV vector pool composition 
This part of the project was aimed at assessing whether it is possible to 
simultaneously obtain pools of AAV vectors with variable complexity. We 
analysed the critical steps in library construction, including vector 
packaging, in vivo transduction, persistence and level of expression. The 
ultimate purpose of this part of the project was to find the experimental 
conditions that guarantee a balanced representation of the different viral 
genomes in each viral vector pool during vector production and after in 
vivo transduction. 
 
4. In vivo functional selection of the AAV vectors collection 
Next we wanted to provide a proof-of-principle result that supported the 
efficacy of FunSel. To identify novel potentially therapeutic secreted 
molecules exerting a protective effect against cardiovascular damage, 
FunSel was applied, using the developed 100 clones, to two models of 
damage in the mouse. The first one corresponded to hind limb ischemia 
while the second to isoproterenol-induced myocardial injury. Two novel 
factors were identified in the tested pool of 100 genes, namely ghrelin in 
the former case and INSL6 in the latter.  
 
5. Validation of the therapeutic effect of the in vivo selected genes 
Ghrelin and INSL6 were individually tested for efficacy after myocardial 
infarction in the mouse after intracardiac AAV gene transfer. Both factors 
were proven to exert a marked effect in preserving cardiac function, as 
concluded by echocardiographic evaluation of cardiac contractility over 






4.2 DEVELOPMENT OF AN IN VIVO FUNCTIONAL SELECTION 
STRATEGY: MATHEMATICAL CONSIDERATIONS 
 
This section reports a mathematical model that, taking into account the 
most relevant variables affecting the outcome of in vivo functional selection 
for potentially therapeutic genes, supports the feasibility of the approach. 
FunSel is essentially based on: 
i) the production of a pool of AAV vectors of variable complexity; 
ii) the transduction of a given tissue in vivo with this pool of vectors; 
iii) the delivery of a selection stimulus to the tissue, typically the induction 
of cell damage; cells transduced with a protective gene will preferentially 
survive over cells transduced with an irrelevant vector or cells that are not 
transduced. 
iv) at a give time from damage, the recovery of vectors from the tissue and 
the analysis of the representation of each individual vector; 
v) the eventual cloning of the recovered vectors to generate a new pool of 
vectors and the iterative repetition of the selection. 
The success of FunSel essentially depends on the capacity of an AAV 
vector pool to transduce a target tissue by delivering several genes 
simultaneously, on the capacity of one or more of these genes to induce 
selection against an insult and thus become enriched compared to the 
others, and on the number of iterations required for the selection to 











4.1.1 Mathematical model: variables and formula 
The ultimate purpose of the AAV selection procedure is the in vivo selection 
of one AAV coding for a desired transgene (T) from a pool of several AAVs 
(POOL), each one coding for a different factor. The ratio between T and 
POOL is defined as R (R=T/POOL).  
The increase of R is an indication of the success of the selection procedure.  
At the beginning of the selection experiment: R=T/POOL=1/(number of 
vectors in the analyzed pool); 
At the end of the experiment: R=1/(number of selected vectors). 
For example, if a pool of 25 vectors, each one present in equimolar amount 
to the others, is injected, R=1/25=0.04 at start. Any increase (up to R=1) 
at the end of the experiment indicates successful selection. 
















Variable Description Symbol Range of reasonable values 
Transduction 
efficiency 
Measures the fraction of 
cells transduced 
ET 
>0 to 1 (ET=1 when 




Measures how many AAV 
genomes are present in a 
single cell nucleus 
MOI >0 to 1,000 
Co-selection effect 
Measures the extension of 
the selection effect exerted 
by the transgene on 
neighboring cells 
COSEL 0 to 100 
Efficiency of 
selection 
Measures how efficient is 
the selection process, 
namely the selective 
advantage offered by the 
transgene 
ES 
>0 to 1 (ES=1 when 
all cells not containing 
the desired transgene 




Measures how many 
different AAV vectors are 
used for transduction 





At each cycle of selection, when the number of vectors with the desired 
transgene is set to 1 (T=1), the total number of AAV vectors after 
transduction and selection consists of the sum of:  
 (i) The number of vectors co-infecting the same cell as the desired vector 
(MOI); 
 (ii) The number of vectors present in the cells close to the selected cell and 
co-selected with this (COSEL*ET*MOI); 
 (iii) The total number of vectors in the cells containing other transgenes 
but surviving the selection ((POOL-MOI)-COSEL*ET*MOI)*(1-ES). 
 Thus:  
 R=1/(i + ii + iii) 
 Or: 
R=1/(MOI + (COSEL*ET*MOI) + ((POOL-MOI)-COSEL*ET*MOI)* 
(1-ES)) 
The value of R at the end of each cycle of the selection procedure has to 
be compared with its value at start, when R=1/POOL. 
POOL represents the number of vectors that are initially used for the 
selection, when all these are equimolarly represented. Thus, 1/POOL is the 
fraction corresponding to the vector of interest. When subsequent cycles of 
selection are iteratively applied, at each cycle 1/POOL corresponds to the 
R-value obtained from the previous cycle of selection.  
 
Note: In the above formula and all throughout the following calculations, it 
is assumed that the number of different AAVs forming each pool is 
sufficiently large and the multiplicity of infection is sufficiently low to render 
the possibility that more than one AAV containing the transgene of interest 





4.1.2 Selection under ideal conditions 
Under ideal conditions, multiplicity of infection is 1 (a single vector 
transduces each cell; MOI=1), there is no co-selection of cells not 
expressing the desired, selectable transgene (COSEL=0), and no cells 
other than those containing the transgene are selected (ES=1). Under 
these conditions, R=1. Therefore, a single round of selection is sufficient 
to completely select the transgene-expressing cells (Figure 4.2). Of 
notice, under these conditions, the efficiency of transduction (ET) is 








4.1.3 Effect of multiplicity of infection (MOI) 
Since AAV can transduce cells at a high multiplicity of infection, this 
parameter needs to be taken into account during the selection procedure. 
If COSEL=0 (no coselection of cells due to the diffusion of the transgene 
effect) and ES=1 (selection affects only the transduced cells), then 
R=1/MOI. 
In simple terms, under these conditions, the efficiency of the strategy will 
be reflected by the number of genomes that are co-selected together with 
the transgene within the same cell. Additional cycles of selection beyond 
the first one will not improve selection; similar to above, the complexity of 
the pool (POOL) and the efficiency of transduction (ET) are irrelevant 
(Figure 4.3).  
 
Figure 4.2 Ideal conditions of selection 
If we are under ideal selection conditions 
(MOI=1, COSEL=0 and ES=1) in a single round 
(R=1) we are able to select the cells expressing 













As noted in the first paragraph, this conclusion holds true if it is assumed 
that the complexity of the analyzed pool of AAV vectors is sufficiently large 
and the multiplicity of infection is comparatively low to exclude that more 













We suppose to transduce cells at an efficiency of 40% (ET=0.4), that 3 
vectors enter each cell (MOI=3), that we start with a complexity of the 
library of 6 vectors (POOL=6), that the efficiency of selection is complete 
(ES=1) and there is no coselection due to transgene diffusion (COSEL=0). 
If we analyze 25 cells, 10 cells will be transduced, each one harbouring 3 
AAVs (10x3=30 vectors in total). Of these, 30/6=5 will correspond to the 
selectable transgene. After selection, only the 5 cells containing the 
transgene will survive; when the total AAV vectors will be recovered and 
analyzed for the presence of the transgene, there will be 15 total vectors, 
out of which 5 will correspond to the transgene (T). Thus, R=5/15, which 
equals 1/3=0.33. This value has to be compared to R=1/MOI=1/6=0.17 at 
start. 
 
Figure 4.3 Effect of multiplicity of infection (MOI) 
If COSEL=0 and ES=1 then R=1/MOI. In this case the efficiency of the strategy is 




















4.1.4 Influence of the coselection of other cells due to 
transgene bystander effect 
Now we consider a case in which the efficiency of selection (ES)=1, and 
thus only the cells containing T survive the selection, but there is a 
bystander effect due to the diffusion of the product of T. In this case, the 
formula becomes:  
R=1/(MOI + (COSEL*ET*MOI))  
Under these conditions, a certain number of cells will be co-selected 
together with those containing T. This effect is taken into account by the 
COSEL parameter, which ranges from 0 (no coselection) to a positive 
number, which is proportional to the number of cells selected with every 
cell containing T. The probability that a co-selected cell contains an AAV 
vector depends on the efficiency of transduction (ET), while the number of 
AAV vectors contained inside this cells is measured by MOI.  
The graphs below (Figure 4.4) show the combined influence of the 
multiplicity of infection (MOI; 1 to 10) and the coselection parameter 
(COSEL; 0 to 9) variations at three fixed efficiencies of transduction (ET=1, 
0.5 and 0.1). In this case R changes independently from the complexity of 
the vector pool (POOL). As above, performing iterative cycles of selection 


































































































 COSEL 0    COSEL 1    COSEL 2 
 COSEL 3    COSEL 4    COSEL 5 
 COSEL 6    COSEL 7    COSEL 8 






As it can be appreciated, the problem of the coselection due to the 
transgene bystander effect becomes less and less relevant (the lines 
corresponding to different COSEL values are closer each other) as the 
efficiency of transduction decreases (the lower the number of transduced 
cells, the lower the chance that cells containing an irrelevant transgene 
neighbour those containing T).  
Figure 4.4 Effect of coselection (COSEL) 
Combined influence of the multiplicity of infection (MOI; 1 to 10) and the 
coselection parameter (COSEL; 0 to 9) at three fixed efficiencies of transduction 
(ET=1, 0.5, and 0.1). 
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The following graphs (Figure 4.5) well illustrate this concept at three fixed 















 COSEL 0    COSEL 1    COSEL 2 
 COSEL 3    COSEL 4    COSEL 5 
 COSEL 6    COSEL 7    COSEL 8 
 COSEL 9 
 
As in the cases considered above, performing subsequent cycles of 
selection beyond the first one does not improve T enrichment, since it is 
assumed that only cells containing the transgene survive the selection itself 
(ES=1).  
For the same reason, complexity of the vector pool (POOL) equally has no 
influence. 
Figure 4.5 Effect of coselection (COSEL) 
Combined influence of the coselection parameter (COSEL; 0 to 9) and the 
efficiencies of transduction (ET; 0.1 to 1) at three fixed multiplicity of infection 
(MOI=1, 3 and 10). 
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4.1.5 Effect of poor efficiency of selection 
In the case the efficiency of selection (ES) is <1 (for example that a certain 
number of cells survive the selection although not containing the transgene 
or anyhow not because of a bystander transgene effect), then the equation 
describing R needs to also take into account the presence of these cells. 
These can be described as:  
((POOL-MOI)-COSEL*ET*MOI)*(1-ES)  
In this case, POOL-MOI describes the number of surviving cells while 
COSEL*ET*MOI the transduced cells anyhow selected because of the 
transgene bystander effect (taken into account in the previous paragraph). 
Here, the complexity of the initial pool of vectors becomes important 
(POOL). If COSEL=0, then the equation measuring R becomes 
R=1/(MOI+(POOL-MOI)*(1-ES). 
Of notice, when no coselection due to transgene bystander effect occurs 
(COSEL=0), the efficiency of transduction (ET) does not influence the ratio 
between the selectable transgene and the other AAV inserts. 
 
The graphs below (Figure 4.6) describe R according to POOL for different 
MOIs considering efficiency of selection (ES) of 0.9, 0.6 and 0.3.  
As it can be appreciated, the probability of selecting T decreases 
dramatically concomitant with an increase in the initial vector pool 














































 POOL 10    POOL 20    POOL 30 
 POOL 40    POOL 50    POOL 60 
 POOL 70    POOL 80    POOL 90 






4.1.6 Performing iterative cycles of selection 
When the efficiency of selection (ES) is <1, the performance of the process 
is substantially increased by performing subsequent, iterative cycles of 
selection, which includes the recovery of all transgenes from the cells or 
tissues (by PCR) and re-cloning of these inserts into new vector plasmids, 
followed by production of a new vector pool which is then resubmitted to 
the selection process. At each of these steps, the complexity of the vector 
pool (POOL) reflects the number of different vectors recovered from the 
tissue, in which the ratio between T and all the other transgenes 
progressively increases.  
As discussed above, performing multiple cycles of selection does not 
improve selection in conditions when there is an effect of the transgene 
extending to other cells, since, in this case, the ratio between the 
transgene of interest and the other AAV inserts essentially depends on the 
Figure 4.6 Effect of poor efficiency of selection (ES) 
Combined influence of the complexity of vector pools (POOL; 10 to 100) and the 
multiplicity of infection (MOI; 1 to 10) at three, fixed efficiency of selection (ES=0.9, 














































multiplicity of infection and the transduction efficiency. Similar to above, we 
will therefore only consider cases in which there is no co-selection of cells 
not containing the transgene (COSEL=0).  
We analyzed a case in which we start with 25 different vectors (POOL=25), 
assume a fixed value for MOI (MOI=3) and consider the influence of the 
efficiency of selection (ES). The graph below (Figure 4.7) reports the 
effect of performing 1-10 subsequent cycles of selection in these 








 ES 0.1    ES 0.2    ES 0.3 
 ES 0.4    ES 0.5    ES 0.6 
 ES 0.7    ES 0.8    ES 0.9 






As it can be appreciated, subsequent cycles of selection progressively 
improve enrichment of the desired transgene, up to a maximum 
corresponding to the theoretical value of 1/MOI (1/3=0.33 in the specific 
considered case, to be compared with R=0.04 before initiating the 
selection procedure).  
 
Figure 4.7 Effect of iterative cycles of selection 
Combined influence of efficiency of selection (ES; 0.1 to 1) and rounds of selection 
(number of cycles from 1 to 10), at a fixed multiplicity of infection (MOI=3) and 


































We now consider the influence of the POOL size on the selection, again by 
choosing a fixed value of MOI=3 and an efficiency of selection ES=0.5 










 POOL 10    POOL 20    POOL 30 
 POOL 40    POOL 50    POOL 60 
 POOL 70    POOL 80    POOL 90 





Also in this case, R progressively reaches a plateau corresponding to 
1/MOI; this plateau is already reached at cycle 7 when POOL=10 or at 
cycle 10 when POOL=80. In this respect, however, it is worth noting that, 
even in the worst scenario (POOL=100), while R=1/100=0.01 before the 
selection, it becomes R=0.02 at the first cycle and 0.32 at cycle 10, thus 
rendering the identification of the effective transgene theoretically possible.  
 
To conclude, a realistic (or even slightly unfavourable) scenario, might 
entail an efficiency of transduction (ET) of 10% of the cells, an average 
number of 3 vectors per cell (MOI), a bystander co-selection effect of 2 
additional cells every cell expressing the selectable transgene (COSEL), an 
efficiency of selection (ES) of 30% and a pool size (POOL) of 50 different 
vectors. 
Figure 4.8 Effect of iterative cycles of selection 
Combined influence of pool complexity (POOL; 10 to 100) and number of selection 































As shown in Figure 4.9 under these conditions it is possible to clearly 
observe a progressive increase in the enrichment of the desired transgene 
upon 10 cycles of selection. Indeed, at the tenth cycle of selection, R=0.18, 
a value that has to be compared with the initial value R=1/50=0.02 before 










submitted to selection in the absence of selection 
 
CYCLE 1 2 3 4 5 6 7 8 9 10 









Taken together, the theoretical considerations illustrated in this Thesis 






Figure 4.9 Transgene enrichment upon iterative cycles of selection 
Example of transgene enrichment, taking into account all the variables individually 
analyzed in the previous paragraphs. Considering the combined influence of 
ET=0.1, MOI=3, COSEL=2, ES=0.3 and POOL=50 the R-values plotted in the graph 
and summarized in the table below are generated. Initially, R=0.02 (plotted in red) 


































4.2 GENERATION OF AN ARRAYED LIBRARY OF AAV 
VECTORS EXPRESSING SECRETED FACTORS 
 
The ultimate purpose of the FunSel project is the creation of an arrayed 
library of cDNAs corresponding to the mouse secretome, their delivery in 
vivo using AAV vectors and the in vivo selection of clones exerting a 
beneficial effect. This Thesis reports a pilot experiments, demonstrating the 
feasibility of the FunSel approach, using a subset of 100 clones.  
 
4.2.1 The mouse secretome cDNA arrayed library 
A first step in the project was the creation of a collection of cDNAs coding 
for secreted proteins cloned into an AAV-backbone plasmid, followed by the 
generation of the correspondent collection of AAV vectors.  
The arrayed library we generated is composed of clones derived from the 
mouse secretome, which can be defined as the subset of proteins secreted 
into the extracellular environment of a cell. In particular, we had access to 
portions of the RIKEN secretome collection of clones (Grimmond et al., 
2003), selected by a computational approach, from the RIKEN mouse 
genes encyclopedia (Kawai et al., 2001; Okazaki et al., 2002). This is a 
collection of more than 60,000 fully sequenced cDNA clones, created by the 
Fantom (Functional Annotation of the mouse) Consortium, led by the 
RIKEN Institute. During the process of generation of the mouse secretome, 
these authors identified 2,033 unique soluble proteins that are potentially 
secreted from the cell, including hundreds of novel proteins of unknown 
function.  
Since the work described in this Thesis was the generation of a collection 
of recombinant AAV vectors coding for secreted factors, we had to face the 
restrain posed by the small size of the AAV genome, which limits the length 






By a careful initial selection of the clones in the database 
http://fantom3.gsc.riken.jp/ we eventually reduced the number of factors 
eligible for the individual sub-cloning into the pZac2.1 vector, a specific 
AAV backbone-plasmid for AAV production, to approximately 1,600 cDNAs. 
The main criteria applied for the selection of these cDNAs were:  
- cDNA size <3,000 bp;  
- Availability of the complete coding sequence; 
- Lack of transmembrane domain or intracellular localization signal; 
- Presence of a signal peptide (required for entry into the secretory 
pathway); 
- 5' and 3' UTR not truncated.  
Abundant and rare transcripts are equally represented in this arrayed 
collection of clones, and the majority of the cDNAs included in our selection 
(a total of 1,600 cDNAs representing the 85% of the full collection) are less 








































Among the 1,600 cDNAs eligible for FunSel, we arbitrarily choose a first 
group of 100 cDNAs, for the set-up and proof-of-principle work described in 
this Thesis. These 100 factors were chosen without any a priori selection 
for their function. 
 
In Figure 4.11 is reported a list of the chosen factors which are members 
of different classes of secreted molecules, namely chemokines, interleukins, 
hormones, growth factors, secreted enzymes, extracellular matrix proteins, 
secreted molecules of unknown function and others. 
 
  
Figure 4.10 cDNAs size distribution 
Size distribution of the cDNAs of mouse genes coding for putative secreted 
proteins. The boxed are shows those selected for possible cloning into AAV vectors. 
Chemokines and Interleukins GENEBANK NCBI RefSeq
chemokine (C-C motif) ligand 6 Ccl6 NM_009139
chemokine (C-C motif) ligand 7 Ccl7 NM_013654
chemokine (C-C motif) ligand 8 Ccl8 NM_021443
chemokine (C-C motif) ligand 11 Ccl11 NM_011330
chemokine (C-C motif) ligand 12 Ccl12 NM_011331
chemokine (C-X-C motif) ligand 9 Cxcl9 NM_008599
chemokine (C-X-C motif) ligand 13 Cxcl13 NM_018866
chemokine (C motif) ligand 1 Xcl1 NM_008510
interleukin 17A Il17 NM_010552
interleukin 20 Il20 NM_021380
interleukin 27 Il27 NM_145636
Hormones and Growth Factors
apelin Apln NM_013912
insulin-like 6 Insl6 NM_013754
family with sequence similarity 198, member A Fam198a NM_177743
family with sequence similarity 3, member B Fam3b NM_020622
follicle stimulating hormone beta Fshb NM_008045
gastrin Gast NM_010257
growth hormone releasing hormone Ghrh NM_010285
ghrelin Ghrl NM_021488
gastric inhibitory polypeptide Gip NM_008119 
neuromedin U Nmu NM_019515
natriuretic peptide precursor type C Nppc NM_010933
neurotensin Nts NM_024435
pro-opiomelanocortin-alpha Pomc NM_008895






prolactin family 3, subfamily b, member 1 Prl3b1 NM_008865
prolactin family 3, subfamily d, member 1 Prl3d1 NM_008864
prolactin family 5, subfamily a, member 1 Prl5a1 NM_023746
prolactin family 7, subfamily b, member 1 Prl7b1 NM_029355
prolactin family 7, subfamily d, member 1 Prl7d1 NM_011120
prolactin family 8, subfamily a, member 81 Prl8a8 NM_023741 
prolactin family8, subfamily a, member 9 Prl8a9 NM_023332
trefoil factor 1 Tff1 NM_009362
trophoblast specific protein beta Tpbpb NM_026429
thyrotropin releasing hormone Trh NM_009426
vasoactive intestinal polypeptide Vip NM_011702
Secreted Enzymes
arylsulfatase A Arsa NM_009713
biotinidase Btd NM_025295
carboxylesterase 2A Ces2a NM_133960
carboxylesterase 2E Ces2e NM_172759
cystatin 9 Cst9 NM_009979
cystatin 11 Cst11 NM_030059
cystatin 12 Cst12 NM_027054
cystatin 13 Cst13 NM_027024
chymotrypsinogen B1 Ctrb1 NM_025583 
cathepsin R Ctsr NM_020284 
glucosidase, beta, acid Gba NM_008094 
kallikrein 1 Klk1 NM_010639
lysozyme-like 1 Lyzl1 NM_026092
matrix metallopeptidase 1a Mmp1a NM_032006
napsin A aspartic peptidase Napsa NM_008437
progastricsin (pepsinogen C) Pgc NM_025973
phospholipase A2, group IB Pla2g1b NM_011107
renin 1 Ren1 NM_031192
Extracellular Matrix Proteins
amelogenin X chromosome Amelx NM_009666
asporin Aspn NM_025711
fibromodulin Fmod NM_021355
intelectin b Itlnb NM_001007552
keratocan Kera NM_008438
matrilin 3 Matn3 NM_010770
nephrocan Nepn NM_025684
nephronectin Npnt NM_033525
spondin 2 Spon2 NM_133903
transforming growth factor, beta induced Tgfbi NM_009369
vitronectin Vtn NM_011707
Secreted Molecules (Unknown Function)
RIKEN cDNA D730048I06 gene D730048I06Rik NM_026593 
RIKEN cDNA 1600029D21 gene 1600029D21Rik NM_029639
RIKEN cDNA 1700016D06 gene 1700016D06Rik NM_024271
RIKEN cDNA 1700029I15 gene 1700029I15Rik NM_183112
RIKEN cDNA 1700040I03 gene 1700040I03Rik NM_028505
RIKEN cDNA 2010109I03 gene 2010109I03Rik NM_025929 
RIKEN cDNA 2210415F13 gene 2210415F13Rik NM_001083884
RIKEN cDNA 4930568D16 gene 4930568D16Rik NM_029463
RIKEN cDNA 4930597L12 gene 4930597L12Rik
RIKEN cDNA 5430402E10 gene 5430402E10Rik NM_027768
RIKEN cDNA 5530400C23 gene 5530400C23Rik NM_027784
Hypothetical protein Gm10344












4.2.2 Generation of a collection of AAV vectors expressing 
100 secreted factors  
In order to perform several rounds of in vivo selection, according to the 
FunSel strategy, each cDNA needs to be cloned into the same vector 
backbone, exploiting common restriction sites. The cDNAs were therefore 
obtained from the original RIKEN plasmids (either modified pBluescript SK 
(+) or pFlcI) by PCR amplification with common primers carrying Xho I and 
Not I restriction sites at their 3' extremities, to allow oriented cloning into 
the Multiple Cloning Site (MCS) of pZac2.1 AAV backbone plasmid. This 
vector contains two Inverted Terminal Repeat sequences (ITRs), essential 
Figure 4.11 cDNAs selected for FunSel approach set up 
Different classes of factors (chemokines, interleukins, hormones, growth factors, 
secreted enzymes, extracellular matrix proteins, secreted molecules of unknown 
function and others belonging to different classes), have been chosen among the 
1,600 cDNAs eligible for FunSel and included in the group of 100 cDNAs used for 
the set-up and proof-of-principle validation of the selection strategy. 
 
Others
proacrosin binding protein Acrbp NM_016845
acrosomal vesicle protein 1 Acrv1 NM_007391
alpha fetoprotein Afp NM_007423
anterior gradient homolog 3 Agr3 NM_207531
complement component 8, beta polypeptide C8b NM_133882
carcinoembryonic antigen-related cell adhesion molecule 13 Ceacam13 NM_027210
CD48 antigen Cd48 NM_007649
defensin, alpha, 20 Defa20 NM_183268
defensin beta 22 Defb22 NM_001002791
ephrin A1 Efna1 NM_010107
coagulation factor VII F7 NM_010172
GLI pathogenesis-related 1 like 1 Glipr1l1 NM_027018 
lipocalin 9 Lcn9 NM_029959
odorant binding protein Ia Obp1a NM_008754
oocyte secreted protein 1 Oosp1 NM_133353
phosphatidylethanolamine binding protein 4 Pebp4 NM_028560
regenerating islet-derived 3 delta Reg3d NM_013893
regenerating islet-derived 3 gamma Reg3g NM_011260
salivary protein 1 Spt1 NM_009267
seminal vesicle antigen-like 1 Sval1 NM_027832
testis expressed gene 101 Tex101 NM_019981





for recombinant vector production, the CMV IE promoter to drive transgene 
expression and the SV40 polyadenylation site (Figure 4.12).  
Each plasmid clone was obtained individually by the described approach, 
and its identity and preservation of correct sequence were verified by direct 
DNA sequencing. Indeed, in addition to allowing the in vivo functional 
selection of possible therapeutic genes, the availability of individual AAV 
clones from the library will represent an important tool for any future 



































4.2.3 Recombinant AAV vector pooled production 
The model of functional selection we developed entails the concomitant in 
vivo expression of several genes obtained from the collection; therefore the 
first essential goal was to demonstrate the feasibility of viral vectors pooled 
production. For this purpose, after the individual cloning of the cDNAs 
collection, we wanted to validate the production of individual viral 
preparations composed by pools of AAV vectors expressing different genes. 
A first experiment was performed by selecting 10 different AAV plasmids, 
having inserts of different length, mixing them each one a 1/10 
concentration compared to the amount commonly used for AAV vector 
production, and transfecting them into HEK 293T cells together with and 
AAV2 helper plasmid. 
After vector production, viral genomes, recovered from each pooled AAV 
preparation, were submitted to PCR amplification using a single pair of 
primers annealing to the common pZac2.1 vector sequence and spanning 
the MCS. As shown in the representative pool of 10 genes in Figure 4.13, 
the competitive amplification of the cDNAs composing the pool allowed the 
unambiguous identification of each clone in the viral lysate, confirming the 




Figure 4.12 Scheme of the sub-cloning in the AAV backbone plasmid 
pZac2.1 
A. The selected cDNAs have been obtained from the original RIKEN cloning vectors 
modified pBluescript SK (+) or pFlcI by PCR amplification with common primers 
carrying XhoI and NotI restriction sites at their 3' extremities.  
B. The same restriction sites have been used for a directional cloning of each cDNA 
into the MCS of pZac2.1 AAV-backbone plasmid, containing the ITRs sequences, 
necessary for recombinant viral vector production, a CMV IE promoter that drives 









































Figure 4.13 Recombinant AAV vectors can be generated in pool 
Transgene PCR amplification from single plasmids coding for 10 different factors 
composing a pool (left panel) and from the total viral lysate recovered after pooled 






4.3 VALIDATION OF THE AAV VECTOR POOLS 
COMPOSITION 
 
To guarantee a balanced representation of each viral genome in a pool of 
vectors, different vector pools were then tested for their packaging 
potential, ability of in vivo transduction, and level of transgene expression. 
These results gave us important information for a better definition of the 
advantages and limitations of the FunSel strategy. 
  
4.3.1 Generation of pools of AAV vectors homogeneous for 
transgenes size is essential to guarantee the faithful 
maintenance of AAV vector genomes during pooled 
production 
Once demonstrated that it is possible to generate AAV vectors in pools, we 
decided to investigate which are the critical steps that influence the 
packaging process of the viral particles, in order to take them into account 
during pooled vector production.  
First, we wanted to understand whether differences in cDNA length might 
affect the DNA packaging process. We constructed an AAV pool composed 
of 25 cDNAs of different length (Figure 4.14), representative of the 
variety of clone lengths present in the secretome collection (from 459 bp to 
2941 bp), and analyzed the packaging efficiency after viral vector 
production. Equimolar amounts of each plasmid were used to obtain a 25-
vector pool, which was transfected into the packaging cells to generate 
infectious AAV virions (AAV2-Pool25).  
Then, we quantified the copy number of 10 genes in both the plasmid 
preparation and the viral lysate by quantitative Real-Time PCR using insert-
specific primer pairs. The 10 analyzed genes were selected in order to be 





number of vector DNA copies in the pool was quantitatively measured by 
real-time amplification with a Taqman probe using primers specific for the 
CMV promoter, common to all vectors.  
The proportion of each gene in the pool was calculated by the ratio 
between total viral genomes and the genomes corresponding to each cDNA 
(expected value: 25) followed by normalization with the number of cDNAs 















The results obtained showed that representation of all the investigated 
constructs in the infectious viral preparations remained substantially similar 
to that in the input pool of plasmids. There was a trend of reduced 
packaging correlating with increase insert length (Figure 4.15A). Despite 
this evidence, the ratio between the individual cDNA representation in the 
plasmid and the vector pools was within a ±2 fold range for 9 out of 10 
clones (Figure 4.15B). This relatively narrow variation was considered 


















































































Figure 4.14 Size distribution of 25 AAV plasmids, each one coding for a 
different secreted protein (indicated by codes), composing the AAV2-
Pool25  
The insert lengths ranged from 459 bp to 2941 bp. Clones shown in black were 
subsequently chosen for PCR quantification in the plasmid pool and in the AAV 






The three clones having >1500 bp were packaged at efficiencies of 0.55, 
0.68 and 0.46 compared the expected value of 1, confirming the relevance 
of insert size on packaging efficiency; the only gene that dropped out the 
±2 fold interval was 1D12, the longer one (2340 bp).  
From these results we can conclude that clones of similar length show 
comparable packaging efficiency. Therefore, it appears important to 
generate homogeneous pools, in order to give all the cDNAs an equal 
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To further explore this issue and exclude that the relatively reduced 
packaging efficiency observed for clones 2E4, F2 and 1D12 might correlate 
with intrinsic properties of their genomic sequences, rather than size, these 
clones were then mixed with other 22 clones of length >1500 bp, and an 
additional AAV pool of 25 factors with large size genomes was generated 















As in the previous experiment, we designed specific primers for 10 genes 




































































































Figure 4.15 Packaging efficiency of 10 genes from the AAV2-Pool25 
A. Packaging efficiency of 10 cDNAs of different size from the AAV2-Pool25 was 
calculated both in the pool of plasmids and in the viral lysate upon viral production. 
The efficiency is expressed as a ratio between total viral genomes (quantified as 
CMV promoter copy number) and genomes corresponding to each cDNA, followed 
by a normalisation on the total number of cDNAs in the pool.  
B. Abundance of 10 selected constructs in the vector and plasmid pools 
(Collaboration), distributed according to size. The green area indicates the ±2 fold 
Figure 4.16 Size distribution of 25 AAV plasmids, each one coding for a 
different secreted proteins (indicated by codes), composing the AAV2-
Pool25Big (1500 bp - 3000 bp) 
Clones shown in black were subsequently chosen for PCR quantification in the 






verified by quantitative PCR their relative amount, before and after AAV 
production (Figure 4.17A).  
In this case, most of the cDNAs were packaged at good efficiency (within 
±2-fold range compared to expected). These also included 2E4 and F2, 
thus supporting the conclusion that the relatively poor packaging efficiency 
of these clones observed previously was a consequence of their length and 
not their primary DNA sequence.  
On the other hand, also in this pool, genomes of major size exhibited 
reduced packaging ability. In particular, the three longest clones (1D12, 
2C11 and 1C9) dropped out the fixed tolerance range of ±2 fold compared 
to the expected packaging efficiency value (Figure 4.17B).  
From these results we can conclude that, to generate AAV pools for in vivo 
selection, it is essential to organize the clones in groups homogeneous for 
insert length, in order to guarantee that all factors are packaged into the 

























































4.3.2 The complexity of a pool does not influence viral 
packaging efficiency  
To investigate whether AAV vector production might be influenced by the 
number of different, simultaneously packaged constructs, we generated 
two pools of vectors, composed of equimolarly represented 50 or 100 
clones (AAV2-Pool50 and AAV2-Pool100). Both pools included the clones of 
the previous analyzed AAV2-Pool25, consisting of cDNAs representative of 
all possible insert lengths; Pool100 included the entire collection of the 
selected, secreted molecules. 
In both AAV2-Pool50 and AAV2-Pool100, quantification of the same 10 
genes already analyzed in AAV2-Pool25 revealed that these were all 
Figure 4.17 Packaging efficiency of 10 genes from the AAV2-Pool25B 
A. Packaging efficiency of 10 cDNAs of different size from the AAV2-Pool25B 
calculated in both the pool of plasmids and the corresponding viral lysate upon viral 
production. The efficiency is expressed as a ratio between total viral genomes 
(quantified as CMV promoter copy number) and the genomes corresponding to each 
cDNA, followed by a normalisation on the total number of cDNAs in the pool. The 
clones previously analyzed in the AAV2-pool25 are indicated in red. 
B. Abundance of 10 selected factors, when mixed in a pool of 25 vectors carrying 
inserts with size >1500 bp. The ratios between abundance of each construct in the 
vector and plasmid pools is shown, distributed according to size. The green area 
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represented within the ±2-fold range compared to the expected values, 
again with the exception of clones F2 and 1D12 (Figure 4.18). This result 
indicated that, in order to generate a vector collection in which all vectors 
are equally represented, the complexity of the collection itself in terms of 

























Figure 4.18 Packaging efficiency of 10 genes from the AAV2-Pool50 and 
AAV2-Pool100 
Abundance of the same 10 selected constructs analyzed in the AAV2-Pool25, when 
included in (A) 50- and (B) 100-vector pools. Shown are the ratios between 
abundance in the virus and plasmid preparations, distributed according to size. The 
green area shows the ±2-fold interval.  
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When considered collectively, these results are consistent with the 
conclusion that multiple (at least up to 100) AAV vectors can be packaged 
simultaneously and that the individual representation of each construct in 
the vectors pool fairly represents its original amount in the mix of plasmids.  
An exception to this rule is represented by constructs carrying inserts 
>1500-2000 bp, which may be not favoured in competitive packaging.  
To be included in complex vector mixtures, these constructs should better 
be considered in combination with other constructs carrying inserts of 
comparable size. 
 
4.3.3 AAV vectors genomes ratios are maintained after in 
vivo transduction and persist in the transduced tissue  
An additional important question needing investigation was the in vivo 
transduction performance of the AAV pools. Therefore, we investigated 
whether individual AAV vectors maintained their infectivity when present in 
complex mixtures.  
To address this issue, the original AAV2-Pool25 was injected into the 
murine skeletal muscle, followed by the quantification of the same 
previously investigated 10 genes before and after in vivo transduction, 
comparing their relative genome copy number in the viral lysate and in the 
transduced tissue.  
We delivered ~50 µl of a 1x1012 viral genomes (vg)/ml vector preparation 
of AAV2-Pool25 in the tibialis anterior (TA) muscle of C57/Bl6 mice (n=4) 
and sacrificed the animals three days after transduction. Total DNA was 
extracted from the tissue and then quantitative PCR was performed as 
already described. In particular, we quantified the copy numbers 
corresponding to the 10 genes and verified whether each of these genes, 
as expected, actually represented 1/25 of the total viral genomes rescued 





All vectors were able to efficiently transduce skeletal muscle, since all the 
viral genomes were detectable in tissue extracts 3 days after vector 
delivery. The proportion of each vector over the total viral DNA content in 
the tissue (expressed as CMV copy number) was perfectly comparable with 
that measured in the viral preparation, before in vivo transduction.  
From this result we can conclude that pools of AAV vectors are able to 
efficiently transduce skeletal muscle and that individual vector abundance 
is maintained in vivo, with no evidence of unbalanced representation of the 















Subsequently, we analyzed the skeletal muscle vector genome content at a 
longer time point after transduction, to evaluate persistence and 
maintenance of pool composition in vivo. A second group of C57/Bl6 mice 
(n=4), was sacrificed 30 days after TA muscle transduction with ~50 µl of 
a 1x1012 vg/ml viral preparation of AAV2-Pool25; the individual genome 
ratios were analyzed as described above (Figure 4.20).  
Figure 4.19 In vivo transduction efficiency 
Analysis of TA muscle transduction efficiency 3 days after AAV2-Pool25 delivery, by 
quantification of the relative abundance of genomes corresponding to 10 factors in 
the tissue and in the viral lysate (ratio), distributed in the graph according to size. 
The pink area shows the ± 2-fold interval. 












0.1 Pool of 25 - Day 3 after transduction


























Previous experiments in our laboratory had indicated that the levels of AAV 
DNA found in the skeletal muscle in vivo undergoes a decline of ~1 order 
of magnitude in the first month after injection, while it remains constant 
afterwards for prolonged periods of time (Tafuro et al., 2009; Zentilin et 
al., 2010). Our experiment indicated, as expected, a reduction in the total 
viral content recovered from the muscle at day 30 after transduction (data 
not shown). The ratios between different viral genomes were close to the 
values observed at day 3-post transduction for 8 out of 10 analyzed genes 
(within the ±2-fold range), with the exception of clones D11 and E2, which 
appeared significantly enriched after 30 days. From this finding we can 
speculate that, even in the absence of specific selective pressure, some 
transgenes are preferentially maintained in vivo, possibly because they give 
an advantage to the transduced cells. In this specific case, clone D11 
encodes for gastrin, a gene never associated with specific functions into 
the skeletal muscle so far, while clone E2 encodes for ghrelin, whose action 














Figure 4.20 In vivo viral genomes maintenance 30 days after skeletal 
muscle transduction 
Analysis of viral vectors persistence in the muscle 30 days after in vivo 
transduction, by quantification of the relative amount of genomes corresponding to 
10 factors from the AAV2-Pool25 in the tissue and in the viral lysate (ratio), 
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4.3.4 The levels of transgene expression in vivo reflect the 
original complexity of the AAV pools 
The results reported above indicate that homogeneity of insert size, more 
than total number of grouped clones, is a key parameter to generate 
balanced pools of AAV vectors. However, the complexity of these pools still 
is expected to impact on the levels of expression of each viral transgene.  
To assess whether the level of expression of the a given vector is 
maintained proportionally to its abundance in the pool after in vivo delivery, 
we injected, into the TA muscle of C57/Bl6 mice (n=3 for each 
experimental condition), the AAV2-Pool25, AAV2-Pool50 and AAV2-Pool100, 
as well as two additional vectors singularly encoding for two selected 
factors (E2 and C12, both included in all three pools), plus an empty vector 
as a control. All animals received the same amount of AAV viral particles 
(~1x1011 vg) and the expression levels of the two transgenes were 
analyzed, after total RNA extraction, 15 days after transduction.  
The level of E2 gene expression was 1595 fold over control when the gene 
was administered alone (complexity: 1:1), after normalization over the 
levels of the corresponding endogenous gene. Its levels decreased to 62.5, 
36.8 and 13.5 in the AAV2 pools with complexity 1:25, 1:50 and 1:100 
respectively (Figure 4.21A). These values have to be compared to the 
expected values of 63.8, 31.9 and 15.9 respectively.  
The level of C12 gene expression was 981 fold over control when the gene 
was administered alone. This value is lower in comparison with E2 because 
the higher level of expression of the corresponding endogenous gene in the 
muscle. C12 expression levels decreased to 41.3, 23.2 and 7.0 in the AAV2 
pools with complexity 1:25, 1:50 and 1:100 respectively (Figure 4.21B). 
These values have to be compared to the expected values of 39.2, 19.6 
and 9.8 respectively. From these results we demonstrated that each 





vectors and that there was a reasonable proportionality between the 




























Figure 4.21 Transgenes overexpression in vivo: comparison between AAV 
vectors expressing single factors and AAV-Pools 
Quantification of transgene overexpression over endogenous gene (all the samples 
are also normalized for the housekeeping gene GAPDH) for two factors included in 
all the AAV-Pools: (A) E2 and (B) C12. The analysis was performed on transduced 
muscle 15 days after empty vector (Control), AAV2-E2 or AAV2-C12, AAV2-Pool25, 





































































































4.3.5 Generation of the AAV vector pools for in vivo 
functional selection 
Once confirmed the feasibility of pooled AAV production, we started to 
generate pools of vectors for the in vivo functional selection of the 
collection of secreted factors. Taking into account the important indications 
gained from the experiment described in the previous paragraphs, we 
decided to group the 100 cDNAs in pool of 10 clones with similar genome 
size (Figure 4.22).  
This decision was prompted by the consideration that the parameter most 
influential on pooled production and infection was insert size. Therefore, it 
appeared that the production of vector pools with low complexity would 
allow most efficient grouping of vectors carrying inserts of comparable 
length. 
The collection is composed by clones containing cDNAs with length ranging 
from ~300 to ~3000 bp. Therefore, we decided to organize the clones into 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































   








































































   




























































































































































































   













































































































































































































   







































































































































































































































































































































































4.4 IN VIVO FUNCTIONAL SELECTION OF NOVEL SECRETED 
MOLECULES CONFERRING SKELETAL MUSCLE AND 
CARDIAC PROTECTION  
 
As already mentioned, the main purpose of this Thesis work was the 
development of an innovative strategy for the in vivo, functional selection 
of secreted factors providing therapeutic benefit in conditions of tissue 
degeneration, after gene transfer of an arrayed cDNA collection using AAV 
vectors. All the results described so far clearly supported the feasibility of 
this approach and gave us important information on the key points to take 
into account during each step of this project.  
Based on the extensive similarities between the biology and the functional 
regulation of cardiomyocytes and muscle cells, and considering that several 
molecules protecting the skeletal muscle also exert a similar beneficial 
effect on cardiac muscle, FunSel was applied to different murine models of 
tissue damage, one in the skeletal muscle (hind limb ischemia) and the 

















4.4.1 In vivo functional selection in a model of hind limb 
ischemia  
The first model we exploited for the in vivo selection was based on hind 
limb ischemia induction by femoral artery ligation, a surgical procedure that 
causes massive skeletal muscle degeneration. FunSel was performed using 
30 random AAV2 clones, which were injected into the tibialis anterior 
muscle of mice, which were then subjected to femoral artery ligation, 




















Three AAV2 pools (pools A, B and C), each one containing 10 different 
clones, were obtained transfecting HEK 293T cells with mixtures of 10 
Figure 4.23 Outline of the experimental procedure for AAV vectors 
selection after induction of skeletal muscle ischemia 
Mice were injected with AAV vector pools in the tibialis anterior (TA) muscles of 
both legs and, after 5 days, an ischemic damage was induced by femoral artery 
ligation only in the right limb, in order to trigger the selection in one muscle and to 
use the controlateral one as a control. After 2 weeks viral genomes still present in 
surviving tissues were recovered, the vector cDNAs from each of the two DNA pools 
were amplified by PCR using common primers, cloned again into the vector 
backbone, and the new viral preparations obtained were resubmitted to further 
cycles of selection up to the identification of a candidate gene (In red, vector 
coding for a putative beneficial factor, which becomes enriched during selection). 
 
Direct injection 
of AAV2 pool in 















plasmids per pool.  As previously mentioned, in order to avoid possible bias 
in packaging efficiency due to extensive different in insert length, plasmids 
were grouped into three pools according to their cDNA size. Pool A, B and 
C were afterwards mixed to obtain a single AAV pool composed of 30 
clones, whose inserts ranged from 580 to 1600 bp (named “Tot” in Figure 
4.24). The PCR pattern generated by amplifying DNA from each pool (A, B, 
C and Tot) using primers positioned in the common AAV backbone in 













The obtained AAV2-cDNA pool, expressing 30 different factors, was 
injected into the tibialis anterior muscles of both legs of CD1 mice (n=10; 
30 µl; 3x1010 AAV2-cDNA vector particles per muscle). After 5 days, uni-
lateral hind-limb ischemia was induced in the right limb by ligating the right 
femoral artery, according to experimental conditions established in the 
laboratory (Arsic et al., 2004). This treatment is known to induce marked 
muscle fiber degeneration, followed by adipose tissue substitution, as 
shown in Figure 4.25; muscle fiber regeneration then starts, and becomes 
complete, in the absence of treatment, in ~40 days. 
1 k







Figure 4.24 PCR amplification of 
AAV2-cDNA pools before in vivo 
injection. PCR primers spanning the 
cDNA inserts were used for 
amplification of three pools of AAV2 
vectors (pools A, B and C); grouping 
of constructs in the pools was 
according to insert length. The last 
line shows PCR amplification of the 
total (Tot), pooled group (A+B+C) of 
the 30 vectors before in vivo injection. 






















Animals were sacrificed 15 days after femoral artery ligation and total DNA 
from both the ischemic and the non-ischemic muscles was recovered. The 
DNA samples from different animals were pooled, maintaining the 
separation between ischemic and non-ischemic muscles.  
The vector cDNAs from each of the two pools were then amplified by PCR 
using primers common to all constructs, checked on a gel to identify 
possibly enriched vectors among the viral genome recovered from the 
ischemic muscles and then pooled-cloned again into the pZac2.1 vector 
backbone, to obtain two new viral preparations. The tibialis anterior of the 
right leg of additional mice (n=10) were afterwards injected with the AAV2-
cDNA vectors generated from the ischemic DNA pool, while the 
corresponding muscles of the left leg with the vectors from the non- 
ischemic DNA pool. As we did for the first round of selection, after five 
days, the right leg was subjected to ischemia according to the same 
experimental procedure outlined above. The cycle of selection of AAV-
cDNAs separately from the ischemic and non-ischemic limbs was repeated 
Tibialis anterior, 3 d after ischemia
Hematoxylin-Eosin
Figure 4.25 Effects of femoral artery ligation on muscle fiber survival  
The picture shows the histology of tibialis anterior muscle sections at two 
magnifications after 3 days from femoral artery ligation. Extensive loss of muscle 
fibers and the initial presence of regenerating new fibers, characterized by the 





for a total of 3 times.  
At the end of the procedure, the representation of the original 30 different 
cDNA clones after each cycle of selection was analyzed by PCR 
amplification of the inserts, in order to assess whether one or more vectors 
were enriched upon selection. As shown in Figure 4.26 for two 
representative mice, the PCR pattern of the DNA extracted from the 
muscles not subject to ischemia resembled that obtained by amplification 
of vector inserts before the beginning of the selection procedure, thus 
indicating that in vivo injection and recovery of vectors did not introduce 
any essential bias. After the first cycle of selection, moreover, we did not 
notice any difference in the pattern of viral genomes rescued from the 
ischemic muscles. In contrast, an individual band was enriched in the DNA 
pools recovered from the ischemic legs after the second, and more sharply, 
after the third round of selection. Sequencing of this enriched band 
revealed that it corresponded to the cDNA of clone E2 coding, quite 
unexpectedly, for the secreted hormone with peculiar endocrine functions, 
ghrelin.  
Of course after the identification of candidate genes we needed to validate 
their effective protective role in vivo. The beneficial properties of ghrelin in 
conditions of ischemic damage were therefore extensively characterized. 















































Figure 4.26 PCR amplification of AAV2-cDNA pools after each of three 
rounds of in vivo selection in the muscle 
The cDNA inserts of the AAVs recovered from the tibialis anterior muscles after 
each of three rounds of selection in vivo were amplified with PCR primers spanning 
the inserts. In the picture the pattern of bands referred to two representative mice 
for each selection cycle; the two lanes show amplification of vectors recovered from 
the ischemic and non-ischemic legs. The band highly enriched after the third round 
of selection induced by ischemia corresponds to the cDNA of ghrelin.  
Ischemia:  +          -          +         -            +          -          +          -            +           -           +           -
First round of 
selection
Second round of 
selection
Third round of 
selection






4.4.2 In vivo functional selection in a model of cardiac 
damage induced by isoproterenol treatment 
The second model of degenerative disease we exploited for the in vivo 
selection of the AAV collection was a model of cardiac damage induced by 
an acute treatment with a toxic drug. In particular the chemical compound 
isoproterenol (Iso), a synthetic -adrenergic receptors agonist structurally 
similar to adrenaline and having a strong chronotropic/inotropic effect on 
the heart, when administered at high dosage, induces a very well described 
infarct-like myocardial lesion including myocytes degeneration, necrosis and 
subsequent interstitial and perivascular fibrosis (Grimm et al., 1998a). 
These damages usually result in gradual LV-enlargement and progression 
towards mild heart failure.  
The model is characterized by technical simplicity and excellent 
reproducibility. 
In this model, FunSel was performed using the entire collection of 
secreted molecules, namely all the 100 AAV clones, organized in 10 
separated pools expressing 10 factors each (Pools A-L). These were 









































For the functional selection in the heart, we generated AAV vectors with 
serotype 9, which shows, as already described, preferential cardiac 
transduction (Bish et al., 2008; Pacak et al., 2006).  
Before starting the actual selection procedure, we first wanted to 
understand which was the most suitable route of vector administration. For 
this purpose, we generated a viral preparation expressing the previously 
identified ghrelin transgene, administered it in vivo (3x1010 viral particles) 
using three different routes and then evaluated the levels of expression of 
the transgene in the heart at day 15 after transduction. The three delivery 
routes were: intraperitoneal (IP) injection in neonatal mice (day 3 after 
birth), intravenous (IV) and IP injection in adult mice (1 month old). 
Figure 4.28 shows the intracardiac levels of the transgene as a ratio to 
the corresponding endogenous gene after the three administration 
modalities. The results indicate that IP injection in pups was the most 






Figure 4.27 Outline of the experimental procedure used to select clones 
after induction of myocardial damage using isoproterenol 
Neonatal mice (n=12) were injected, 3 days after birth, with AAV9 pools 
intraperitoneally (IP) to reach high levels of heart transduction and 3 weeks later 
myocardial damage was induced by IP administration of isoproterenol (Iso). After 2 
weeks, viral genomes still present in the surviving tissue were recovered, the vector 
cDNAs amplified by PCR using common primers and compared with the vectors 
recovered from the hearts of control mice, transduced with the AAV pools, but not 
submitted to functional selection. As in the previous model, the recovered cDNAs 
were cloned again into the vector backbone, to generate new viral preparations to 
resubmit to further cycles of selection up to the identification of a candidate gene 




















Next we wanted to determine the optimal isoproterenol dosage that elicited 
marked damage to the myocardium (necessary to trigger the selection) 
without inducing significant lethality in the treated mice. In particular, three 
isoproterenol concentrations (100, 200 and 300 mg/kg) were tested 
(Figure 4.29). Histological analysis at 1 week revealed widespread 
necrotic areas in the myocardium of all the treated animals but, for the 200 
and 300 mg/kg concentrations, the myocyte loss was more evident and a 
fibrotic scar largely replaced cardiac tissue. The survival rates were 
respectively 100%, 90% and 50%, therefore the isoproterenol dose of 200 
mg/kg, that better balanced heart toxic insult and animal survival, was 




Figure 4.28 Comparison of ghrelin cardiac expression levels upon delivery 
of AAV9-Ghrelin according to different routes.  
Levels of ghrelin cardiac expression (expressed over normal expression of the 
corresponding cellular gene) 15 days after administration of 3x1010 viral particles by 
3 different routes: IP injection in neonatal mice 3 days after birth, IV and IP 
injection in adult mice (1 month old). The most efficient level of heart transduction 


























































Based on these preliminary results, the actual selection experiment was 
initiated. AAV pools were obtained as previously described and each pool, 
expressing 10 different factors, was tested individually by intraperitoneal 
(IP) injection in C57/Bl6neonatal mice (n=12; 30 µl; 3x1010 AAV9-cDNA 
vector particles) 3 days after birth. Three weeks after AAV9 pool delivery, 
functional selection for cardiac protective factors was triggered by a single 
treatment with a toxic dose of isoproterenol (200 mg/kg) in half of the 
animals.  
For all the ten analyzed AAV pools, animals were sacrificed 2 weeks after 
toxic damage and total DNA was recovered from the surviving cardiac 
Control ISO i.p. 100 mg/kg
ISO i.p. 200 mg/kg ISO i.p. 300 mg/kg
Figure 4.29 Toxic cardiac effects induced by different dosages of 
isoproterenol  
Histological cardiac sections after intraperitoneal injection of different dosages of 
isoproterenol (100, 200 and 300 mg/kg) in 3 weeks old mice. In the Azan’s 
trichromic stained heart sections at day 7 after damage is evident the extent of 
myocytes loss and initial fibrotic substitution. The insets show high-magnifications 






tissue. The vector cDNAs were then amplified by PCR using primers 
common to all constructs and the pattern of amplified inserts in animals 
submitted and non-submitted to isoproterenol treatment was compared.  
Quite surprisingly, in the AAV-Pool A, a specific cDNA appeared distinctly 
enriched already after a single cycle of selection (Figure 4.30A). 
Sequencing of this enriched band revealed that it corresponded to the 
cDNA of clone C12, coding for insulin-like peptide 6 (INSL6), a still poorly 
described growth factor, which is a member of the known anti-fibrotic 
family of relaxin proteins.  
The identification of a candidate that belongs to this class of genes 
perfectly fitted with the selection model we exploited in this experiment, 
since this was based, as already mentioned, on the action of a pro-fibrotic 
drug.  
 
None of the remaining nine analyzed pools (B-L) showed factors that were 
appreciably enriched after selection (as shown for the representative AAV-
PoolE in Figure 4.30B). Thus, these pools might either not contain any 
pro-surviving molecule or necessitate of subsequent rounds of selection to 
lead to enrichment for a beneficial factor.  
Preliminary results on the beneficial properties of INSL6, in conditions of 










































Figure 4.30 PCR amplification of AAV9-cDNA pools after a single round of 
in vivo functional selection in the heart 
The cDNA of the AAVs recovered from the hearts after a single round of in vivo 
selection were amplified with PCR primers spanning the inserts. The picture shows 
a band ladder corresponding to Pool A and Pool E. Each lane corresponds to the 
viral genome content in the myocardium of each analyzed animal, treated or not 
with isoproterenol (Iso +/-).  
In the upper panel (A), AAV Pool-A, showed, in some of the treated animals, the 
enrichment of a viral genome corresponding to the insulin-like peptide 6 (INSL6). 
No enrichment for any band was instead evident for AAV-Pool E (B), similar to all 
the other 8 pools.  
ISO + + + + + + + - -MW










4.5 CHARACTERIZATION OF THERAPEUTIC EFFECTS OF THE 
IN VIVO SELECTED CANDIDATE GENE GHRELIN 

Next we wanted to assess the actual individual protective potential of the 
two selected clones (Ghrelin and INSL6) in vivo, in order to validate the 
obtained results. 
 
4.5.1 AAV9-Ghrelin prevents isoproterenol and doxorubicin-
induced cell death in neonatal rat cardiomyocytes 
First we wanted to assess whether the beneficial effects of ghrelin might 
also be extended to primary cardiomyocytes. For this purpose, neonatal rat 
cardiomyocyte cultures were established according to conditions already 
set up in the laboratory (Collesi et al., 2008). Immediately after plating, 
cells were transduced with either AAV9-LacZ or AAV9-Ghrelin (multiplicity 
of infection (MOI)=1x104). After 24 h, cardiomyocytes were treated with 
the - adrenoreceptor agonist isoproterenol (10 μM) or the antiblastic drug 
doxorubicin (1 μM), showing exquisite cardiotoxicity, for 48 and 24 hours 
respectively. Since these two conditions are known to induce massive cell 
apoptosis, cell viability was analysed by a live/dead cell viability assay.  
In both experimental settings, AAV9-Ghrelin transduction was shown to 
exert an impressive protective effect, as shown in Figure 4.31. 
Quantification of these experiments indicated that >70% and >50% 
cardiomyocytes survived after AAV9-Ghrelin transduction compared to 







































Figure 4.31 Protective effect of ghrelin on cardiomyocytes survival 
Rat neonatal cardiomyocytes, transduced with AAV9-LacZ or AAV9-Ghrl 
(transduction efficiency >40%) were either left untreated or treated with 
isoproterenol 10 9M (Iso) or doxorubicin 1 9M (Doxo). Upper panel: representative 
experiment. Nuclei of dead cardiomyocytes are shown in red, living cells in green. 
Lower panel: quantification of the results. Values are expressed as mean ± SEM of 
























Isoproterenol (10 uM):      -    -        +    +          -    - 



























4.5.2 Long-lasting ghrelin expression in mouse heart 
preserves cardiac function after myocardial infarction (MI) 
The outstanding protection observed by AAV9-Ghrelin transduction in 
cultured, primary cardiomyocytes prompted us to investigate whether the 
same vector might also be effective in vivo, thus providing a rationale why 
it was originally selected.  
We choose myocardial infarction (MI) as a model to evaluate the cardiac 
protective properties of ghrelin and the experiment was conducted 
















CD1 mice (n=20 per group) underwent permanent left descendent 
coronary artery ligation and were immediately injected into the LV peri-
infarcted area with 5x1010 viral particles of AAV9-Ghrelin or a control AAV9 
vector containing the empty poly-linker (AAV9-Control). Analysis of the 
ghrelin mRNA levels at day 90 after the procedure by real-time PCR 
Figure 4.32 AAV9-Ghrelin in a model of myocardial infarction (MI): 
experimental outline 
CD1 mice were submitted to myocardial infarction (MI) and immediately treated by 
intracardiac (IC) injection of either AAV9-Ghrelin or AAV9-Control. Cardiac function 
was analysed by echocardiography at 2, 7, 30, 60 and 90 days after MI. For each 
treatment, a group of mice (n=5) was sacrificed 2 days after infarction to evaluate 
apoptotic rate, 4 animals were sacrificed at day 7 post-infarction to analyze 
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indicated robust ghrelin mRNA expression up to this time point (Figure 
4.33A). In a consistent manner, quantification of acyl- and des-acyl ghrelin 
protein levels by ELISA also confirmed increased cardiac presence of both 
peptides at this time point (Figure 4.33B). Of notice, the former assay 
only detects ghrelin expressed in the heart, while the latter both cardiac 




















A group of animals (n=5) was sacrificed at day 2 and another group (n=4) 
at day 7 after MI to measure apoptotic rate in the peri-infarcted area and 
upregulation of inflammatory gene markers, respectively. Cardiac function 

















































Figure 4.33 Long lasting ghrelin 
expression in the heart upon 
AAV9-Ghrl IC delivery 
A. Levels of ghrelin expression 
evaluated by Real-time PCR analysis 
on total ventricular RNA extracted 
90 days after vector injection 
(Transgene expression levels are 
normalized for those of the 
endogenous ghrelin gene). 
B. Acyl and des-acyl ghrelin peptide 
levels evaluated by EIA assay on 
ventricular protein lysate, 90 days 
after vector intracardiac injection. 
Values are expressed as mean ± 



































To evaluate global and regional LV function, transthoracic 
echocardiography was performed at 2, 7, 30 60 and 90 days after 
myocardial infarction and transduction in sedated mice using the Vevo 
echocardiography system. As shown in Figure 4.34, the LV ejection 
fraction (LVEF) and fractional shortening (LVFS) were significantly 
preserved in infarcted mice injected with AAV9-Ghrelin, compared to 
controls. Of notice, the effect persisted at long times after infarction (90 
days), while cardiac performance was progressively deteriorated in control 
animals (LVEF: 33±5% vs. 53±3%; LVFS: 17±4% vs. 28±4% in control 
and ghrelin-transduced animals respectively at day 90 after infarction, 

























Time after MI (days)
* * * *




































4.5.3 Maintenance of myocardial thickening and reduction 
of infarct size in AAV9-Ghrelin transduced mice 
Other important functional parameters, indicating changes of regional 
cardiac contractility, were significantly different between ghrelin treated 
and untreated animals, again also at longer time points after myocardial 
infarction (Figure 4.35). At both 1 and 3 months after cardiac gene 
transfer, the LV end-systolic wall thickening (AWTK) in the border zone of 
the infarcted hearts injected with AAV9-Ghrelin was markedly improved 
compared to control mice (24±5% vs. 34±4 and 19±4% vs. 31±3% in 
control and ghrelin-transduced animals, respectively at day 30 and 90 after 
infarction, P <0.05 at all time points).  
Moreover the LV internal diameter was clearly more enlarged in the control 
animals, confirming a better progression of cardiac performances after 











Figure 4.34 AAV9-Ghrelin preserves cardiac function for a prolonged time 
after myocardial infarction 
Left Ventricular Ejection Fraction (LVEF) and Left Ventricular Fractional Shortening 
(LVFS) of infarcted mice treated with AAV9-Ghrelin or AAV9-Control were measured 
by echocardiography. Values are expressed as mean ± SEM; *P<0.05. 
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In the representative transthoracic echocardiographic images shown in 
Figure 4.36, taken 90 days after myocardial infarction, the LV dilatation of 














At the end of the echocardiography study, animals were sacrificed, hearts 
were collected and the left ventricle, including the interventricular septum, 
was carefully dissected and examined for post-infarction fibrosis and 
chamber remodeling. After washing in PBS, each specimen was cut into 5 
pieces of equal thickness from base to apex, fixed in 4% paraformaldeyde 
and embedded in paraffin for histological analysis.  
Morphometric analysis of trichromic-stained LV sections showed that the 
anterior wall of infarcted, control animals underwent considerable thinning, 








Figure 4.35 Ghrelin improves cardiac contractility after MI  
Anterior Wall Thickening (AWTK) and LV internal diameter of infarcted mice treated 
either with AAV9-Ghrelin or AAV9-Control were measured by echocardiography. 
Values are expressed as mean ± SEM; *P<0.05. 
 
Figure 4.36 Echocardiographic analysis of infarcted hearts  
Echocardiographic analysis of AAV9-Ghrelin and AAV9-Control treated mice 3 
months after MI. Representative transthoracic parasternal short axis 






Ghrelin-treated hearts showed significant preservation of contractile tissue 
and reduction of the fibrotic area; representative images are shown in 
Figure 4.37A. 
Infarct size was measured on 5 µm thick sections as the percentage of 
(endocardial + epicardial circumference of infarct area) / (endocardial + 
epicardial circumference of LV). Figure 4.37B reports the quantification of 
infarct size (47±6% vs. 23±3% in control and ghrelin-transduced animals, 





















Figure 4.37 Reduction of infarct size in AAV9-Ghrelin transduced hearts 
A. Representative AAV9-Control and AAV9-Ghrelin-injected hearts, their LV 
transverse sections and Azan trichromic staining of the tissue. Fibrotic areas are 
stained in blue.  
B. Quantification of infarct size expressed as percentage of LV. Values are 

































4.5.4 Marked decrease of myocardial apoptosis and 
inflammatory infiltrate after ghrelin transduction in 
infarcted mice 
Given the massive preservation of myocardial tissue after infarction, and 
considering the protective effect observed in the in vitro experiments 
shown above, in a set of animals (n=5 per group) we assessed the extent 
of apoptosis in the infarcted hearts treated with the control and ghrelin-
expressing vectors.  
Infarcted hearts were collected and snap frozen 2 days after MI and vector 
transduction. As shown in Figure 4.38, at this time point ghrelin 
transgene already started to be expressed in the LV of mice injected with 











To evaluate apoptosis, frozen sections were fixed in 4% PFA and treated 
for immunostaining and TUNEL assay. As shown in Figure 4.39A a 
marked reduction in the number of apoptotic nuclei in the animals treated 
with AAV9-Ghrelin was clearly noticed. Figure 4.39B reports the 
quantification of TUNEL-positive nuclei (27±4% vs. 7±2% in control and 
ghrelin-transduced animals respectively). 
 
Figure 4.38 Rapid onset of 
ghrelin expression in the LV 
upon AAV9-Ghrl IC delivery 
Levels of ghrelin expression 
evaluated by Real-time PCR 
analysis on total ventricular RNA 
extracted 2 days after vector 
injection (Transgene expression 
levels are normalized for those of 

























































Ghrelin has also been recently described as a molecule able to reduce the 
inflammatory response upon damage (Huang et al., 2009). Therefore, we 
also stained with hematoxylin and eosin (H&E stain) paraffin embedded 












Figure 4.39 Ghrelin anti-apoptotic 
activity on infarcted myocardium 
A. Hearts injected with AAV9-Control or 
AAV9-Ghrelin at 2 days after MI. Red nuclei 
indicated apoptotic cells, negative nuclei are 
stained with DAPI and cardiomyocytes are 
stained in green by an antibody against -
actinin.  
B. In the graph, quantification of positive 
nuclei (%). Values are expressed as mean 

























in order to analyze the inflammatory cell infiltration.  
As shown in Figure 4.40A, a massive inflammatory cells infiltration was 
evident in the peri-infarctual region of control mice, which was significantly 
blunted in the ghrelin-expressing hearts. Figure 4.40B reports the 





















Further evidence of an anti-inflammatory effect of ghrelin was obtained by 
measuring the levels of IL1-, IL6 and TNF, which are known to be 
overexpressed under inflammatory conditions. At day 7 after infarction, the 



















Figure 4.40 Ghrelin reduces inflammatory cell infiltration in the peri-
infarctual region 
A. Hematoxylin and eosin (H&E) staining (200x magnification) of heart sections two 
days after MI and intracardiac delivery of either AAV9-Ghrelin or AAV9-Control.  
B. In the graph, quantification of inflammatory cells infiltration, calculated as 























































group) were recovered, RNA was extracted form the LV, and expression of 
the above mentioned genes was analyzed by Real-time PCR. We observed 
a massive induction of the analyzed factors in AAV9-Control hearts, while 
their level of activation in ghrelin-expressing samples was similar to normal 
mice or significantly reduced (Figure 4.41).  
These results reinforced the idea that the functional beneficial effects we 
previously described for mice transduced with AAV9-Ghrelin upon cardiac 
ischemia, could be partially explained by a direct anti-apoptotic and anti-














Recent work has demonstrated that miR-21 deregulated expression 
contributes to myocardial disease. Upon cardiac damage, this miRNA is 
upregulated in fibroblast contributing to fibrosis and pathological cardiac 
hypertrophy (Thum et al., 2008), also acting as a regulator of the matrix 
metalloprotease-2 (MMP-2) in these cells (Roy et al., 2009). 
We therefore compared the levels expression of these miR-21 and MMP-2 
in RNA samples of control and ghrelin-expressing animals at day 7 after 
 -  MI
+ MI + AAV9-Control














































Figure 4.41 Ghrelin reduces the induction of genes upregulated by 
inflammation 
Control and AAV9-Ghrelin treated animals (n=4 per group) were sacrificed 7 days 
after MI and the expression of the indicated genes was analyzed by Real-time PCR. 
Values are expressed as mean ± SEM of the levels of expression of the factors vs. 





infarction. We noticed that the up-regulation of both factors observed after 
MI was markedly blunted in the ghrelin-expressing hearts (Figure 4.42). 
These results were absolutely in accordance with the previous reported 
histological observations about a reduced fibrotic tissue deposition and the 













4.5.5 Ghrelin overexpression counteracts the induction of 
genes involved in pathological LV remodeling after 
myocardial infarction 
To further confirm the effects of ghrelin on the heart, we analyzed, by 
Real-time PCR, the genes expression profiles of LV tissue from the infarcted 
animals (n=8 per group) sacrificed at 3 months after MI.  
In agreement with the echocardiographic observations, AAV9-Control 
treated animals showed a characteristic pattern of gene expression typically 
associated with pathological LV remodeling, with significant over-
expression of -MHC and cardiac natriuretic peptides (BNP and ANP), and a 
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Figure 4.42 Ghrelin impedes the cardiac damage induced overexpression 
of miR-21 and MMP-2 in fibroblasts 
Levels of expression of miR-21 and MMP-2 were analyzed in control and AAV9-
Ghrelin treated hearts, 7 days after MI. Values are expressed as mean ± SEM of the 
levels of expression of the indicated factors vs. uninfarcted control hearts (- MI), 





normal mice (P<0.05 for all the analysed genes).  
As shown in Figure 4.43 these modifications were all significantly 




































































































































+ MI + AAV9-Control
+ MI + AAV9-Ghrelin
Figure 4.43 Ghrelin prevents gene expression of markers of pathological 
remodeling in the myocardium of infarcted mice 
The expression levels of the indicated genes are analyzed in control and AAV9-
Ghrelin treated hearts, 3 months after MI. Values are expressed as mean ± SEM of 
the levels of expression of the indicated factors vs. uninfarcted control hearts (- 





4.6 CHARACTERIZATION OF THERAPEUTIC EFFECTS OF THE 
IN VIVO SELECTED GENE INSULIN-LIKE PEPTIDE 6 
(INSL6): PRELIMINARY RESULTS 

We also wanted to assess whether insulin-like peptide 6-precursor (INSL6), 
which was originally selected after isoproterenol-induced myocardial 
damage, might exert a beneficial effect after myocardial infarction.  
 
4.6.1 AAV9 mediated INSL6 expression in mouse heart 
preserves cardiac function and reduces infarct size after 
myocardial infarction 
To assess the role of INSL6 in condition of cardiac damage we exploited 
the models of myocardial infarction already described for the in vivo 
validation of ghrelin.  
As in the previous experiment, CD1 mice (n=18 per group) underwent 
permanent left descendent coronary artery ligation and immediately 
injected into the LV peri-infarcted area with 5x1010 viral particles of AAV9-
INSL6 or an AAV9-Control vector. Also for this AAV vector, we measured 
the level of INSL6 transgene expression in the heart, 90 days after viral 
vector delivery. We observed efficient transduction and long lasting 









Figure 4.44 Long lasting INSL6 
expression in the heart upon 
viral vector delivery 
Levels of INSL6 transcripts evaluated 
by Real-time PCR analysis on total 
ventricular RNA extracted 90 days 
after vector injection.  
(Transgene expression levels are 
normalized for those of the 















































To evaluate LV function, transthoracic echocardiography was performed at 
2, 7, 30 60 and 90 days after myocardial infarction and transduction in 
sedated mice. LVEF and LVFS were significantly preserved in infarcted mice 
injected with AAV9-INSL6, compared to control animals. The effect 
persisted at long times after infarction (90 days), while cardiac 
performance was progressively deteriorated in control mice (LVEF: 33±5% 
vs. 47±4%; LVFS: 17±4% vs. 24±3% in control and INSL6-transduced 
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* * * *
































Another main difference between the two groups of animals was the size of 
the infarct scar, as assessed by echocardiographic analysis. The AAV9-
Control-treated mice showed a significant worsening of the ischemic scar 
evolution; on the contrary the infarct size was preserved and eventually 
slightly reduced over time in the INSL6 expressing hearts (42.2±4.4% vs. 
24.5±3.7% and 43.4±6.8% vs. 23.6±3.3% in control and INSL6-
transduced animals respectively at day 30 and day 90 after infarction; P 














4.6.2 INSL6 expression in infarcted hearts induces a marked 
decrease of myocardial apoptosis 
At day 2 after myocardial infarction and AAV vectors delivery a set of 6 
mice for group (Control vs AAV9-INSL6-transduced) was sacrificed and the 
hearts collected. Frozen sections of LV cardiac tissue were fixed in 4% PFA 
and TUNEL staining for apoptosis analysis was performed.  
Figure 4.45 INSL6 AAV vector-mediated expression preserves cardiac 
function for long time after MI 
Left Ventricular Ejection Fraction (LVEF) and Left Ventricular Fractional Shortening 
(LVFS) of infarcted mice treated with AAV9-INSL6 or AAV9-Control were measured 


























Figure 4.46 Reduction of 
infarct size in AAV9-INSL6 
transduced hearts 
Quantification of infarct size 
expressed as percentage of LV. 







As it appears from the pictures in Figure 4.47A, the INSL6-expressing 
infarcted hearts exhibited a significant decrease in the number of apoptotic 
nuclei. Figure 4.47B reports a quantification of this result. In the animals 
treated with the control AAV vector, the percentage of apoptotic nuclei 
detected in the infarcted region at day 2 after infarction approached 30%, 
while this percentage was>5 times lower in the INSL6-expressing hearts 
(P<0.05). 
This result strongly supported the hypothesis that also this gene, like the 
more extensively described secreted factor ghrelin, could immediately exert 
its beneficial properties on the damaged hearts, by reducing the cell death 




























































Figure 4.47 INSL6 anti-apoptotic effect on infarcted myocardium 
A. Hearts injected with AAV9-Control or AAV9-INSL6 at 2 days after MI were 
stained to reveal apoptotic nuclei by TUNEL (red), cardiomyocytes using an 
antibody against α-actinin (green) and total nuclei with DAPI (blue).  
B. Graph reporting quantification of positive nuclei (%). Values are expressed as 





The molecular mechanism by which INSL6 exerts its beneficial effects in 
the infarcted hearts clearly needs to be further elucidated. However, the 
promising preliminary data shown in this Thesis can be considered as 









5.1 DEVELOPMENT OF AN INNOVATIVE STRATEGY FOR THE 
IN VIVO FUNCTIONAL SELECTION OF AAV VECTORS 
EXPRESSING THERAPEUTIC GENES 
 
Degenerative disorders include a broad category of pathologies, among 
which cardiovascular diseases, and represent a foremost health problem all 
over the world, essentially linked to the aging of the human population and 
to the inability of post-mitotic tissues to efficiently regenerate. The notably 
progresses recently achieved in understanding the cellular and molecular 
mechanisms driving tissue degeneration have increased the effort towards 
the development of novel biotherapeutics able to either prevent tissue 
damage or enhance tissue regeneration.  
This Thesis’ project stems exactly from these perspectives, since its final 
purpose was the identification and characterization of novel genes that 
could be exploited therapeutically for their beneficial properties towards 
cardiovascular disorders. The novelty resides in the innovative strategy we 
developed to identify candidate therapeutic factors, based on the 
possibility, given by AAV vectors, to screen nucleic acids libraries for a 
given function directly in vivo. 
Following the birth of genetic engineering, the screening of genetic libraries 
has provided a powerful means for the rapid identification of therapeutic 
molecules. Many screenings of genetic libraries have been attempted in the 
recent past (Kitamura, 1998; Mahon and Whitehead, 2001). Collectively, 
these strategies have generated powerful biological information, with 
important repercussions for drug discovery. Unfortunately, however, in only 





have advanced to clinical experimentation and entered medical therapy. On 
the contrary, the majority of the biological therapeutics currently in the 
clinics is either the result of serendipitous discovery or stem from the 
outcome of molecule identification based on pre-existing biological or 
biochemical information. For this reason, the possibility of screening nucleic 
acid libraries for a particular function directly in vivo appears to represent 
an outstanding tool to identify novel factors, selected by their own 
relevance in the target tissue.  
So far, cDNA libraries have been generated in retroviral (Passioura et al., 
2005) or adenoviral vectors (Hillgenberg et al., 2006; Michiels et al., 2002). 
The former vectors, however, only transduce replicating and not resting 
cells, while the latter induce a potent immunogenic response that leads to 
the elimination of the transduced cells in a relatively short time, thus 
preventing evaluation of the long term effects (Muruve, 2004). The 
development of our strategy was rendered possible by the availability of a 
vector system based on AAV, which is produced at very high titers, infects 
post-mitotic cells in vivo very efficiently, can be targeted to a specific 
tissue/organ and persists in the target cells for prolonged periods of time 
without transgene silencing (Schnepp et al., 2005). In addition, here we 
demonstrated the possibility to simultaneously generate pools of AAV 
vectors composed by a variable numbers of transgenes and use them to 
transduce cells in vivo very efficiently. Since AAV are able to infect cells at 
a relatively high multiplicity of infection, the strategy we devised entails an 
iterative procedure of in vivo selection, based on the progressive 
enrichment for one or more factors exerting a beneficial function and 
therefore favouring, round after round, the survival of the expressing cells. 
In particular, in this Thesis we focused our attention on the functional 
selection, in different degenerative models, of a collection of murine 





more of these factors in the cardiovascular system, these might be clinically 
administered not only by gene therapy, but also as recombinant proteins.  
 
5.1.1 Theoretical confirmation of the feasibility of the AAV-
mediated in vivo functional selection 
To validate the possibility to functionally select AAV transgenes in vivo 
through an iterative transduction procedure, we took into account all the 
variables possibly involved in this process and, by a series of mathematical 
considerations, we confirmed its theoretical feasibility.  
Abundant and rare transcripts are similarly represented in the arrayed 
library and each clone has the same chance to be enriched during the 
iterative process of selection. Therefore, if at the beginning of the 
procedure, the abundance of an AAV coding for a specific transgene is one 
out of the total number of vectors in the pool (1/POOL), at the end of the 
experiment this ratio will be modified according to the influence of the 
different variables, and eventually will correspond to one out of the total 
number of selected vectors. In particular, six variables that affect the 
selection experiment have been considered: multiplicity of infection (MOI), 
transduction efficiency (ET), co-selection effect (COSEL), efficiency of 
selection (ES), complexity of vectors pools (POOL) and number of selection 
cycles (CYCLE).   
Under ideal conditions, the multiplicity of infection is one (a single viral 
particle enters a cell, MOI=1), the selection is effective (no cells other than 
those containing the desired transgene are selected, ES=1) and there is no 
co-selection of cells not expressing the transgene (COSEL=0). In this case 
a single round of selection is potentially sufficient to completely select the 
transgene-expressing cells, independently from the efficiency of 
transduction (ET), the complexity of the pool (POOL) and the number of 





However, during a real selection procedure, most probably ideal conditions 
will not be met, and therefore a mathematical equation was derived to take 
into account all the parameters that could affect the procedure. We noticed 
that, in the case we could efficiently recover all the cells containing the 
desired transgene (ES=1), the MOI has a very important effect on the 
selection efficiency, and should anyhow be lower than 10 to permit 
effective selection. We also observed that the COSEL and ET parameters 
are strictly correlated; of course, the first becomes less relevant as the 
second decreases. As mentioned before, when ES=1, performing 
subsequent cycles of selection does not improve transgene enrichment 
because it is assumed that only cells containing the transgene are still alive 
after the selection. Similarly, the vector pool complexity also has no 
influence.  
In the most probable case in vivo, ES is less than 1, hence a certain 
number of cells not containing the desired transgene survive the selection. 
In this condition, the complexity of the initial pool of vectors (POOL) 
becomes very important and an increase in the AAV pool complexity or a 
decrease in the ES are paralleled by a dramatic decrease in the probability 
of selecting the desired transgene. Whether ES<1, the performance of the 
process is substantially increased by performing iterative rounds of 
selection. The strategy we established indeed entails the recovery, by PCR, 
of all transgenes from the tissues surviving the selection procedure and the 
re-cloning of these inserts into the vector plasmid to obtain a novel vector 
pool, which is resubmitted to the selection process. At every cycle, we 
expect that the ratio between the desired transgene and all the other 
clones progressively increases. Indeed, this was fully confirmed by the 
mathematical model analysis, considering many possible values for the ET, 





Taken together, the theoretical considerations illustrated by the 
mathematical analysis clearly supported the feasibility of the functional 
selection (FunSel) approach. 
 
5.1.2 Recombinant AAV vectors can be generated in pools 
Once demonstrated the theoretical feasibility of the in vivo selection 
strategy, we started generating an arrayed library of clones to be tested by 
the described approach. This library derived from the mouse secretome 
collection, a subset of cDNAs from the RIKEN mouse genes encyclopedia 
(Grimmond et al., 2003). In particular, we selected 100 full-length cDNAs 
mainly coding for hormones and growth factors, and cloned them 
individually into an AAV backbone plasmid for AAV vectors production.  
For the first time, we confirmed that recombinant AAV vectors can be 
generated in pools. In practical terms, we obtained single viral preparations 
expressing 10 (or more) different genes, just mixing proportional amounts 
of each AAV plasmid with the desired packaging plasmid and transfecting 
this mixture into HEK 293T cells for viral production. An accurate, PCR-
based analysis on the viral genomes obtained after pooled AAV vectors 
production demonstrated that all the transgenes composing the pool were 
represented in the viral preparation. 
 
5.1.3 Definition of critical requirements influencing 
packaging, in vivo transduction and expression of pooled 
AAV genomes 
Based on the results obtained by AAV vector pooled production we 
investigated the critical elements influencing essential steps of this process, 
such as viral genomes packaging, in vivo transduction efficiency and level 





Comparable size of vector transgenes guarantees faithful 
maintenance of individual gene representation during pooled 
production 
In the devised in vivo selection procedure, pools of AAV vectors are 
simultaneously generated in HEK 293T cells and then used for in vivo 
transduction. An essential requisite of the procedure, therefore, is that 
packaging of multiple AAV vectors occurs simultaneously in the producing 
cells and that no significant biased is introduced at this step. In order to 
confer to all the vectors the same chance to be effective in the target 
tissue and to be selected after damage only for their functional properties, 
a balanced representation of all the transgenes in each vector pool must be 
guaranteed.  
The relevance of genome size on AAV packaging has been extensively 
described by many groups (Allocca et al., 2008; Grieger and Samulski, 
2005; Wu et al., 2010). In particular, it is known that smaller DNAs are 
packaged more efficiently. So far, however, there have been not systematic 
studies on the mutual influence of genomes of similar or different sizes, 
pooled together to generate a single viral preparation. For this reason we 
investigated whether differences in genome size between the different 
vectors composing a pool, or the total number of vectors in a pool, could 
affect the packaging properties of each individual AAV. 
First of all, we generated a pool composed of 25 vectors of different size 
and quantified the relative amount of 10 randomly chosen clones in the 
AAV plasmids preparation, prepared mixing equimolar amount of each 
plasmid, and in the corresponding viral lysate obtained after pooled AAV 
vector production. As expected, the representation of the constructs in the 
viral preparations remained substantially similar to that in the pool of 
plasmids. Despite a clear trend of decreased packaging efficiency for longer 





window of ±2 fold of variation from the expected value, which appears to 
be an acceptable range in the context of pooled AAV production. The 
results obtained by analyzing clones with large size (>1500 bp) in the 
context of pools of heterogeneous size vs. pools of similar large size clearly 
indicated that the homogeneity of vector insert length was a major 
parameter to be taken into account during pooled AAV production.  
In summary, the results obtained: i) confirmed the relevance of mutual 
influence among the genomes composing a pool during the viral packaging 
process, ii) were against the possibility that the packaging limits of the 
longer genomes observed in the non-homogeneous pool might be due to 
their specific sequences and iii) highlighted that the generation of AAV 
pools homogeneous for size is an essential requirement, which is 
particularly relevant for constructs carrying inserts >1500-2000 bp, which 
may be disfavored in competitive packaging. 
Pool complexity does not influence viral packaging efficiency 
To evaluate the influence that an increasing number of clones in a pool 
could have on their own packaging ability into the corresponding viral 
particles, we compared the packaging capacity of the genes analyzed in 
AAV2-Pool25, when included in a pool of 50 or 100 different vectors. As in 
the previous experiment, an excellent conservation of the investigated, 
individual clones representation in AAV2-Pool50 and AAV2-Pool100 was 
observed (variations still in the range of ±2 fold from the expected value), 
with the exception of the two longer genes, which were packaged less 
efficiently, similarly to the results obtained with the AAV2-Pool25. Also in 
this case, we established that the comparable size of the pooled genomes 
represents an important requirement for equimolar packaging of viral 
particles. In contrast, the total number of different vectors composing the 
pool does not seem to significantly influence packaging, indicating that the 





In conclusion, when considered collectively, these results confirmed the 
possibility to simultaneously package into viral particles several AAV 
constructs (at least 100) carrying different transgenes. In addition, the 
individual representation of each construct in the vectors pool fairly 
reproduced its original proportion in the mix of plasmids, as long as the 
genomes included in the pool carried inserts of comparable size. 
Multiple AAV vectors equally transduce skeletal muscle and 
persist in the tissue for a long time 
An additional major question we investigated was whether individual AAV 
vectors maintain their infectivity in vivo when present in a pool. To address 
this issue, we quantified the relative abundance of the same 10 previously 
investigated clones before and 3 days after in vivo transduction of the 
original AAV2-Pool25 into murine tibialis anterior skeletal muscle. We 
observed that all the viral particles transduced the tissue, that the ratio 
between their abundance in the original vector preparation and in vivo was 
maintained, and that no major bias in infectivity occurred.  
Subsequently, we checked whether the relative vector abundance was 
maintained over time in the transduced tissue. Of course, answer to this 
question was not only a matter of AAV vector biology but also strictly 
correlated with the biology of each single transgene.  
As expected, we confirmed the already described decrease of almost one 
order of magnitude in the global levels of AAV genomes one month after 
skeletal muscle transduction (Tafuro et al., 2009). Despite this drop, viral 
DNAs were still clearly detectable in the tissue at this time, thus supporting 
the in vivo persistence of the vector genomes. After quantification, we 
noticed that the relative abundance of single clones in the muscle was 
maintained in the same proportion as in the initial viral preparation for 8 





A similar result might be explained speculating that, over this time period, 
genes exerting a toxic effect would be progressively more depleted from 
the pool than neutral transgenes while, on the other side, transgenes with 
beneficial properties on the muscle would be preferentially maintained. In 
particular, the enrichment of the E2 transgene, which encodes for the 
endocrine factor ghrelin, at a first examination might appear surprising, 
however if we consider the results obtained by analyzing the functions of 
ghrelin in the cardiac and muscle systems, it can be reasonably speculated 
that its relative enrichment is most likely due to the powerful protective 
effect exerted by this gene on muscle fibers. As far as the second enriched 
transgene, instead, it encodes for gastrin, a peptide able to promote 
contraction on antral smooth muscle cells (Jarrousse et al., 2004), but 
never associated with a specific function on skeletal muscle so far. 
Taking into account these results, we can certainly state that we need to 
carefully define the timing for viral DNA rescue after in vivo functional 
selection, in order to guarantee enrichment of pro-surviving genes 
triggered by damage. For this reason, in the following experiments we 
fixed two weeks after selection induction as the timing for vector genomes 
recovery. 
Proportional maintenance of individual AAV vector expression in 
vivo according to pool complexity 
A final question we wanted to answer was whether expression from the 
same vector was maintained proportionally to its abundance in the pool 
upon injection in vivo. To address this issue, we quantified the level of 
expression of two transgenes when transduced into the skeletal muscle as 
individual vectors or in pools of 25, 50 of 100 AAVs, 15 days after 
transduction. The experimental results indicated that each individual 
plasmid was still transcribed when present in the context of a complex pool 





driven transcription, and that there was a fair proportionality between the 
individual clone representation in the AAV mix and the levels of expression 
of its individual transgene). Despite the considerable dilution of each clone 
included in the AAV2-Pool100, we still observed a level of expression that 
exceeded 5-fold that of the endogenous transcript. From this consideration 
we can conclude that even if AAV pool complexity does not affect viral 
packaging, it certainly influences the levels of individual transgene 
overexpression and therefore the generation of pools of vectors composed 
by a limited number of different clones represents an essential requirement 
for the implementation of the strategy. Obviously, it is impossible to 
determine what would be the optimal levels of expression of an individual 
transgene endowed with potential protective function on the myocardium. 
In the subsequent experiments, therefore, to guarantee effectiveness of 
the in vivo selection strategy, vectors pools had a complexity of 10 clones, 
in order to guarantee expression of individual transgenes at levels at least 
50-fold higher than their endogenous counterparts.  
To summarize, the results shown in this Thesis’ section indicate that:  
i) Almost 85% of secreted factor cDNAs can be cloned into AAV plasmids 
and used to obtain infectious AAV vectors.  
ii) Multiple AAV vectors can be packaged simultaneously; competition for 
packaging is more prominent for clones with insert size >1500 bp and this 
problem can be overcome by packaging clones with insert having similar 
size. 
iii) AAV vector preparations consisting of multiple clones are infectious in 
vivo, where representation of each vector is maintained. 
iv) Expression of individual vectors from vector pools is fairly proportional 






5.2 THE SECRETED FACTORS GHRELIN AND INSL6 
RESULTED ENRICHED AFTER IN VIVO FUNCTIONAL 
SELECTION IN TWO MODELS OF ISCHEMIC DAMAGE 
 
Collectively, the experiments of validation and setting of the FunSel 
strategy appear to fully support the feasibility of the in vivo screening 
project based on transduction with multiple AAV vector pools. Starting from 
this evidence, we organized the collection of 100 AAV plasmids coding for 
secreted molecules in pools composed of 10 different clones with 
comparable genome size. 
In order to identify novel pro-surviving factors that could potentially be 
exploited therapeutically, we took advantage of two murine models of 
ischemic disorders, a model of skeletal muscle hind limb ischemia and a 
model of isoproterenol-induced acute cardiac damage. These models 
guarantee a diffuse damage in the target tissue and thus perfectly fit with 
the requirement of FunSel principles, which entail the functional selection 
of vectors expressing pro-surviving or pro-regenerating genes. It has 
extensively been shown that several molecules protecting skeletal muscle, 
such as IGF-I and VEGF-A, also exert a comparable beneficial effect on 
cardiomyocytes (Arsic et al., 2004; Barton et al., 2002; Ferrarini et al., 
2006; Jacquier et al., 2007; Rissanen et al., 2005; Su et al., 2003).  
 
5.2.1 Ghrelin as a protective gene selected after skeletal 
muscle damage 
For the functional selection in the skeletal muscle, we pooled three AAV 
serotype 2 group of vectors, each one containing 10 constructs of 
comparable genome size, obtaining a final viral preparation of 30 vectors 





Afterwards, hind-limb ischemia was induced only in the right limb to trigger 
the functional selection of the viral genomes.  
Three successive rounds of in vivo injection of the AAV pools, uni-lateral 
induction of ischemia, recovery of viral DNA from both the ischemic and the 
non-ischemic muscles and production of novel viral preparations generated 
from the pooled re-cloning of the rescued genomes, were required to 
detect enrichment of a candidate gene among the genomes recovered from 
the ischemic legs.  
The enriched vector, progressively selected for its own function in vivo, 
codes for the secreted hormone Ghrelin, a peptide mainly produced by the 
stomach (Kojima et al., 1999) and involved in neuroendocrine and 
metabolic metabolism. However, a growing body of literature about this 
gene recently profiled a complex range of functions for this peptide, which 
involve many different tissues, among which also the heart. Also relevant 
to the results presented here, it was shown that ghrelin induce 
differentiation of C2C12 myoblasts by inhibiting their proliferation and 
favoring their differentiation (Filigheddu et al., 2007). 
All these findings suggest that the identification of ghrelin as candidate 
gene in this experimental model is fully consistent with the principle of 
FunSel, and supports its efficacy. 
 
5.2.2 Implementation of the selection strategy in a model of 
isoproterenol-induced cardiac damage identified INSL6 as a 
candidate protective gene 
We also exploited a model of isoproterenol-induced acute cardiac damage 
to test selection of our AAV clone collection. A single intraperitoneal 
administration of high dosage of isoproterenol causes cardiomyocyte 





1998a), and the induced ischemic-like lesion is widespread in all the 
myocardium, thus representing an efficient selection driver.  
For this second selection approach, we screened the full AAV collection of 
100 secreted factors, again organized in pool composed by 10 vectors 
each. We generated 10 pools of AAV vectors with capsid 9 (this serotype 
transduces cardiomyocytes very efficiently), and in this case we selected 
them individually in vivo. The AAV pools were delivered by intraperitoneal 
(IP) injection in newborn mice, since this represents a very effective route 
of administration to obtain whole heart transduction), followed by a single 
acute IP administration of a toxic dose of isoproterenol. 
While for 9 out of 10 pools after the first round of selection we could not 
observe any difference in the genome composition of the vector pools 
rescued from the heart of mice submitted to isoproterenol treatment 
compared to control animals, very unexpectedly one pool revealed the 
clear enrichment of a single clone, corresponding to the insulin-like peptide 
6 (INSL6) cDNA.  
INSL6 is a poorly characterized growth factor belonging to the well-known 
insulin/relaxin superfamily. Its identification in the screening appears very 
interesting, because this factor represents really a novel secreted molecule, 
never associated with the cardiovascular system.  
The anti-fibrotic properties of relaxin have been extensively described in 
the past. The local production of this peptide by cardiomyocytes was 
related to a possible beneficial role of this molecule in cardiac disease 
conditions (Teichman et al., 2010). On the contrary, INSL6 has mainly been 
associated with germ cell development so far (Burnicka-Turek et al., 2009) 
and its identification as a candidate protective gene in a model of cardiac 
fibrosis makes it a very attractive factor to be further investigated. It is 
important to notice that we focused our attention on INSL6 because of its 





and thus we stopped the screening; it is possible that subsequent rounds 
of selection would have brought to light other interesting secreted factors, 




5.3 AAV9-MEDIATED GHRELIN EXPRESSION IN THE MOUSE 
HEART IMPROVES CARDIAC FUNCTION AFTER 
INFARCTION 
 
The molecules identified by the in vivo functional selection were afterwards 
characterized for their protective potential against myocardial infarction.  
 
5.3.1 AAV9-Ghrelin prevents neonatal rat cardiomyocytes 
cell death in vitro 
With reference to ghrelin we initially tested its effects in vitro. Neonatal rat 
cardiomyocyte cultures were established according to conditions already 
set up by the laboratory (Collesi et al., 2008), transduced with an AAV9 
vector expressing ghrelin and then treated with two toxic drugs inducing 
cell death, namely isoproterenol and doxorubicin. In both cases ghrelin 
exerted a potent pro-surviving effect on cardiomyocytes, confirming the 
anti-apoptotic properties of this peptide, already described in other cell 
systems (Kim et al., 2004; Kim et al., 2005).  
As mentioned in the Results section, the AAV vector we generated codes 
for the ghrelin precursor, which is then cleaved to give rise to the mature 
peptide. Since the GOAT enzyme is expressed at very low levels in 
cardiomyocytes, compared to the gut (Lim et al., 2011; Lin et al., 2011), it 
is expected that the prevalent form of the peptide in the cells will be des-





surviving effect in cardiomyocytes, confirming the findings of other groups 
in other cell models (Baldanzi et al., 2002; Granata et al., 2007). 
 
5.3.2 Cardiac gene transfer of ghrelin exerts beneficial 
effects after myocardial infarction in mice 
Following the results obtained in vitro, we investigated the effectiveness of 
AAV9-Ghrelin in a model of murine cardiac infarction, induced by left 
descendent coronary artery ligation, as previously described (Gao et al., 
2000). 
After 3 months of follow-up, LV ejection fraction and fractional shortening 
of infarcted mice transduced with ghrelin were significantly preserved, 
while cardiac performance progressively deteriorated in control mice. In 
addition, LV wall thickness and both global and regional contractile function 
were not significantly changed compared to baseline in AAV9-Ghrelin 
transduced hearts. The fibrotic area was consistently smaller in these 
animals, which exhibited reduced infarct size and no LV dilation. A very 
interesting observation is that these parameters were still improving after 
90 days. 
The protection from apoptosis observed in cultured cardiomyocytes was 
clearly evident also in vivo, 2 days after intracardiac AAV9-Ghrelin vector 
delivery and MI induction, thus explaining the consistent decreased loss of 
cardiac mass exhibited by ghrelin overexpressing mice.  
In addition, a prominent reduction in the massive inflammatory cells 
infiltration usually occurring soon after damage in the peri-infarctual region 
was also observed in the ghrelin-treated animals, thus confirming the anti-
inflammatory properties of this peptide (Huang et al., 2009; Li et al., 
2004). Moreover, the levels of induction of genes generally overexpressed 
under inflammatory conditions, such as IL1-, IL6 and TNF were 





Recently, it was demonstrated that, after cardiac damage, miR-21 is 
strongly upregulated in fibroblasts (Thum et al., 2008). This overexpression 
contributes to fibrotic tissue deposition and cardiac hypertrophy, also 
through a direct action of the miR-21 on MMP-2 expression (Roy et al., 
2009). Our data are fully consistent with these findings. Indeed, after 
myocardial infarction, we observed a massive induction of miR-21 and 
MMP-2 transcription in control animals, while the ghrelin-treated mice 
exhibited a normalization of the levels of activation of these genes. 
In agreement with the echocardiographic observations, we also noticed 
that AAV9-Ghrelin transduced mice did not exhibit the typical pattern of 
deregulated gene expression usually associated with pathological LV 
remodeling (Gidh-Jain et al., 1998). Ghrelin overexpression indeed 
significantly counteracted the increase in transcriptional levels of genes 
such as -MHC and the cardiac natriuretic peptides (ANF and BNP), which 
we instead observed in control animals, and also normalized the expression 
of markers like -MHC, Serca2a, RYR2 and PGC1, typically downregulated 
in pathological hypertrophy conditions. 
The major conclusion that can be drown from these results is that a 
persistent expression of Ghrelin after myocardial infarction exerts 
prolonged beneficial effects in terms of contractility, preservation of viable 
cardiac tissue and prevention of pathological LV remodeling. The anti-
apoptotic and anti-inflammatory actions of this gene soon after infarction 
certainly contributed to the preservation of cardiac function, impeding a 
massive loss of myocardial tissue and therefore maintaining contractility 
and wall thickening after damage. 
The definition of the relative contribution of acylated and des-acylated 
ghrelin in protecting the infarcted myocardium still needs to be clearly 
defined, in order to clarify and eventually definitively demonstrate the 





GHSR-1a, and thus able to also bind des-acyl ghrelin (Lear et al., 2010; Li 
et al., 2006). Different groups have hypothesized the existence of this 
putative receptor, showing the effectiveness of both acyl and des-acyl 
ghrelin in different cell types, not expressing GHSR-1a (Gauna et al., 2006; 
Muccioli et al., 2004; Thompson et al., 2004). The potential observation of 
the AAV9-Ghrelin beneficial effects in GHSR null mice (Sun et al., 2004) 
submitted to myocardial infarction could represent a final demonstration of 
the outstanding role of this alternative receptor in supporting the 
cardioprotective functions of this molecule. 
 
 
5.4 CARDIAC GENE TRANSFER OF INSL6 EXERTS 
BENEFICIAL EFFECTS AFTER MYOCARDIAL 
INFARCTION IN MICE 
 
As we did for Ghrelin, the other secreted factor identified by the in vivo 
functional selection, namely INSL6, was also afterwards characterized for 
its protective potential against myocardial infarction.  
AAV9-mediated INSL6 expression in infarcted mouse hearts improved 
cardiac performance preserving LV ejection fraction and LV fractional 
shortening and reducing the ischemic scar evolution after three months. 
Unexpectedly, a reduction in infarct size was observed in these animals 
already at day 2 after damage, and infarcts remained smaller than in the 
controls over time. As we described for ghrelin-transduced animals also 
INSL6 overexpressing hearts exhibited a marked decrease in myocardial 
apoptosis soon after infarction.  
In this Thesis we report only preliminary data related to the INSL6 
cardioprotective effects. A more extensive characterization of the functions 





should this molecule be further considered potential therapeutic 
applications. Of notice, our results are consistent with the recent evidence 
that INSL6 acts as a pro-regenerative factor in conditions of muscular 
injury induced by cardiotoxin (Zeng et al., 2010), thus confirming the 
concept that several molecules protecting skeletal muscle often also exert a 





In conclusion, in this Thesis work we propose for the first time the 
development of FunSel, an innovative functional selection procedure, 
based on in vivo gene transfer of an arrayed library cloned into AAV 
vectors, for the identification of novel secreted factors sustaining cardiac 
function. Collectively, the obtained results support both the theoretical and 
technical feasibility of this strategy and fully validate the possibility to 
generate and transduce in vivo multiple AAV vector pools and to screen 
them for their functional effect under degenerative conditions. The 
detected cardioprotective effect of Ghrelin and INSL-6 not only represent a 
proof-of-principle of the efficacy of the FunSel procedure, but also 
represent a potentially interesting result by itself. The dissection of the 
molecular pathways through which the two factors exert their beneficial 
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Cardiomyocyte VEGFR-1 activation by VEGF-B induces
compensatory hypertrophy and preserves cardiac
function after myocardial infarction
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ABSTRACT Mounting evidence indicates that the func-
tion of members of the vascular endothelial growth factor
(VEGF) family extends beyond blood vessel formation.
Here, we show that the prolonged intramyocardial expres-
sion of VEGF-A165 and VEGF-B167 on adeno-associated
virus-mediated gene delivery determined a marked im-
provement in cardiac function after myocardial infarction
in rats, by promoting cardiac contractility, preserving
viable cardiac tissue, and preventing remodeling of the
left ventricle (LV) over time. Consistent with this func-
tional outcome, animals treated with both factors showed
diminished fibrosis and increased contractile myocar-
dium, which were more pronounced after expression of
the selective VEGF receptor-1 (VEGFR-1) ligand VEGF-B,
in the absence of significant induction of angiogenesis.
We found that cardiomyocytes expressed VEGFR-1,
VEGFR-2, and neuropilin-1 and that, in particular,
VEGFR-1 was specifically up-regulated in hypoxia and on
exposure to oxidative stress. VEGF-B exerted powerful
antiapoptotic effect in both cultured cardiomyocytes and
after myocardial infarction in vivo. Finally, VEGFR-1
activation by VEGF-B was found to elicit a peculiar gene
expression profile proper of the compensatory, hypertro-
phic response, consisting in activation of !MHC and
repression of "MHC and skeletal !-actin, and an increase
in SERCA2a, RYR, PGC1!, and cardiac natriuretic pep-
tide transcripts, both in cultured cardiomyocytes and in
infarcted hearts. The finding that VEGFR-1 activation by
VEGF-B prevents loss of cardiac mass and promotes
maintenance of cardiac contractility over time has obvious
therapeutic implications.—Zentilin, L., Puligadda, U.,
Lionetti, V., Zacchigna, S., Collesi, C., Pattarini, L., Ruozi,
G., Camporesi, S., Sinagra, G., Pepe, M., Recchia, F. A.,
Giacca, M. Cardiomyocyte VEGFR-1 activation by
VEGF-B induces compensatory hypertrophy and pre-
serves cardiac function after myocardial infarction.
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Members of the vascular endothelial growth factor
(VEGF) family and their receptors are essential regulators
of vasculogenesis, angiogenesis, and vessel mainte-
nance in both embryo and adults (for reviews, see refs.
1–4). In particular, the 165-aa isoform of VEGF-A
(VEGF-A herein for brevity) possesses full angiogenic and
arteriogenic activity, mainly through binding to VEGFR-2,
which stimulates pathways important for mitogenesis,
migration, and survival of endothelial cells (4, 5).
VEGF-A also binds VEGFR-1 with an affinity that is
!10 times higher than that of VEGFR-2 (6); however,
the significance of this interaction remains elusive,
especially since this receptor appears unable to trans-
duce an angiogenic signal in endothelial cells (7).
Multiple evidence suggests that VEGF-B, a VEGFR-1-
exclusive ligand that is produced in a heparin-binding
isoform of 167 aa (VEGF-B167) and a diffusible isoform
of 186 aa (VEGF-B186) (7, 8) might selectively be active
in the myocardium. Indeed, the VEGF-B gene, shows
prominent expression in the heart during embryonic
development (9), and mice with knockouts for this
factor display a mild cardiac phenotype, characterized,
at least in one strain, by decreased heart size (10). In
addition, recent evidence indicates that transgenic
mice specifically expressing VEGF-B167 in the myocar-
dium undergo massive myocardial hypertrophy, in the
absence of a significant increase of cardiac angiogene-
sis (11).
A few studies have also explored the effects of
VEGF-A and VEGF-B in the heart after myocardial
infarction. In particular, VEGF-B167 was described to
significantly increase revascularization of the infarcted
myocardium; however, it failed to enhance vascular
growth in the skin or ischemic limb (12). The reasons
1 These authors contributed equally to this work.
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for the selective cardiac benefit of VEGF-B delivery
remained unexplained. Another recent study, entailing
the delivery of VEGF-B186 after infarction in pigs and
rabbits using adenoviral vectors, indicated that the
factor induced myocardial-specific angiogenesis and
arteriogenesis and, most notably, improved myocardial
function a few days after vector injection (13). As far as
VEGF-A is concerned, in a previous study of acute
myocardial infarction in dogs, we observed that the
sustained expression of this factor, delivered to the
heart using an adeno-associated virus (AAV)-based vec-
tor determined remarkable recovery of the regional
myocardial contractility, up to 4 wk after injury (14).
Surprisingly, the improvement in myocardial function
started to be significant as early as 48 h after vector
injection, a temporal frame not compatible with the
formation of new blood vessels and suggestive of a
direct effect of VEGF on resident cardiomyocytes, ad-
ditional to angiogenesis (14).
Taken together, this variegated information leaves a
series of essential questions outstanding, including to
what extent the cardiac effects of the VEGFs are sec-
ondary to the induction of angiogenesis or directly
exerted onto myocardial cells, which is the receptor
involved, and how long the beneficial effect exerted by
the factors lasts after cardiac injury. To provide answers
to these questions, we took advantage of the possibility
of delivering in vivo VEGF-A and VEGF-B167 (herein
VEGF-B for brevity) to the heart using vectors based on
the AAV, and to assess their effects for prolonged
periods of time both in normal conditions and after
myocardial infarction. Over the past few years, these
vectors have gained increasing popularity due to several
favorable characteristics, in particular, their ability to
transduce postmitotic cells, including cardiomyocytes,
at high efficiency and to drive gene expression for very
prolonged periods of time in the absence of noticeable
inflammation (15, 16).
Here, we show that the AAV-mediated, intramyocar-
dial expression of VEGF-A and, most notably, of
VEGF-B determines a marked improvement in cardiac
function after permanent coronary artery occlusion in
rats, ensuing from the direct protection of cardiomyo-
cytes from apoptosis and up-regulation of genes driving
compensatory, hypertrophic response. These results
clearly indicate that the role of VEGFs in the heart
extends beyond their angiogenic properties, and point
toward VEGFR-1 signaling as an important mediator of
cardiomyocyte function, with clear therapeutic implica-
tions.
MATERIALS AND METHODS
Production, purification, and characterization of rAAV
vectors
rAAV vectors were prepared by the AAV Vector Unit at ICGEB
Trieste (http://www.icgeb.org/avu-core-facility.html), as de-
scribed previously (17, 18). AAV titers were in the range of 1 !
1012 to 1 ! 1013 genome copies (gc)/ml.
Animal studies and echocardiography
Animal care and treatment were conducted in conformity
with institutional guidelines in compliance with national and
international laws and policies (European Economic Com-
munity Council Directive 86/609, OJL 358, December 12,
1987), after institutional review board approval. Myocardial
infarction (MI) was produced in male Wistar rats at 2 mo of
age, by permanent left anterior descending coronary artery
ligation, as described previously (19). After ligation, they were
immediately injected into the LV with 10 "l of recombinant
AAV vectors, corresponding to 5 ! 1010 gc, with 3 separate
injections into the viable myocardium bordering the infarct
using a tubercoline syringe with a 30-gauge needle. Four
groups of animals were studied (n#10/group), receiving
AAV2-VEGF-A, AAV2-VEGF-B, AAV2-LacZ, or saline.
To evaluate global and regional LV function, transthoracic
echocardiography was performed before thoracotomy, 28 d and
3 mo after MI in sedated rats with a commercially available
echocardiography system (MyLab 30; Esaote, Genoa, Italy)
equipped with a 12-MHz linear transducer, as described previ-
ously (20). Analysis was as recommended by the American
Society of Echocardiography (21); all measurements were per-
formed by an experienced cardiologist and an echocardiogra-
phy expert blinded to treatment groups.
At the end of the echocardiography study, hearts were
collected, and the LV, including the interventricular septum,
was carefully dissected. After washing in PBS, each specimen
was cut into 4 or 5 pieces of equal thickness from base to apex,
fixed in 4% paraformaldeyde, and embedded in paraffin for
histological analysis. Infarct size was measured on 5-"m-thick
sections as the percentage of (endocardial$epicardial cir-
cumference of infarct area)/(endocardial$epicardial cir-
cumference of LV).
For the detection of apoptosis in vivo, infarcted hearts were
collected and snap-frozen 3 d after MI. Frozen sections from
each sample were fixed in 4% buffered paraformaldehyde
(PFA) and then treated as described above for immunostain-
ing and TUNEL.
Isolation and treatment of neonatal rat ventricular
cardiomyocytes
Ventricular myocytes from 1- to 2-d-old rats were prepared
according to a previously detailed protocol, yielding !90%
purity (22). Cells were collected and plated at a density of 500
cells/mm2 into 100-mm dishes (for RNA and protein analy-
sis), or multiwell slides coated with 0.2% gelatin (for immu-
nofluorescence staining). When indicated, cells were treated
with rhVEGF-A (100 ng/ml; R&D Systems, Minneapolis, MN,
USA), rhVEGF-B (100 ng/ml; R&D Systems), thyroid hor-
mone (100 nM; Sigma, St. Louis, MO, USA) and phenyleph-
rine (20 "M; Sigma). For the detection of VEGF receptors,
growth-factor stimulation was performed at 37°C for 7 min in
serum-free medium containing 4.5 g/L glucose, 0.1% w/v
BSA, 4 "g/ml B12, 10 "g/ml insulin, and 10 "g/ml trans-
ferrin.
Apoptosis was induced by culturing serum-starved cells for
48 h at 37°C in a 5% O2-95% N2 atmosphere using a hypoxia
incubator chamber (Billups-Rothenberg, San Diego, CA,
USA) and then switching to 20% O2 for an additional 24 h.
Cells were then fixed in 3% PFA and 2% sucrose in PBS.
Apoptotic cells were visualized by the TUNEL (TdT-mediated
dUTP nick-end labeling) assay, using the in situ cell death
detection kit, TMR red (Roche Diagnostics, Mannheim, Ger-
many), according to the manufacturer’s instructions. At least
10 high-magnification fields were counted for each experi-
mental condition. Analysis of cardiomyocyte survival was
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performed using the Live&Dead assay (Molecular Probes,
Eugene, OR, USA) after treatment with 200 nM epirubicin
for 90 m in serum free medium.
Quantification of nucleic acids by real-time PCR
Total RNA from isolated cardiomyocytes or dissected LV
heart tissue samples was extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions, and reverse-transcribed using hexameric
random primers.
Quantification of gene expression was performed by real-
time PCR, using predeveloped and custom-designed assays
(Applied Biosystems, Foster City, CA, USA) or SYBRGreen
(Bio-Rad Laboratories, Hercules, CA, USA). Total RNA from
isolated cardiomyocytes or dissected LV heart tissue samples
was extracted using TRIzol reagent (Invitrogen) according to
manufacturer’s instructions and reverse transcribed using
hexameric random primers. The cDNA was used as a tem-
plate for real-time PCR amplification to detect the expression
levels of the rat VEGF receptors (VEGFR-1, VEGFR-2, NP-1), as
well as of !-MHC, "-MHC, sk !-actin, ANF, BNP, SERCA2a,
RYR2, and PGC1!. The housekeeping genes GAPDH and
HPRT were used to normalize the results.
For the detection of vector specific DNA in heart samples,
total DNA, purified by Proteinase K/phenol-chloroform ex-
traction method, was subjected to real-time PCR amplifica-
tion using a TaqMan probe and primers that specifically
match sequences in the CMV promoter, common to all AAV
vectors used in this study.
Sequences of primers and probes used
Primers
Rat PGC-1 F 5#-TGCAGCCAAGACTCTGTATGG-3#, R 5#-
GGCAAAGAGGCTGGTCCTC-3#; rat BNP : F 5#-CAGCTCT-
CAAAGGACCAAGG-3#, R 5#-GCCCAAAGCAGCTTGAACTA-
3#; rat HPRT: F 5#-GCCCTTGACTATAATGAGCACTCAG-3#,
R 5#-GTAGATTCAACTTGCCGCTGTTT-3#; mouse iVEGF-B:
F 5#-TTGCACTGCTGCAGCTGGCTC-3#, R 5#-GCTGGGCAC-
TAGTTGTTTGA-3#; CMV promoter: F 5#-TGGGCGGTAG-
GCGTGTA-3#, R 5#-CGATCTGACGGTTCACTAAACG-3#.
Taqman probes (assay)
Rat "-MHC: (FAM)-Rn00568328_m1; rat !-MHC: (FAM)-
Rn00568304_m1; rat RYR2: (FAM)-Rn01470303_m1; rat SERCA2a:
(FAM)-Rn00568762_m1; rat ANP: (FAM)-Rn00561661_n1; rat sk
!-actin: (FAM)-Rn00570060_g1; rat Flk1: (FAM)-Rn 00564986_m1;
rat Flt1: (FAM)-Rn 01409523_g1; rat NP1: (FAM)-Rn 00435380_m1;
human VEGF-A165: (FAM)-Hs00173626_m1; rat GAPDH: (VIC)-
TaqMan Endogenous control (4352338E); CMV: (FAM)-
TGGGAGGTCTATATAAGC.
Histology and immunofluorescence
Vasculature staining was performed on paraffin-embedded
sections, blocked for 1 h with 2% BSA in PBS; endothelial
cells were detected using FITC-conjugated Lycopersicum escu-
lentum lectin (Vector Laboratories) and vascular smooth
muscle cells (VSMCs) using a Cy3-conjugated anti-!-SMA
mouse monoclonal antibody (clone 1A4, Sigma). Pericytes
were detected using a rabbit polyclonal anti-NG2 antibody
(Chemicon, Temecula, CA, USA) on 4% paraformaldehyde-
fixed frozen sections after overnight blocking with 5% horse
serum. The detection of VEGF receptors by immunofluores-
cence was performed on frozen sections (5 $m thick), fixed
in IHC Zinc Fixative (Pharmingen, BD Biosciences, San Jose,
CA, USA), and blocked for 30 m with 5% goat or 5% horse
serum in PBS, depending on the secondary antibody.
The following primary antibodies were used for immuno-
fluorescence studies in cardiomyocytes: goat anti-mouse Flk-1
(AF644; R&D Systems), 1:100; goat polyclonal anti-mouse
Flt-1 (AF471; R&D Systems), 1:20; goat polyclonal anti-rat
neuropilin-1 (AF566; R&D Systems), 1:50; and mouse anti-!-
sarcomeric actinin monoclonal antibody (EA-53; Abcam,
Cambridge MA, USA), 1:100. Alexa Fluor 594 donkey anti-
goat, Alexa Fluor 594 donkey anti-rabbit, and Alexa Fluor 488
donkey anti-mouse were used as secondary antibodies (Mo-
lecular Probes). Nuclei were counterstained with DAPI.
Images were acquired at room temperature with a DMLB
upright fluorescence microscope (Leica Microsystems, Wet-
zlar, Germany) equipped with a charge-coupled device cam-
era (CoolSNAP CF; Roper Scientific, Trenton, NJ, USA) using
MetaView 4.6 quantitative analysis software (MDS Analytical
Technologies, Toronto, ON, Canada).
Immunoprecipitation and Western blot analysis
For the detection of VEGF receptors, freshly isolated cardio-
myocytes were allowed to attach in 100-mm dishes and then
left overnight in serum-free medium. Stimulation was per-
formed by incubating the cell cultures at 37°C for 7 min in 2
ml of serum or 2 ml of serum-free medium containing 50
ng/ml recombinant huVEGF-A165 and 100 ng/ml huVEGF-B.
After washing with PBS on ice, samples were lysed in RIPA
buffer (20 mM Tris-HCl, pH 7.4; 150 mM NaCl; 5 mM EDTA;
1% NaDoc; 1% Triton X-100; and 0.1% SDS) containing 90
$g/ml PMSF, 100 $M NaVO4, 50 mM NaF, 20 $g/ml
aprotinin, and 20 $g/ml leupeptin (Sigma-Aldrich). Protein
concentration was determined by the Bradford method (Bio-
Rad Laboratories); 200 $g of proteins was resolved on 6%
SDS-PAGE and transferred to nitrocellulose membranes (GE
Healthcare, New York, NY, USA). Immunoblots were blocked
in 5% bovine serum albumin in TBS-Tween (50 mM Tris-HCl,
pH 7.4; 200 mM NaCl; and 0.1% Tween 20). Membranes were
incubated with the following primary antibodies (dilution
1:1000) overnight at 4°C: rabbit polyclonal anti-Flk-1 (C-1158;
Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit poly-
clonal anti-Flt-1 (C-17; Santa Cruz Biotechnology), mouse mono-
clonal anti-phospho-Tyrosine (PY20; Biolegend, San Diego, CA,
USA), goat polyclonal anti-rat neuropilin-1 (AF566; R&D Sys-
tems), and mouse monoclonal tubulin (B-5–1-2; Sigma). Mem-
branes were then washed in Tris-buffered saline and 0.1%
Tween 20 in blocking buffer and incubated with the appro-
priate HPR-conjugated secondary antibodies for 45 m at
room temperature. Proteins were detected by enhanced
chemiluminescence (GE Healthcare).
In vivo VEGF receptor tyrosine phosphorylation was evalu-
ated by Western blot analysis with anti-phosphotyrosine anti-
bodies on immunoprecipitates. Two milligrams of cell lysates
was incubated with either rabbit polyclonal anti-Flk-1 (C-1158;
Santa Cruz Biotechnology) or rabbit polyclonal anti-Flt-1
(C-17; Santa Cruz Biotechnology) antisera coupled to Sepha-
rose-Protein A (20 ml packed beads/ml lysate) overnight at
4°C with agitation. Sepharose-protein A-bound proteins were
washed 4 times with RIPA buffer and separated on 6%
SDS–polyacrylamide gels, followed by immunoblotting with
either mouse monoclonal anti-phosphotyrosine antibodies
(PY20; Biolegend) or with anti-Flk-1 specific phosphotyrosine
antibodies (VEGF-Receptor2-Y1175; Cell Signaling, Beverly,
MA, USA).
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Statistical analysis
One-way ANOVA and Bonferroni/Dunn’s post hoc test were
used to compare multiple groups. Pairwise comparison be-
tween groups was performed using the Student’s t test.
Dose-response effect was assessed by regression analysis. P !
0.05 was set as a threshold for statistical significance.
RESULTS
Long-term effects of AAV-mediated VEGF-B and
VEGF-A expression in normal rat myocardium
To comparatively assess the effects of VEGF-A and
VEGF-B, we generated two AAV vectors, based on AAV
serotype 2 (AAV2), expressing the respective cDNAs in
a constitutive manner from the CMV IE gene promoter.
The efficiency of transduction and expression of these
vectors were first assessed by injecting 5 " 1010 AAV
particles into the LV free wall of normal rats; control
animals were injected with either saline or AAV2-LacZ
(n#6/group). As detected by real-time PCR quantifica-
tion, the levels of expression of the two transgenes was
persistent at both 30 d (not shown) and 90 d postinjec-
tion (Fig. 1A, B). Consistent with our previous observa-
tions (14, 17, 23), no inflammatory response was de-
tected in the animals injected with either saline or
AAV2-LacZ at either time point (data not shown). No
differences were detected between AAV2-LacZ- or sa-
line-injected animals in none of the parameters consid-
ered throughout this work, neither in normal nor in
infarcted animals. The results obtained in the two
groups were therefore pooled and collectively labeled
as control in all figures.
Representative images of the vasculature in the AAV-
injected and control hearts at 30 d after injection are
shown in Fig. 1C after staining with anti-CD31 and
anti-$SMA antibodies to detect endothelial and smooth
muscle cells (SMCs), respectively. Consistent with our
previous findings in the normoperfused skeletal muscle
(17, 18), we observed that the prolonged expression of
VEGF-A in the heart determined a marked angiogenic
response, characterized by a significant increase in the
number of capillaries (Fig. 1D) and, most notably, of
small arteries in the 20- to 250-%m-diameter range (Fig.
1E), with a consequent increase in the arteriole/capil-
lary ratio (Fig. 1F). In contrast, AAV2-VEGF-B had a
very modest angiogenic effect, with the exception of
the sporadic formation of enlarged vascular structures,
connected to the circulation, apparently devoid of
$SMA- and NG2-positive mural cells (arrows in Fig. 1C
and Supplemental Fig. 1).
VEGF-B, a specific VEGFR-1 ligand, preserves
myocardial function after infarction
Next, we assessed the effects of the two vectors on
cardiac function after myocardial infarction. Rats
(n#10/group) underwent permanent left descendent
coronary artery ligation and immediate injection into
the LV peri-infarcted area of 5 " 1010 viral particles of
AAV2-VEGFA, AAV2-VEGFB, AAV2-LacZ, or saline
(pooled control group). Global and regional LV func-
tion was analyzed by echocardiography at 1 and 3 mo
after infarction; representative M-mode echocardio-
grams at the latter time point are shown in Fig. 2A. The
LV ejection fraction (LVEF) and LV fractional shorten-
ing (LVFS) were significantly preserved in infarcted rats
injected with both AAV2-VEGF-B and AAV-VEGF-A,
compared to untreated animals, in the absence of
significant changes in heart rate (P!0.05 for both
treatments at either time point; Fig. 2B, C, respectively).
Preservation of LV performance was significantly more
pronounced in the infarcted hearts treated with
Figure 1. Effects of AAV-mediated VEGF-B and VEGF-A
expression in normal rat myocardium. A, B) Levels of
VEGF-A (A) and VEGF-B (B) transgene transcripts evaluated
by real-time PCR analysis on total ventricular RNA extracted 90 d after vector injection. Transgene expression levels (n#8)
are normalized for those of the endogenous HPRT gene. C) Left panels: representative immunostainings of the vasculature
in rat myocardium injected with AAV-LacZ (control), AAV-VEGF-A, and AAV-VEGF-B, as indicated. Right panels: enlarged
views. Capillaries were detected using FITC-conjugated L. esculentum lectin (Vector Laboratories), staining endothelial cells,
and VSMCs using a Cy3-conjugated anti-$SMA mouse monoclonal antibody; nuclei were stained in blue with DAPI. Scale
bars # 500 %m. D, E) Quantification of capillary and arteriole density. F) Ratio between number of arteries and capillaries.
Values are expressed as means & se. *P ! 0.05.
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VEGF-B at 1 mo and, in particular, at 3 mo of treatment
(LVEF: 48!8 vs. 85!9%; LVFS: 29!8 vs. 52!7% in
control and VEGF-B animals, respectively; P"0.05 in all
cases). At both time points, the LV end-diastolic diam-
eter (EDD) and LV end-systolic diameter (ESD) were
also significantly reduced in rats that had received
AAV2-VEGF-B (EDD: 7.9!1.2 and 6.8!0.8 mm; ESD:
5.9!0.7 and 3.8!0.9 mm in control and VEGF-B ani-
mals at 3 mo of treatment; P"0.05 in all cases; Figs. 2D,
E, respectively).
The changes of regional cardiac contractility are
shown in Fig. 2F, G. At both 1 and 3 mo after cardiac
gene transfer, the LV end-systolic wall thickening
(AWTK) in the border zone of the infarcted hearts
injected with AAV2-VEGF-B was markedly improved
compared to control rats (18.5!3.0 vs. 32.2!2.9% for
control and VEGF-B at 3 mo; P"0.05). Similarly, the LV
anterior wall end-diastolic and end-systolic thickness
(AWTd and AWTs, respectively) of the border zone,
two indexes of regional mass, were selectively preserved
in the infarcted hearts expressing VEGF-B (P"0.05 in
both cases; Supplemental Fig. 2A, C). No changes in
the function and structure of the LV remote regions of
the infarcted hearts were observed in any experimental
group.
With the caveat that echocardiography in small ani-
mals might not provide sufficient sensitivity to detect
differences in thickening of the border zone of a small
MI, these data unanimously indicated that the pro-
longed expression of both VEGF-A and VEGF-B mark-
edly improved recovery of LV performance after infarc-
tion.
Animals were sacrificed at 3 mo by induction of
ischemia, and the hearts were examined for postinfarc-
tion fibrosis and chamber remodeling. Morphometric
analysis of trichromic-stained LV sections showed that
the anterior wall of infarcted control animals under-
went considerable thinning, consistent with the echo-
cardiographic results. In contrast, the AAV2-VEGFA-
and, more remarkably, the AAV2-VEGFB-treated hearts
showed significant preservation of contractile tissue
and reduction of the fibrotic area (see Fig. 3A for
representative cross-sections and Fig. 3C for high-mag-
nification view of the extent of fibrotic substitution);
the infarct size was determined as 36.2 ! 6.0% of the
LV in control animals vs. 21.5 ! 2.5 and 17.2 ! 3.5% in
the VEGF-A- and VEGF-B-expressing animals, respec-
tively (P"0.05 in both cases; Fig. 3B).
Molecular characterization of heart samples on ani-
mal sacrifice confirmed the persistence of the vector
genomes in the injected myocardium (Supplemental
Fig. 3A). Consistently, AAV-mediated expression of
both VEGF-A and VEGF-B was detected by real-time
PCR using transgene specific primers (Supplemental
Fig. 3B). The local expression of the transgenes did not
induce significant variation of the levels of VEGF recep-
tors mRNA (Supplemental Fig. 3C).
Similar to noninfarcted hearts (Fig. 1), the animals
treated with VEGF-A showed a significant increment in
the number of capillaries and arterioles, which was not
evident in those injected with AAV2-VEGF-B (see Fig.
3D for representative images and Fig. 3E, F for quanti-
fication of the number of capillaries and arterioles,
respectively).
Thus, the marked recovery of LV ventricular perfor-
mance after myocardial infarction, in particular, ob-
served on VEGF-B gene delivery occurred in the ab-
sence of significant induction of angiogenesis.
Cardiomyocytes express functional VEGF receptors in
vitro and in vivo
To explore whether VEGF exerted a direct effect on
cardiomyocytes, we first assessed the levels of expres-
sion of the VEGF receptors in these cells. A first set of
experiments was performed using total RNA extracted
from primary cultures highly enriched in #-actinin-
positive cardiomyocytes by three subsequent subplating
steps ($90% purity; see Materials and Methods and ref.
22); these cultures were established along complemen-
tary cultures of #-actinin-negative stromal cells ("1%
#-actinin positivity). Both cultures were maintained for
Figure 2. Echocardiographic analysis in AAV2-injected and control
mice at 1 and 3 mo after MI. A) Representative transthoracic
M-mode echographic profiles. B) LV ejection fraction (LVEF). C)
LV fractional shortening (LVFS). D) LV end-diastolic diam-
eter(EDD). E) LV end-systolic diameter (ESD). F) LV end-systolic
anterior wall thickening (AWTK). G) LV end-systolic posterior wall
thickening (PWTK). Values are expressed as means ! se. *P "
0.05.
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7–14 d. We found that VEGFR-1, VEGFR-2, and Np1
were all expressed in neonatal rat cardiomyocytes,
albeit at levels that were 3 orders of magnitude lower
than those of human umbilical vein endothelial cells
(HUVECs); stromal cells only expressed VEGFR-1 and
Np1, not VEGFR-2 (Fig. 4A). Of potential interest,
expression of VEGFR-1 selectively increased when
cardiomyocytes were placed in a hypoxic environ-
ment (2% O2) or exposed to oxidative stress (H2O2
100 !M); "5 fold and #3-fold induction, respec-
tively; Fig. 4B).
Expression of VEGFR-1, VEGFR-2, and Np1 was also
detected by Western blot analysis in neonatal cardio-
myocyte cell lysates (Fig. 4C, top panel). Most nota-
bly, these receptors appeared to be functional, since
immmunoprecipitation using specific anti-VEGFR-1
and anti-VEGFR-2 antibodies followed by Western
blot analysis with anti-phosphotyrosine antibodies
revealed specific phosphorylation of both VEGFR-1
and VEGFR-2 in response to recombinant VEGF-A
and of VEGFR-1 in response to recombinant VEGF-B
(Fig. 4C, bottom panel).
Finally, expression of VEGF receptors was also de-
tected by immunofluorescence on histological sections
of frozen adult rat heart tissue (Fig. 4D). Of interest,
while the localization of VEGFR-2 and Np1 fluores-
cence was consistent with the prominent expression of
these receptors on vascular endothelial cells, VEGFR-1
appeared to cluster at the intercalated disks between
cardiomyocytes.
VEGF-A and VEGF-B inhibit cardiomyocyte apoptosis
The reduction in infarct size and preservation of mus-
cle mass in animals treated with VEGF-A and VEGF-B
suggested that these factors either stimulated the lim-
ited cardiomyocyte proliferation that is normally ob-
served in the infarct border zone (24) or prevented
delayed cardiomyocyte loss after infarction. The former
possibility was tested by evaluating the effects of the two
factors on cardiomyocyte proliferation. Under standard
culture conditions (22), #0.2% of neonatal cardio-
myocytes incorporate BrdU at d 1 after isolation; this
percentage was unchanged on addition of either re-
combinant VEGF-A or VEGF-B (Fig. 5A). We also
explored the possibility that the expression of the two
factors after AAV-mediated gene delivery in the in-
farcted hearts in vivo might promote regeneration of
the damaged cardiac tissue through stimulation of
cardiomyocyte replication or cardiac stem cell recruit-
ment. However, we failed to detect any increase in the
number of BrdU-positive, proliferating cells in infarct
border zone in any of the treated animals compared to
controls (data not shown).
An alternative possibility is that the VEGFs might
induce protection of cardiomyocytes against ischemic
death. To test this hypothesis, we exposed cardiomyo-
cytes to hypoxia for 48 h followed by 24 h reoxygen-
ation either in the absence, or presence, of recombi-
nant VEGF-B or VEGF-A. As revealed by a TUNEL assay,
the percentage of apoptotic cells dropped from
Figure 3. Morphometric and histological analysis of infarcted hearts 3 mo after gene transfer. A) Representative Azan trichrome
stainings of LV transverse sections of control and AAV2-VEGF-A- and AAV2-VEGF-B-injected hearts. B) Quantification of infarct
size (% of LV). C) High-magnification ($200) microphotographs of trichrome-stained sections showing the extent of fibrotic
substitution of the infarcted scars (asterisks); arrows indicate new vessels in the VEGF-A expressing hearts. D) Visualization of
vessels by immunofluorescence in the peri-infarcted area (green, endothelial cells; red, %-SMA& cells; blue, cell nuclei).
E) Quantification of capillary density (FITC-lectin& vessels). F) Quantification of %-SMA& arterioles. Values are expressed as
means ' se. *P ( 0.05. Scale bars ) 200 !m.
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!17.2 " 3.3% of controls to 7.6 " 1.2 and 8.0 " 1.0%
in the VEGF-A and VEGF-B-treated cultures, respec-
tively (P#0.05 in both cases; Fig. 5B). The protection
from death was also evident when cardiomyocytes were
exposed for 90 min to the cardiotoxic drug epirubicin.
Under these conditions, the number of dead cells in
the cultures added with either recombinant VEGF
decreased from 61.8 " 8.5% in controls to 13.8 " 6.0
and 11.2 " 4.2% in the VEGF-A and VEGF-B-treated
cultures, respectively (P#0.05 in both cases; Fig. 5C).
Consistent with the conclusion that VEGF exerts an
antiapoptotic effect, we also observed that the number
of TUNEL-positive cells in the infarct border zone at
48 h after infarction was significantly lower in the
animals injected with either AAV2-VEGF-A or AAV2-
VEGF-B compared to controls (from 17.2"8.0 to
4.5"1.4 and 5.5"1.5%, respectively; n$4/group; P #
0.05 vs. control in both cases; Fig. 5D).
VEGF-A and VEGF-B activate expression of genes
involved in the regulation of myocardial contractility
and metabolism
Besides protection from apoptosis, the changes in
regional contractility observed in the infarcted animals
treated with VEGF-A and VEGF-B also suggested that
these factors might directly affect cardiomyocyte activ-
ity. To further explore this issue, we analyzed the levels
of expression of a series of genes involved in cardio-
myocyte function in cells treated for 24 h with recom-
binant VEGF-A or VEGF-B. In particular, we evaluated
the expression profile of genes specifically involved in
cardiac contractility (%MHC, &MHC), intracellular cal-
cium handling (SERCA2a, RYR2), mitochondrial ener-
getics (PGC1%), and of some typical genetic markers of
hypertrophy, such as skeletal %-actin (sk %-act) and
cardiac natriuretic peptides (ANF and BNP). The mod-
ifications in the levels of expression of these genes were
compared to those found in response to the %-adren-
ergic agonist phenylephrine (PE) or to the thyroid
hormone triiodo-l-thyronine (T3). These compounds
are known to induce characteristic myocyte hypertro-
phy responses, consisting in the up-regulation of fetal
genes of pathological hypertrophy (including &MHC,
sk %-act, ANF, and BNP) in the case of PE (25, 26), while
reproducing physiological hypertrophy (increase of
%MHC and SERCA2a, and repression of &MHC tran-
scripts) in the case of T3 (27, 28).
Both VEGFs were found to increase expression of
%MHC (which is the predominant contractile protein
in adult rodents; ref. 29) and repress that of &MHC,
similar to T3, and different from PE (P#0.05 between
VEGF-treated and control cardiomyocytes). VEGF-B
also inhibited expression of sk %-act. Both factors pro-
moted elevation of the ANF and BNP transcripts and,
most notably, they also determined elevation of the
SERCA2a, RYR, and PGC1% mRNAs, similar to T3
(P#0.05) (Fig. 6).
Taken together, these data indicate that both
VEGF-A and VEGF-B evoke, in isolated cardiomyocytes,
a gene expression program proper of compensatory
hypertrophy similar to that induced by the thyroid
hormone. Of note, this response can be initiated by the
sole treatment with VEGF-B, a selective VEGFR-1 li-
gand.
Figure 4. Cardiomyocytes express functional VEGF receptors. A) Levels of
expression of VEGFR-1, VEGFR-2, and Np1 by real-time PCR in rat %-actinin-
positive neonatal cardiomyocytes, %-actinin-negative cardiac stromal cells, and
HUVECs. B) Levels of expression of VEGF receptors in cardiomyocytes in
response to hypoxic (2% O2) or oxidative stress (H2O2 100 'M). C) Top panel:
Western blotting showing specific detection of VEGFR-1, VEGFR-2, and Np1 in
cell lysates of neonatal cardiomyocytes, with or without stimulation with fetal
calf serum (FCS), recombinant VEGF-A, or VEGF-B, as indicated. Bottom
panel: immunodetection of VEGF receptor phosphorylation on stimulation.
VEGFR-1- or VEGF-2-specific immunocomplexes were probed with the indi-
cated anti-phosphotyrosine-specific antibodies. D) Immunofluorescence stain-
ing of VEGFR-1, VEGFR-2, and Np1 on histological sections of frozen adult rat
heart tissue. Larger pictures at left and magnifications at right show fluores-
cence in all three channels (red, receptors; green, sarcomeric %-actinin; blue,
cell nuclei); smaller pictures show 2-channel fluorescence (top: blue/red;
bottom: blue/green). Arrows indicate VEGFR-1 clusters at the intercalated disks between cardiomyocytes. Scale bars $ 200
'm. Values are expressed as means " se. *P # 0.05.
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VEGF-B overexpression counteracts the induction of
genes involved in pathological LV remodeling after
myocardial infarction
To further explore the effects of VEGF receptor stim-
ulation in vivo, we also analyzed the expression profile
of LV tissue from a subset of AAV-transduced, infarcted
animals (n!6/group) by real-time PCR. Consistent
with the echocardiography results, control animals at 3
mo after infarction showed the characteristic pattern of
gene expression commonly associated with pathologi-
cal LV remodeling, involving significant (P"0.05) over-
expression of #MHC and sk $-act contractile proteins,
an increase in the cardiac natriuretic peptides, and a
decrease in the levels of SERCA2a, RYR, and PGC1$
mRNAs as compared to normal rats (Fig. 7). Remark-
ably, these modifications were all significantly counter-
acted by both VEGF-A and, most notably, VEGF-B
overexpression. In the VEGF-A and VEGF-B-treated
hearts, the levels of #MHC, ANF, BNP, SERCA2a, and
RYR were unchanged compared to normal animals;
those of $MHC and PGC1$ were even significantly
Figure 5. VEGFs protect cardiomyocytes from apoptosis in vitro and in vivo.
A) Recombinant VEGFs do not induce neonatal rat cardiomyocyte prolifera-
tion. Left panels: representative images of $-actinin-positive cardiac myocytes
showing positivity to BrdU immunostaining (red; arrows) with or without
exposure to recombinant VEGF-B. Right panel: quantification of BrdU-positive
nuclei. B) VEGFs protect cardiomyocytes from apoptosis in vitro. Left panels:
representative images of TUNEL% cardiomyocytes (arrows) exposed to hyp-
oxia for 48 h followed by 24 h with or without VEGF-B. Right panel:
quantification of TUNEL% nuclei. C) Left panels: representative images of a
cell viability assay based on the simultaneous determination of live (green,
calcein) and dead (red, ethidium homodimer-1, Eth; arrow) cardiomyocytes
after in vitro exposure to epirubicin in the presence or absence VEGF-B. Right
panel: quantification of dead cells. D) Detection of apoptotic nuclei in vivo at
d 3 after MI. Right panels: representative images of TUNEL% nuclei (arrows) in infarcted hearts from a control and a
VEGF-B-injected mouse; cardiomyocytes are stained by positivity to $-actinin (green). Right: quantification of TUNEL%
nuclei. Values are expressed as means & se. *P " 0.05. Scale bars ! 20 'm (A, D); 50 'm (B, C).
Figure 6. Cardiomyocyte treatment with VEGF-A and VEGF-B induces
a gene expression pattern proper of compensatory hypertrophy re-
sponse. Results of real-time PCR quantification of the levels of expres-
sion of the indicated factors in neonatal rat cardiomyocytes after
exposure to recombinant VEGF-A, VEGF-B, phenylephrine (PE), or
thyroid hormone (T3). Values are expressed as means & se, after
normalization for HPRT expression. *P " 0.05 vs. untreated control
cells (C).
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increased, and that of sk !-act was decreased (P"0.05
in all cases).
Collectively, these observations further support the
conclusion that VEGFR-1 stimulation by specific ligands
exerts a beneficial effect on the myocardial tissue.
DISCUSSION
A relevant conclusion of this study is that the continu-
ous expression of VEGF after myocardial infarction
exerts prolonged beneficial effects in terms of increase
in contractility, prevention of pathological LV remod-
eling, and preservation of viable cardiac tissue. All our
findings are consistent with the notion that VEGF
exerts these effects through the activation of VEGFR-1
expressed in cardiomyocytes: 1) isolated rat cardiomy-
ocytes express VEGFR-1; 2) VEGFR tyrosine kinases
becomes activated on binding to the recombinant
VEGFR-1 ligands PlGF and VEGF-B; 3) the levels of
expression VEGFR-1 are selectively up-regulated in
hypoxia and on oxidative stress; and 4) most notably,
cardiomyocyte treatment with VEGF-B activates a pecu-
liar gene expression program, reminiscent of that ob-
served during compensatory hypertrophy. In this con-
text, the localization of VEGFR-1 in the intercalated
disks between cardiomyocytes appears intriguing, since
these structures also act as mechanical stress sensors
during muscle contraction, besides supporting synchro-
nized cardiomyocyte contraction (30). Further studies
are clearly required to understand the functional sig-
nificance of VEGFR-1 localization at these structures. In
this respect, it might be worth noting that, both in
zebrafish and in cultured rat cardiomyocytes, VEGF-A
has been reported to exert a positive inotropic effect by
increasing calcium transients through its interaction
with VEGFR-1 and downstream PLC#-1 activation (31).
The observation that VEGFs exert a direct activity on
cardiomyocytes is indeed not surprising. A large body
of evidence now indicates that expression of the VEGF
receptors is not restricted to endothelial cells and that
their ligands exert a variety of fundamental functions in
other cell types. These nonangiogenic functions of
VEGFs include, among others, the potential to prevent
neuronal cell death from ischemia and promote neu-
rogenesis (32, 33), the capacity to stimulate hepatocyte
regeneration after liver damage (34), and the ability to
promote osteoblast migration and differentiation (35,
36). In the skeletal muscle, we showed that VEGF-A
exerts a powerful regenerative effect after ischemic and
nonischemic muscle damage by promoting satellite cell
differentiation (23, 37). Finally, several groups have
described an effect of VEGF-A on various cells of
hematopoietic origin, showing that this factor is able to
mediate monocyte chemotaxis (38), hematopoietic
stem cell survival (39), mobilization of endothelial
progenitor cells (40), and the selective recruitment of a
population of bone marrow-derived, CD11b$ mononu-
clear cells, which are essential for vessel maturation at
the sites of adult neoangiogenesis (18).
The different VEGF receptors appear variably in-
volved in mediating these nonangiogenic functions of
their ligands. For example, skeletal muscle regenera-
tion appears to selectively require VEGFR-2, since PlGF
is ineffective at stimulating this process compared to
VEGF-A (23); in contrast, the effects on monocytes
require VEGFR-1 (38), those on hematopoietic progen-
itors are mediated by both VEGFR-1 and VEGFR-2
(39–41), and those determining the recruitment of
bone marrow-derived CD11b$ cells require the pres-
ence of Np1 (18).
The prolonged expression of VEGF-B in the heart
elicits only a modest angiogenic response compared to
VEGF-A, essentially consisting in the generation of
enlarged vessels devoid of !-SMA-positive cells. A lack
Figure 7. AAV2-mediated VEGF-B and VEGF-A expression prevents
pathological hypertrophy gene expression in the myocardium of
infarcted rats. RNA was extracted from the left ventricle of control and
AAV2-VEGF-B- and AAV2-VEGF-A injected rats at 3 mo after MI. Values
are expressed as means % se of the real-time PCR quantifications of
the levels of expression of the indicated factors, after normalization for
HPRT. *P " 0.05 vs. uninfarcted control hearts (C).
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of angiogenesis and presence of abnormally enlarged
capillaries was also recently reported in a VEGF-B-
transgenic mouse (11). An apparent controversy exists
concerning the possible angiogenic role of VEGF-B
exogenously delivered in vivo, ranging from promotion
of unrestricted angiogenesis (42), ability to potentiate,
rather than induce, angiogenesis when transgenically
expressed in endothelial cells (43), induction of selec-
tive revascularization of the ischemic myocardium but
not of other organs (12), or no angiogenic effect at all
in several tissues after adenoviral gene delivery (44, 45).
Recent work has also indicated that the delivery
VEGF-B to the infarcted myocardium in rabbits and
pigs using an adenoviral vector promoted angiogenesis
and arteriogenesis by acting on endothelial cells (13).
All these apparent discrepancies might be attributable
to differences in genetic background, phenotyping
methodology, use of different VEGF-B isoforms, or,
most important, use of different strategies for VEGF-B
overproduction (recombinant proteins, naked plasmid
DNA, or adenoviral vectors). In this respect, AAV
vectors currently represent the only available system to
deliver genes to the adult myocardium and allow their
prolonged expression over time. Other vector systems,
such as the first generation adenoviruses used in other
studies, are fraught with the induction of a potent
inflammatory and immune reaction (46), which, be-
sides blurring the biological response, restricts observa-
tion to a few days after vector inoculation.
Besides the possible direct modulation of cardiac
contractility, the main consequences of VEGF expres-
sion are, on one hand, the protection of cardiomyo-
cytes from apoptosis while, on the other hand, the
induction of a gene expression program of compensa-
tory hypertrophy. Cardiomyocytes thus join the list of
the numerous cell types in which different VEGF family
members exert a powerful antiapoptotic effect, includ-
ing endothelial cells (5), neurons (47), embryonic stem
cells, (48) and skeletal muscle cells (23, 49). Protection
from apoptosis was clearly evident when VEGF-B was
administered, in both cultured cardiomyocytes and
after myocardial infarction in vivo, again suggesting
that a relevant receptor mediating the antiapoptotic
effect was VEGFR-1. The recent observations that
VEGF-B rescues retinal and motor neurons from apop-
tosis (50, 51) and inhibits the expression of a number
of proapoptotic genes in noncardiomyocyte cells (50) is
fully consistent with this conclusion.
In addition to protection from apoptosis, VEGF-B
transduction in the heart elicited a peculiar gene
expression profile, consisting of the activation of
!MHC and the repression of "MHC and skeletal !-ac-
tin, and the increase in SERCA2a, RYR, and PGC1!
gene expression, together with the increase in the levels
of the cardiac natriuretic peptide mRNAs. This pattern
of gene expression resembles that induced by the
thyroid hormone T3, which is usually considered a
marker of benign, compensatory hypertropic response
to cardiac stimulation (52, 53). These findings appear
to be in full agreement with the recent observation that
a transgenic mouse overexpressing VEGF-B showed
clear signs of cardiac hypertrophy, but without compro-
mising cardiac function (11); with the report that
VEGF-B-knockout mice have smaller hearts (10); and
with the observation that the injection of the VEGF-B
protein after infarction leads to myocardial hypertro-
phy (54). Our results extend these findings further,
and show that these effects of VEGF-B are exerted
through direct activity on cardiomyocytes. Of note, in
our experiments, VEGF-A and VEGF-B equally pro-
tected cardiomyocytes from apoptosis and induced a
beneficial gene expression profile; however, VEGF-B
scored superior to VEGF-A in preserving LV function
after myocardial infarction. This observation might
either indicate that the two factors activate VEGFR-1
differently, for example, exploiting different corecep-
tors, or that the prolonged activation of VEGFR-2 by
VEGF-A might be somehow detrimental for the in-
farcted myocardium, for example, by inducing a leaky
vasculature. Further experiments will obviously be re-
quired to distinguish between these possibilities.
In conclusion, the finding that VEGF-B exerts a
marked beneficial effect on the infarcted myocardium
by preventing loss of cardiac mass and promoting
cardiac contractility has obvious therapeutic implica-
tions, in terms of both direct utilization of VEGF-B (or
PlGF) for therapeutic purposes and the identification
of alternative, synthetic activators of VEGFR-1.
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